WO2017054086A1 - Treatment of genetic myopathies using bioengineered exosomes - Google Patents
Treatment of genetic myopathies using bioengineered exosomes Download PDFInfo
- Publication number
- WO2017054086A1 WO2017054086A1 PCT/CA2016/051141 CA2016051141W WO2017054086A1 WO 2017054086 A1 WO2017054086 A1 WO 2017054086A1 CA 2016051141 W CA2016051141 W CA 2016051141W WO 2017054086 A1 WO2017054086 A1 WO 2017054086A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- muscular dystrophy
- type
- exosomes
- muscle
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 308
- 201000009623 Myopathy Diseases 0.000 title claims abstract description 80
- 208000021642 Muscular disease Diseases 0.000 title claims abstract description 79
- 230000002068 genetic effect Effects 0.000 title claims description 18
- 238000011282 treatment Methods 0.000 title description 29
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 169
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 133
- 238000000034 method Methods 0.000 claims abstract description 65
- 102000008934 Muscle Proteins Human genes 0.000 claims abstract description 63
- 108010074084 Muscle Proteins Proteins 0.000 claims abstract description 63
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 60
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 59
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 59
- 241000124008 Mammalia Species 0.000 claims abstract description 46
- 201000006938 muscular dystrophy Diseases 0.000 claims description 60
- 230000008685 targeting Effects 0.000 claims description 54
- 210000003205 muscle Anatomy 0.000 claims description 48
- 108010069091 Dystrophin Proteins 0.000 claims description 47
- 102000001039 Dystrophin Human genes 0.000 claims description 46
- 108020004459 Small interfering RNA Proteins 0.000 claims description 44
- 239000006228 supernatant Substances 0.000 claims description 32
- 239000000047 product Substances 0.000 claims description 31
- 230000004927 fusion Effects 0.000 claims description 30
- 201000006709 muscular dystrophy-dystroglycanopathy Diseases 0.000 claims description 30
- 206010010356 Congenital anomaly Diseases 0.000 claims description 28
- 239000012528 membrane Substances 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 26
- 239000008188 pellet Substances 0.000 claims description 26
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 24
- 238000005119 centrifugation Methods 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 23
- 210000002027 skeletal muscle Anatomy 0.000 claims description 23
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 21
- 239000003550 marker Substances 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 19
- 230000035772 mutation Effects 0.000 claims description 18
- 238000005199 ultracentrifugation Methods 0.000 claims description 17
- 102100025222 CD63 antigen Human genes 0.000 claims description 16
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 16
- 239000012472 biological sample Substances 0.000 claims description 16
- 102100037904 CD9 antigen Human genes 0.000 claims description 15
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 15
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 claims description 15
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 claims description 15
- 208000007345 glycogen storage disease Diseases 0.000 claims description 14
- 102100031518 Collagen alpha-2(VI) chain Human genes 0.000 claims description 13
- 101000941585 Homo sapiens Collagen alpha-2(VI) chain Proteins 0.000 claims description 13
- 238000010362 genome editing Methods 0.000 claims description 13
- 102100027221 CD81 antigen Human genes 0.000 claims description 12
- 108091033409 CRISPR Proteins 0.000 claims description 12
- 108010043741 Collagen Type VI Proteins 0.000 claims description 12
- 102000002734 Collagen Type VI Human genes 0.000 claims description 12
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims description 12
- 101001094684 Homo sapiens Protein O-mannosyl-transferase 2 Proteins 0.000 claims description 12
- 101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 claims description 12
- 102100021171 Mannose-1-phosphate guanyltransferase beta Human genes 0.000 claims description 12
- 101710119386 Mannose-1-phosphate guanyltransferase beta Proteins 0.000 claims description 12
- 102100028120 Protein O-mannosyl-transferase 1 Human genes 0.000 claims description 12
- 101710093787 Protein O-mannosyl-transferase 1 Proteins 0.000 claims description 12
- 102100035490 Protein O-mannosyl-transferase 2 Human genes 0.000 claims description 12
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 claims description 12
- 235000019169 all-trans-retinol Nutrition 0.000 claims description 12
- 239000011717 all-trans-retinol Substances 0.000 claims description 12
- 230000001413 cellular effect Effects 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 12
- 102100036912 Desmin Human genes 0.000 claims description 11
- 108010044052 Desmin Proteins 0.000 claims description 11
- 102100023781 Selenoprotein N Human genes 0.000 claims description 11
- 101710095024 Selenoprotein N Proteins 0.000 claims description 11
- 210000005045 desmin Anatomy 0.000 claims description 11
- 102000004420 Creatine Kinase Human genes 0.000 claims description 10
- 108010042126 Creatine kinase Proteins 0.000 claims description 10
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 10
- 208000036626 Mental retardation Diseases 0.000 claims description 10
- 108010002947 Connectin Proteins 0.000 claims description 9
- 102000004726 Connectin Human genes 0.000 claims description 9
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims description 9
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 claims description 9
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 claims description 9
- 102100031774 Ribitol 5-phosphate transferase FKRP Human genes 0.000 claims description 9
- 101710087595 Ribitol 5-phosphate transferase FKRP Proteins 0.000 claims description 9
- 102100031754 Ribitol-5-phosphate transferase FKTN Human genes 0.000 claims description 9
- 101710087566 Ribitol-5-phosphate transferase FKTN Proteins 0.000 claims description 9
- 230000007812 deficiency Effects 0.000 claims description 9
- 101100165655 Arabidopsis thaliana BRO1 gene Proteins 0.000 claims description 8
- 101100082597 Homo sapiens PDCD6IP gene Proteins 0.000 claims description 8
- 101000594629 Homo sapiens Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 Proteins 0.000 claims description 8
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 claims description 8
- 101710116771 Lysosome-associated membrane glycoprotein 2 Proteins 0.000 claims description 8
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 claims description 8
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 claims description 8
- 102100036226 Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 Human genes 0.000 claims description 8
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 claims description 8
- 108010027273 Valosin Containing Protein Proteins 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 8
- 230000002950 deficient Effects 0.000 claims description 8
- 108030001375 Calpain-3 Proteins 0.000 claims description 7
- 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 claims description 7
- 102100025682 Dystroglycan 1 Human genes 0.000 claims description 7
- 102000013366 Filamin Human genes 0.000 claims description 7
- 108060002900 Filamin Proteins 0.000 claims description 7
- 206010018462 Glycogen storage disease type V Diseases 0.000 claims description 7
- 101000909313 Homo sapiens Carnitine O-palmitoyltransferase 2, mitochondrial Proteins 0.000 claims description 7
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 claims description 7
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims description 7
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 201000004534 glycogen storage disease V Diseases 0.000 claims description 7
- 102100040743 Alpha-crystallin B chain Human genes 0.000 claims description 6
- 102100030685 Alpha-sarcoglycan Human genes 0.000 claims description 6
- 102100040894 Amylo-alpha-1,6-glucosidase Human genes 0.000 claims description 6
- 102000000412 Annexin Human genes 0.000 claims description 6
- 108050008874 Annexin Proteins 0.000 claims description 6
- 102100027954 BAG family molecular chaperone regulator 3 Human genes 0.000 claims description 6
- 101710089791 BAG family molecular chaperone regulator 3 Proteins 0.000 claims description 6
- 102100035388 Beta-enolase Human genes 0.000 claims description 6
- 102100030686 Beta-sarcoglycan Human genes 0.000 claims description 6
- 208000016473 Bethlem myopathy 1 Diseases 0.000 claims description 6
- 102100033849 CCHC-type zinc finger nucleic acid binding protein Human genes 0.000 claims description 6
- 102000003904 Caveolin 3 Human genes 0.000 claims description 6
- 108090000268 Caveolin 3 Proteins 0.000 claims description 6
- 102100031082 Choline/ethanolamine kinase Human genes 0.000 claims description 6
- 101710147336 Choline/ethanolamine kinase Proteins 0.000 claims description 6
- 102100031515 D-ribitol-5-phosphate cytidylyltransferase Human genes 0.000 claims description 6
- 108010093818 D-ribitol-5-phosphate cytidylyltransferase Proteins 0.000 claims description 6
- 102100021790 Delta-sarcoglycan Human genes 0.000 claims description 6
- 102100035425 DnaJ homolog subfamily B member 6 Human genes 0.000 claims description 6
- 102100021158 Double homeobox protein 4 Human genes 0.000 claims description 6
- 102000004168 Dysferlin Human genes 0.000 claims description 6
- 108090000620 Dysferlin Proteins 0.000 claims description 6
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 claims description 6
- 102100030695 Electron transfer flavoprotein subunit alpha, mitochondrial Human genes 0.000 claims description 6
- 102100034239 Emerin Human genes 0.000 claims description 6
- 102100038651 Four and a half LIM domains protein 1 Human genes 0.000 claims description 6
- 102100039262 Glycogen [starch] synthase, muscle Human genes 0.000 claims description 6
- 102100029492 Glycogen phosphorylase, muscle form Human genes 0.000 claims description 6
- 101710141660 Glycogen synthase 1 Proteins 0.000 claims description 6
- 102100030338 Hexokinase-1 Human genes 0.000 claims description 6
- 101710198391 Hexokinase-1 Proteins 0.000 claims description 6
- 101000891982 Homo sapiens Alpha-crystallin B chain Proteins 0.000 claims description 6
- 101000703500 Homo sapiens Alpha-sarcoglycan Proteins 0.000 claims description 6
- 101000877537 Homo sapiens Beta-enolase Proteins 0.000 claims description 6
- 101000703495 Homo sapiens Beta-sarcoglycan Proteins 0.000 claims description 6
- 101000616408 Homo sapiens Delta-sarcoglycan Proteins 0.000 claims description 6
- 101000804112 Homo sapiens DnaJ homolog subfamily B member 6 Proteins 0.000 claims description 6
- 101000968549 Homo sapiens Double homeobox protein 4 Proteins 0.000 claims description 6
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 claims description 6
- 101001010541 Homo sapiens Electron transfer flavoprotein subunit alpha, mitochondrial Proteins 0.000 claims description 6
- 101001031607 Homo sapiens Four and a half LIM domains protein 1 Proteins 0.000 claims description 6
- 101000700475 Homo sapiens Glycogen phosphorylase, muscle form Proteins 0.000 claims description 6
- 101000994363 Homo sapiens Integrin alpha-7 Proteins 0.000 claims description 6
- 101001023021 Homo sapiens LIM domain-binding protein 3 Proteins 0.000 claims description 6
- 101000760730 Homo sapiens Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 claims description 6
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 claims description 6
- 101000958753 Homo sapiens Myosin-2 Proteins 0.000 claims description 6
- 101000945267 Homo sapiens Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform Proteins 0.000 claims description 6
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 claims description 6
- 101000845685 Homo sapiens Protein Dok-7 Proteins 0.000 claims description 6
- 101001129345 Homo sapiens Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2 Proteins 0.000 claims description 6
- 102100032832 Integrin alpha-7 Human genes 0.000 claims description 6
- 102100035112 LIM domain-binding protein 3 Human genes 0.000 claims description 6
- 101710200519 Laminin subunit alpha-2 Proteins 0.000 claims description 6
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 claims description 6
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 claims description 6
- 102100024590 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 claims description 6
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 claims description 6
- 102100038303 Myosin-2 Human genes 0.000 claims description 6
- 102100038894 Myotilin Human genes 0.000 claims description 6
- 101710100281 Myotilin Proteins 0.000 claims description 6
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 claims description 6
- 102100022437 Myotonin-protein kinase Human genes 0.000 claims description 6
- 102100033341 N-acetylmannosamine kinase Human genes 0.000 claims description 6
- 102100037385 Phosphoglycerate mutase 2 Human genes 0.000 claims description 6
- 101710093483 Phosphoglycerate mutase 2 Proteins 0.000 claims description 6
- 102100033547 Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform Human genes 0.000 claims description 6
- 102100030477 Plectin Human genes 0.000 claims description 6
- 108010054050 Plectin Proteins 0.000 claims description 6
- 102100026531 Prelamin-A/C Human genes 0.000 claims description 6
- 102100031135 Protein Dok-7 Human genes 0.000 claims description 6
- 102100031305 Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2 Human genes 0.000 claims description 6
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 claims description 6
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 claims description 6
- 102100026508 Tafazzin Human genes 0.000 claims description 6
- 101710175789 Tafazzin Proteins 0.000 claims description 6
- 208000025125 Ullrich congenital muscular dystrophy 1 Diseases 0.000 claims description 6
- 102000011054 glycogenin Human genes 0.000 claims description 6
- 108010062764 glycogenin Proteins 0.000 claims description 6
- 102100029103 3-ketoacyl-CoA thiolase Human genes 0.000 claims description 5
- 102100032922 ATP-dependent 6-phosphofructokinase, muscle type Human genes 0.000 claims description 5
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 claims description 5
- 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 claims description 5
- 208000032000 Glycogen storage disease due to muscle glycogen phosphorylase deficiency Diseases 0.000 claims description 5
- 102100035616 Heterogeneous nuclear ribonucleoproteins A2/B1 Human genes 0.000 claims description 5
- 101000730838 Homo sapiens ATP-dependent 6-phosphofructokinase, muscle type Proteins 0.000 claims description 5
- 101000854026 Homo sapiens Heterogeneous nuclear ribonucleoproteins A2/B1 Proteins 0.000 claims description 5
- 101000997654 Homo sapiens N-acetylmannosamine kinase Proteins 0.000 claims description 5
- 101000624947 Homo sapiens Nesprin-1 Proteins 0.000 claims description 5
- 101000624956 Homo sapiens Nesprin-2 Proteins 0.000 claims description 5
- 101000825933 Homo sapiens Structural maintenance of chromosomes flexible hinge domain-containing protein 1 Proteins 0.000 claims description 5
- 101000597193 Homo sapiens Telethonin Proteins 0.000 claims description 5
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 claims description 5
- 102100023306 Nesprin-1 Human genes 0.000 claims description 5
- 102100023305 Nesprin-2 Human genes 0.000 claims description 5
- 101710105361 Phosphoglucomutase 1 Proteins 0.000 claims description 5
- 102100030999 Phosphoglucomutase-1 Human genes 0.000 claims description 5
- 108010041472 Poly(A)-Binding Protein II Proteins 0.000 claims description 5
- 102100039427 Polyadenylate-binding protein 2 Human genes 0.000 claims description 5
- 102100022770 Structural maintenance of chromosomes flexible hinge domain-containing protein 1 Human genes 0.000 claims description 5
- 238000010459 TALEN Methods 0.000 claims description 5
- 102100035155 Telethonin Human genes 0.000 claims description 5
- 201000004502 glycogen storage disease II Diseases 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 102100035893 CD151 antigen Human genes 0.000 claims description 4
- 102100027217 CD82 antigen Human genes 0.000 claims description 4
- 208000011518 Danon disease Diseases 0.000 claims description 4
- 108010071885 Dystroglycans Proteins 0.000 claims description 4
- 208000013135 GNE myopathy Diseases 0.000 claims description 4
- 102100021792 Gamma-sarcoglycan Human genes 0.000 claims description 4
- 208000001500 Glycogen Storage Disease Type IIb Diseases 0.000 claims description 4
- 208000035148 Glycogen storage disease due to LAMP-2 deficiency Diseases 0.000 claims description 4
- 101000946874 Homo sapiens CD151 antigen Proteins 0.000 claims description 4
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 claims description 4
- 101000616435 Homo sapiens Gamma-sarcoglycan Proteins 0.000 claims description 4
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 4
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 claims description 4
- 101000713288 Homo sapiens Solute carrier family 22 member 5 Proteins 0.000 claims description 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 4
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 4
- 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 claims description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 4
- 102100036924 Solute carrier family 22 member 5 Human genes 0.000 claims description 4
- 102100037455 Trafficking protein particle complex subunit 11 Human genes 0.000 claims description 4
- 101710105968 Trafficking protein particle complex subunit 11 Proteins 0.000 claims description 4
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 4
- 108700036262 Trifunctional Protein Deficiency With Myopathy And Neuropathy Proteins 0.000 claims description 4
- 201000006793 Walker-Warburg syndrome Diseases 0.000 claims description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 230000030279 gene silencing Effects 0.000 claims description 4
- 238000012226 gene silencing method Methods 0.000 claims description 4
- 230000002440 hepatic effect Effects 0.000 claims description 4
- 201000003645 multiple acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
- 208000024365 proximal myopathy and ophthalmoplegia Diseases 0.000 claims description 4
- HCHFRAXBELVCGG-JYFOCSDGSA-N (2z,3z)-2,3-bis[(4-methoxyphenyl)methylidene]butanedinitrile Chemical compound C1=CC(OC)=CC=C1\C=C(/C#N)\C(\C#N)=C\C1=CC=C(OC)C=C1 HCHFRAXBELVCGG-JYFOCSDGSA-N 0.000 claims description 3
- 102100028734 1,4-alpha-glucan-branching enzyme Human genes 0.000 claims description 3
- 108010043797 4-alpha-glucanotransferase Proteins 0.000 claims description 3
- 102100034732 Beta-1,3-glucuronyltransferase LARGE1 Human genes 0.000 claims description 3
- 101710116319 CCHC-type zinc finger nucleic acid binding protein Proteins 0.000 claims description 3
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 3
- HCHFRAXBELVCGG-UHFFFAOYSA-N Emerin Natural products C1=CC(OC)=CC=C1C=C(C#N)C(C#N)=CC1=CC=C(OC)C=C1 HCHFRAXBELVCGG-UHFFFAOYSA-N 0.000 claims description 3
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 claims description 3
- 108010023922 Enoyl-CoA hydratase Proteins 0.000 claims description 3
- 102000011426 Enoyl-CoA hydratase Human genes 0.000 claims description 3
- 208000006562 Glycogen Storage Disease Type VII Diseases 0.000 claims description 3
- 101001058479 Homo sapiens 1,4-alpha-glucan-branching enzyme Proteins 0.000 claims description 3
- 101000841262 Homo sapiens 3-ketoacyl-CoA thiolase Proteins 0.000 claims description 3
- 101000893559 Homo sapiens Amylo-alpha-1,6-glucosidase Proteins 0.000 claims description 3
- 101001090662 Homo sapiens Beta-1,3-glucuronyltransferase LARGE1 Proteins 0.000 claims description 3
- 101000710837 Homo sapiens CCHC-type zinc finger nucleic acid binding protein Proteins 0.000 claims description 3
- 101000855983 Homo sapiens Dystroglycan 1 Proteins 0.000 claims description 3
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 claims description 3
- 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 claims description 3
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 claims description 3
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 claims description 3
- 101000693993 Homo sapiens Sodium channel protein type 4 subunit alpha Proteins 0.000 claims description 3
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 claims description 3
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 claims description 3
- 102000014750 Phosphorylase Kinase Human genes 0.000 claims description 3
- 108010064071 Phosphorylase Kinase Proteins 0.000 claims description 3
- 102100027732 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Human genes 0.000 claims description 3
- 101710109123 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Proteins 0.000 claims description 3
- 102100027195 Sodium channel protein type 4 subunit alpha Human genes 0.000 claims description 3
- 206010072656 Very long-chain acyl-coenzyme A dehydrogenase deficiency Diseases 0.000 claims description 3
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 3
- 108010056197 emerin Proteins 0.000 claims description 3
- 201000009339 glycogen storage disease VII Diseases 0.000 claims description 3
- 210000003000 inclusion body Anatomy 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 208000014305 mitochondrial trifunctional protein deficiency Diseases 0.000 claims description 3
- 201000010866 very long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 3
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 claims description 2
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 claims description 2
- 102000000326 Anoctamin-5 Human genes 0.000 claims description 2
- 108050008799 Anoctamin-5 Proteins 0.000 claims description 2
- 201000005943 Barth syndrome Diseases 0.000 claims description 2
- 206010058892 Carnitine deficiency Diseases 0.000 claims description 2
- 108700017419 Carnitine-Acylcarnitine Translocase Deficiency Proteins 0.000 claims description 2
- 208000015374 Central core disease Diseases 0.000 claims description 2
- 108700043208 Dimauro disease Proteins 0.000 claims description 2
- 201000006328 Fanconi syndrome Diseases 0.000 claims description 2
- 102000006479 Heterogeneous-Nuclear Ribonucleoproteins Human genes 0.000 claims description 2
- 108010019372 Heterogeneous-Nuclear Ribonucleoproteins Proteins 0.000 claims description 2
- 101000803527 Homo sapiens Vacuolar ATPase assembly integral membrane protein VMA21 Proteins 0.000 claims description 2
- 108010085895 Laminin Proteins 0.000 claims description 2
- 108010051910 Long-chain-3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 claims description 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims description 2
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims description 2
- 108700036266 Muscle Glycogen Storage Disease 0 Proteins 0.000 claims description 2
- 206010028424 Myasthenic syndrome Diseases 0.000 claims description 2
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 claims description 2
- 108700010203 Phosphoglycerate Kinase 1 Deficiency Proteins 0.000 claims description 2
- 102000002932 Thiolase Human genes 0.000 claims description 2
- 108060008225 Thiolase Proteins 0.000 claims description 2
- 201000000509 Tibial muscular dystrophy Diseases 0.000 claims description 2
- 102100035048 Vacuolar ATPase assembly integral membrane protein VMA21 Human genes 0.000 claims description 2
- 201000001520 X-linked Emery-Dreifuss muscular dystrophy 1 Diseases 0.000 claims description 2
- 201000001584 X-linked Emery-Dreifuss muscular dystrophy 6 Diseases 0.000 claims description 2
- 230000004900 autophagic degradation Effects 0.000 claims description 2
- 201000009564 autosomal recessive limb-girdle muscular dystrophy type 2A Diseases 0.000 claims description 2
- 201000009562 autosomal recessive limb-girdle muscular dystrophy type 2C Diseases 0.000 claims description 2
- 201000009561 autosomal recessive limb-girdle muscular dystrophy type 2D Diseases 0.000 claims description 2
- 201000009553 autosomal recessive limb-girdle muscular dystrophy type 2E Diseases 0.000 claims description 2
- 201000009539 autosomal recessive limb-girdle muscular dystrophy type 2J Diseases 0.000 claims description 2
- 201000009538 autosomal recessive limb-girdle muscular dystrophy type 2L Diseases 0.000 claims description 2
- 201000009537 autosomal recessive limb-girdle muscular dystrophy type 2Q Diseases 0.000 claims description 2
- 201000009535 autosomal recessive limb-girdle muscular dystrophy type 2S Diseases 0.000 claims description 2
- 208000005071 carnitine-acylcarnitine translocase deficiency Diseases 0.000 claims description 2
- 201000007303 central core myopathy Diseases 0.000 claims description 2
- 201000009338 distal myopathy Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000015402 facioscapulohumeral muscular dystrophy 1 Diseases 0.000 claims description 2
- 208000015401 facioscapulohumeral muscular dystrophy 2 Diseases 0.000 claims description 2
- 208000036917 glutaric acidemia IIa Diseases 0.000 claims description 2
- 201000004504 glycogen storage disease IV Diseases 0.000 claims description 2
- 201000006739 glycogen storage disease XV Diseases 0.000 claims description 2
- 208000028157 inclusion body myopathy with Paget disease of bone and frontotemporal dementia type 1 Diseases 0.000 claims description 2
- 208000015452 inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2 Diseases 0.000 claims description 2
- 208000015451 inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 3 Diseases 0.000 claims description 2
- 208000025855 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Diseases 0.000 claims description 2
- 208000024886 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 Diseases 0.000 claims description 2
- 208000022090 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 10 Diseases 0.000 claims description 2
- 208000016772 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 7 Diseases 0.000 claims description 2
- 208000025715 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8 Diseases 0.000 claims description 2
- 201000006951 muscular dystrophy-dystroglycanopathy type B5 Diseases 0.000 claims description 2
- 208000011599 myopathy, proximal, and ophthalmoplegia Diseases 0.000 claims description 2
- 208000001146 phosphoglycerate kinase 1 deficiency Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims description 2
- 102000046744 Calpain-3 Human genes 0.000 claims 4
- 102100035179 Ribitol-5-phosphate xylosyltransferase 1 Human genes 0.000 claims 4
- 101710161553 Ribitol-5-phosphate xylosyltransferase 1 Proteins 0.000 claims 4
- 102100024108 Dystrophin Human genes 0.000 claims 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
- 101710186512 3-ketoacyl-CoA thiolase Proteins 0.000 claims 1
- 108010003902 Acetyl-CoA C-acyltransferase Proteins 0.000 claims 1
- 101001036856 Arabidopsis thaliana 1,4-alpha-glucan-branching enzyme 3, chloroplastic/amyloplastic Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 101710147349 Carnitine transporter Proteins 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 229920001503 Glucan Polymers 0.000 claims 1
- 101000859570 Homo sapiens Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 claims 1
- 101000989606 Homo sapiens Cholinephosphotransferase 1 Proteins 0.000 claims 1
- 102000007547 Laminin Human genes 0.000 claims 1
- 108010029147 N-acylmannosamine kinase Proteins 0.000 claims 1
- 108091006207 SLC-Transporter Proteins 0.000 claims 1
- 102000037054 SLC-Transporter Human genes 0.000 claims 1
- 102100023153 Sodium- and chloride-dependent creatine transporter 1 Human genes 0.000 claims 1
- 108010019965 Spectrin Proteins 0.000 claims 1
- 102000005890 Spectrin Human genes 0.000 claims 1
- 108010037026 Vacuolar Proton-Translocating ATPases Proteins 0.000 claims 1
- 102000011731 Vacuolar Proton-Translocating ATPases Human genes 0.000 claims 1
- 108700005875 X-linked Creatine deficiency Proteins 0.000 claims 1
- 208000034091 X-linked creatine transporter deficiency Diseases 0.000 claims 1
- 201000009531 autosomal recessive limb-girdle muscular dystrophy type 2G Diseases 0.000 claims 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 108010007169 creatine transporter Proteins 0.000 claims 1
- 201000002997 creatine transporter deficiency Diseases 0.000 claims 1
- 229960002442 glucosamine Drugs 0.000 claims 1
- 210000000633 nuclear envelope Anatomy 0.000 claims 1
- 150000002892 organic cations Chemical class 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 119
- 108020004999 messenger RNA Proteins 0.000 description 43
- 239000000243 solution Substances 0.000 description 38
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 30
- 101710163270 Nuclease Proteins 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 27
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 22
- 239000002953 phosphate buffered saline Substances 0.000 description 22
- 102000017946 PGC-1 Human genes 0.000 description 20
- 108700038399 PGC-1 Proteins 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 210000004443 dendritic cell Anatomy 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- -1 Rab5b Proteins 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- 239000012096 transfection reagent Substances 0.000 description 13
- 108020005004 Guide RNA Proteins 0.000 description 12
- 210000002950 fibroblast Anatomy 0.000 description 12
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 12
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 11
- 229930006000 Sucrose Natural products 0.000 description 11
- 238000002955 isolation Methods 0.000 description 11
- 239000005720 sucrose Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 239000012097 Lipofectamine 2000 Substances 0.000 description 10
- 206010068836 Metabolic myopathy Diseases 0.000 description 10
- 208000010316 Myotonia congenita Diseases 0.000 description 10
- 201000011474 congenital myopathy Diseases 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 102000010660 flotillin Human genes 0.000 description 7
- 108060000864 flotillin Proteins 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102100034523 Histone H4 Human genes 0.000 description 6
- 101001067880 Homo sapiens Histone H4 Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108091028113 Trans-activating crRNA Proteins 0.000 description 6
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 6
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 206010064571 Gene mutation Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 102000004271 Tryptophan 5-monooxygenases Human genes 0.000 description 5
- 108090000885 Tryptophan 5-monooxygenases Proteins 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000008119 colloidal silica Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 5
- 229960005205 prednisolone Drugs 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 102000007456 Peroxiredoxin Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 4
- 241000589892 Treponema denticola Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 4
- 229960004359 iodixanol Drugs 0.000 description 4
- 230000034217 membrane fusion Effects 0.000 description 4
- 210000000663 muscle cell Anatomy 0.000 description 4
- 108030002458 peroxiredoxin Proteins 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102100032539 Calpain-3 Human genes 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 101000933665 Homo sapiens Complement component C1q receptor Proteins 0.000 description 3
- 101001134621 Homo sapiens Programmed cell death 6-interacting protein Proteins 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 206010039020 Rhabdomyolysis Diseases 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000001471 micro-filtration Methods 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 description 2
- 102100027831 14-3-3 protein theta Human genes 0.000 description 2
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 description 2
- YUDPTGPSBJVHCN-JZYAIQKZSA-N 4-Methylumbelliferyl-alpha-D-glucopyranoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-JZYAIQKZSA-N 0.000 description 2
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 2
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 2
- 102000004146 ATP citrate synthases Human genes 0.000 description 2
- 108090000662 ATP citrate synthases Proteins 0.000 description 2
- 102100030374 Actin, cytoplasmic 2 Human genes 0.000 description 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 2
- 102000005234 Adenosylhomocysteinase Human genes 0.000 description 2
- 108020002202 Adenosylhomocysteinase Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102000040717 Alpha family Human genes 0.000 description 2
- 108091071248 Alpha family Proteins 0.000 description 2
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 2
- 102100038910 Alpha-enolase Human genes 0.000 description 2
- 102100034613 Annexin A2 Human genes 0.000 description 2
- 108090000668 Annexin A2 Proteins 0.000 description 2
- 102000004148 Annexin A4 Human genes 0.000 description 2
- 108090000669 Annexin A4 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102100034278 Annexin A6 Human genes 0.000 description 2
- 108090000656 Annexin A6 Proteins 0.000 description 2
- 102100032412 Basigin Human genes 0.000 description 2
- 108091079001 CRISPR RNA Proteins 0.000 description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 2
- 102100025051 Cell division control protein 42 homolog Human genes 0.000 description 2
- 108010010706 Chaperonin Containing TCP-1 Proteins 0.000 description 2
- 102100034667 Chloride intracellular channel protein 1 Human genes 0.000 description 2
- 102100026127 Clathrin heavy chain 1 Human genes 0.000 description 2
- 102000004360 Cofilin 1 Human genes 0.000 description 2
- 108090000996 Cofilin 1 Proteins 0.000 description 2
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 2
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 2
- 101000836492 Dictyostelium discoideum ALG-2 interacting protein X Proteins 0.000 description 2
- 102100032037 EH domain-containing protein 4 Human genes 0.000 description 2
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 2
- 102100031334 Elongation factor 2 Human genes 0.000 description 2
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 2
- 101710139370 Eukaryotic translation elongation factor 2 Proteins 0.000 description 2
- 102100020903 Ezrin Human genes 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 102100026561 Filamin-A Human genes 0.000 description 2
- 102100022277 Fructose-bisphosphate aldolase A Human genes 0.000 description 2
- 102100040510 Galectin-3-binding protein Human genes 0.000 description 2
- 108010056771 Glucosidases Proteins 0.000 description 2
- 102000004366 Glucosidases Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102100035354 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 Human genes 0.000 description 2
- 102100035341 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 Human genes 0.000 description 2
- 102100034154 Guanine nucleotide-binding protein G(i) subunit alpha-2 Human genes 0.000 description 2
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 2
- 102100040352 Heat shock 70 kDa protein 1A Human genes 0.000 description 2
- 102220491576 Heat shock 70 kDa protein 1A_D10A_mutation Human genes 0.000 description 2
- 102100027421 Heat shock cognate 71 kDa protein Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 101000773237 Homo sapiens Actin, cytoplasmic 2 Proteins 0.000 description 2
- 101000882335 Homo sapiens Alpha-enolase Proteins 0.000 description 2
- 101000798441 Homo sapiens Basigin Proteins 0.000 description 2
- 101000946430 Homo sapiens Chloride intracellular channel protein 1 Proteins 0.000 description 2
- 101000912851 Homo sapiens Clathrin heavy chain 1 Proteins 0.000 description 2
- 101000921218 Homo sapiens EH domain-containing protein 4 Proteins 0.000 description 2
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 2
- 101000913549 Homo sapiens Filamin-A Proteins 0.000 description 2
- 101000755879 Homo sapiens Fructose-bisphosphate aldolase A Proteins 0.000 description 2
- 101000967904 Homo sapiens Galectin-3-binding protein Proteins 0.000 description 2
- 101001024316 Homo sapiens Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 Proteins 0.000 description 2
- 101001024278 Homo sapiens Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 Proteins 0.000 description 2
- 101001070508 Homo sapiens Guanine nucleotide-binding protein G(i) subunit alpha-2 Proteins 0.000 description 2
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 2
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 2
- 101001037759 Homo sapiens Heat shock 70 kDa protein 1A Proteins 0.000 description 2
- 101001080568 Homo sapiens Heat shock cognate 71 kDa protein Proteins 0.000 description 2
- 101000998629 Homo sapiens Importin subunit beta-1 Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101000590830 Homo sapiens Monocarboxylate transporter 1 Proteins 0.000 description 2
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 2
- 101000931590 Homo sapiens Prostaglandin F2 receptor negative regulator Proteins 0.000 description 2
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 2
- 101000926083 Homo sapiens Rab GDP dissociation inhibitor beta Proteins 0.000 description 2
- 101000620576 Homo sapiens Ras-related protein Rab-14 Proteins 0.000 description 2
- 101001079065 Homo sapiens Ras-related protein Rab-1A Proteins 0.000 description 2
- 101001077405 Homo sapiens Ras-related protein Rab-5C Proteins 0.000 description 2
- 101000584785 Homo sapiens Ras-related protein Rab-7a Proteins 0.000 description 2
- 101000712571 Homo sapiens Ras-related protein Rab-8A Proteins 0.000 description 2
- 101000701334 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-1 Proteins 0.000 description 2
- 101000740523 Homo sapiens Syntenin-1 Proteins 0.000 description 2
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 2
- 102100033258 Importin subunit beta-1 Human genes 0.000 description 2
- 102100032816 Integrin alpha-6 Human genes 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 102100039648 Lactadherin Human genes 0.000 description 2
- 101150048357 Lamp1 gene Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100038884 Major vault protein Human genes 0.000 description 2
- 101710094960 Major vault protein Proteins 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 102100027869 Moesin Human genes 0.000 description 2
- 102100034068 Monocarboxylate transporter 1 Human genes 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101000935036 Ovis aries Integrin beta-1 Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 2
- 102000011195 Profilin Human genes 0.000 description 2
- 108050001408 Profilin Proteins 0.000 description 2
- 102100020864 Prostaglandin F2 receptor negative regulator Human genes 0.000 description 2
- 102100034911 Pyruvate kinase PKM Human genes 0.000 description 2
- 101710152724 Pyruvate kinase PKM Proteins 0.000 description 2
- 102100034328 Rab GDP dissociation inhibitor beta Human genes 0.000 description 2
- 102100022288 Ras-related protein Rab-14 Human genes 0.000 description 2
- 102100028191 Ras-related protein Rab-1A Human genes 0.000 description 2
- 102100039100 Ras-related protein Rab-5A Human genes 0.000 description 2
- 102100025138 Ras-related protein Rab-5C Human genes 0.000 description 2
- 102100030019 Ras-related protein Rab-7a Human genes 0.000 description 2
- 102100033480 Ras-related protein Rab-8A Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102100030458 Sodium/potassium-transporting ATPase subunit alpha-1 Human genes 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 102100021685 Stomatin Human genes 0.000 description 2
- 108700037714 Stomatin Proteins 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 102100037219 Syntenin-1 Human genes 0.000 description 2
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 2
- 108700031126 Tetraspanins Proteins 0.000 description 2
- 102000043977 Tetraspanins Human genes 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- 108010033576 Transferrin Receptors Proteins 0.000 description 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
- 102100022387 Transforming protein RhoA Human genes 0.000 description 2
- 102000014701 Transketolase Human genes 0.000 description 2
- 108010043652 Transketolase Proteins 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 102100033598 Triosephosphate isomerase Human genes 0.000 description 2
- 101710194411 Triosephosphate isomerase 1 Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100037160 Ubiquitin-like modifier-activating enzyme 1 Human genes 0.000 description 2
- 101710191412 Ubiquitin-like modifier-activating enzyme 1 Proteins 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 2
- 238000000942 confocal micrograph Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229960004826 creatine monohydrate Drugs 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000005549 deoxyribonucleoside Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 108010055671 ezrin Proteins 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 108010071525 moesin Proteins 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 108010087917 rhoA GTP Binding Protein Proteins 0.000 description 2
- 239000002342 ribonucleoside Substances 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- 102100021408 14-3-3 protein beta/alpha Human genes 0.000 description 1
- 102100025007 14-3-3 protein epsilon Human genes 0.000 description 1
- 102100024682 14-3-3 protein eta Human genes 0.000 description 1
- 102100027832 14-3-3 protein gamma Human genes 0.000 description 1
- 102100040685 14-3-3 protein zeta/delta Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- 108010016281 ADP-Ribosylation Factor 1 Proteins 0.000 description 1
- 102100034341 ADP-ribosylation factor 1 Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101000980996 Arabidopsis thaliana Phosphatidate cytidylyltransferase 3 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 102000014832 CACNA1S Human genes 0.000 description 1
- 101150052962 CACNA1S gene Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108700005858 Carnitine palmitoyl transferase 2 deficiency Proteins 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 102000016078 Chaperonin Containing TCP-1 Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010072220 Cyclophilin A Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100031702 Endoplasmic reticulum membrane sensor NFE2L1 Human genes 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100022887 GTP-binding nuclear protein Ran Human genes 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940123611 Genome editing Drugs 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031926 Glycogen storage disease due to muscle phosphofructokinase deficiency Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000818893 Homo sapiens 14-3-3 protein beta/alpha Proteins 0.000 description 1
- 101000760079 Homo sapiens 14-3-3 protein epsilon Proteins 0.000 description 1
- 101000760084 Homo sapiens 14-3-3 protein eta Proteins 0.000 description 1
- 101000723517 Homo sapiens 14-3-3 protein gamma Proteins 0.000 description 1
- 101000723543 Homo sapiens 14-3-3 protein theta Proteins 0.000 description 1
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000684275 Homo sapiens ADP-ribosylation factor 3 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000899240 Homo sapiens Endoplasmic reticulum chaperone BiP Proteins 0.000 description 1
- 101000620756 Homo sapiens GTP-binding nuclear protein Ran Proteins 0.000 description 1
- 101001034314 Homo sapiens Lactadherin Proteins 0.000 description 1
- 101000623713 Homo sapiens Motile sperm domain-containing protein 3 Proteins 0.000 description 1
- 101000743870 Homo sapiens Ras-related protein Rab-5A Proteins 0.000 description 1
- 101001077409 Homo sapiens Ras-related protein Rab-5B Proteins 0.000 description 1
- 101001130437 Homo sapiens Ras-related protein Rap-2b Proteins 0.000 description 1
- 101000653663 Homo sapiens T-complex protein 1 subunit epsilon Proteins 0.000 description 1
- 101000595467 Homo sapiens T-complex protein 1 subunit gamma Proteins 0.000 description 1
- 101000850794 Homo sapiens Tropomyosin alpha-3 chain Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020844 Hyperthermia malignant Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101710191666 Lactadherin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 102100023091 Motile sperm domain-containing protein 3 Human genes 0.000 description 1
- 101100236308 Mus musculus Gaa gene Proteins 0.000 description 1
- 101100074203 Mus musculus Lamp1 gene Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 108010071380 NF-E2-Related Factor 1 Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108010016592 Nuclear Respiratory Factor 1 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710111198 Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 241001272996 Polyphylla fullo Species 0.000 description 1
- 108700011066 PreScission Protease Proteins 0.000 description 1
- 101710198445 Programmed cell death 6-interacting protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
- 102100025132 Ras-related protein Rab-5B Human genes 0.000 description 1
- 102100031421 Ras-related protein Rap-2b Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 102000042463 Rho family Human genes 0.000 description 1
- 108091078243 Rho family Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091006313 SLC3A2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010083379 Sarcoglycans Proteins 0.000 description 1
- 102000006308 Sarcoglycans Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- 101150080431 Tfam gene Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100033080 Tropomyosin alpha-3 chain Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 101150114348 cycs gene Proteins 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000002641 enzyme replacement therapy Methods 0.000 description 1
- 208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000009113 gold standard therapy Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 201000007004 malignant hyperthermia Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 108010032037 rab5 GTP-Binding Proteins Proteins 0.000 description 1
- 108010062302 rac1 GTP Binding Protein Proteins 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 108700015182 recombinant rCAS Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- PJHKBYALYHRYSK-UHFFFAOYSA-N triheptanoin Chemical compound CCCCCCC(=O)OCC(OC(=O)CCCCCC)COC(=O)CCCCCC PJHKBYALYHRYSK-UHFFFAOYSA-N 0.000 description 1
- 229940078561 triheptanoin Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000004017 vitrification Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
Definitions
- the present invention generally relates to the treatment of genetic myopathies (muscular dystrophy, congenital myopathy, and metabolic myopathies), and more particularly, relates to a method of treating genetic myopathies using bioengineered exosomes.
- genetic myopathies muscle dystrophy, congenital myopathy, and metabolic myopathies
- Myopathy refers to disease in muscle tissue, and generally results in dysfunctional muscle fibers.
- the myopathies represent a broad category of acquired and genetic entities.
- the genetic myopathies are broadly categorized as muscular dystrophy, congenital myopathy and metabolic myopathies.
- Muscular dystrophy is a broad term relating to muscle diseases that occur due to a gene mutation usually in a structural gene (e.g. dystrophin, sarcoglycan, dystroglycan) or other muscle protein (e.g. calpain 3).
- the muscle eventually shows evidence of centralized nuclei, fibrosis, necrosis and sarcolemmal damage as reflected by an elevation of creatine kinase (CK) in the serum.
- CK creatine kinase
- the congenital myopathies are genetic disorders that often present in the first few years of life, are often less progressive than the muscular dystrophies, may have a characteristic pattern on histology (e.g. central cores, central nuclear myopathy, inclusion bodies, abnormal protein accumulation), and may have a normal serum CK level.
- the metabolic myopathies include glycogen storage diseases (e.g. McArdle disease, Tarui disease), fatty acid oxidation defects (VLCAD deficiency, trifunctional protein deficiency, CPT2 deficiency) and the mitochondrial cytopatbies.
- the defining hallmark of muscular dystrophy and the congenital myopathies is skeletal muscle weakness that can progress and require gait assistive devices (canes, walkers, wheelchairs), and may affect respiratory function leading to progressive respiratory failure and the need for assistive ventilation.
- gait assistive devices canes, walkers, wheelchairs
- the metabolic myopathies often show no weakness or hyperCKemia between episodes (except McArdle disease), yet show episodes of muscle breakdown (rhabdomyolysis) during exercise and other metabolic stressors.
- CK is elevated and there is often muscle pain, cramps and weakness.
- Variable symptomatic relief have been found using high carbohydrate intakes, MCT (medium chain triglyceride) supplementation, and triheptanoin for the fatty acid oxidation defects. Regular exercise is also helpful in all of the metabolic disorders and it is essential to avoid excessive and unaccustomed activity to avoid rhabdomyolysis.
- MCT medium chain triglyceride
- bioengineered exosomes are useful as a vehicle to deliver a protein and/or nucleic acid to muscle tissue to effectively treat myopathies such as muscular dystrophy, congenital myopathy and metabolic myopathies.
- a method of treating myopathy in a mammal comprising administering to the mammal exosomes genetically modified to incorporate a functional muscle protein useful to treat the myopathy and/or nucleic acid encoding the functional protein.
- a method of increasing the level or amount of a functional muscle protein in mammalian muscle comprising administering to the mammal exosomes genetically modified to incorporate the functional muscle protein or nucleic acid encoding the muscle protein.
- exosomes genetically modified to incorporate the functional muscle protein and/or nucleic acid encoding the muscle protein are provided.
- a method of treating a myopathy in a mammal resulting from expression of a mutated gene comprising administering to the mammal exosomes genetically modified to incorporate gene-silencing systems (e.g., siRNA) to reduce the expression of the mutated gene followed by administering to the mammal exosomes genetically modified to incorporate a functional muscle protein useful to treat the myopathy and/or nucleic acid encoding the muscle protein.
- gene-silencing systems e.g., siRNA
- a method of treating myopathy in a mammal comprising administering to the mammal exosomes genetically modified to incorporate gene-editing (e.g., CRISPR-Cas9, TALEN, zinc finger nucleases) systems to correct the inherent primary mutation leading to the myopathy.
- gene-editing e.g., CRISPR-Cas9, TALEN, zinc finger nucleases
- a method of increasing the activity of a muscle protein in a mammal comprising administering to the mammal exosomes which are genetically modified to incorporate a functional muscle protein and/or nucleic acid encoding the muscle protein.
- An exosome produced by a process that comprises: (a) isolating exosomes from a biological sample from an organism or from a conditioned medium from a cultured cell; and (b) introducing a modification into the exosome selected from the group consisting of: (i) at least one functional muscle protein or precursor thereof; (ii) at least one nucleic acid comprising a nucleotide sequence that encodes the functional muscle protein or precursor thereof; (iii) at least one fusion product comprising a skeletal muscle targeting sequence linked to an exosomal membrane marker; (iv) at least one nucleic acid comprising a nucleotide sequence that encodes the fusion product; and (v) two or more of (i), (ii,) (iii), and (iv).
- An exosome that comprises a modification selected from the group consisting of: (i) at least one functional muscle protein or precursor thereof; (ii) at least one nucleic acid comprising a nucleotide sequence that encodes the functional muscle protein or precursor thereof; (iii) at least one fusion product comprising a skeletal muscle targeting sequence linked to an exosomal membrane marker; (iv) at least one nucleic acid comprising a nucleotide sequence that encodes the fusion product; and (v) two or more of (i), (ii,) (iii), and (iv).
- exosome according to any of paragraphs Al - AS, that comprises a nucleic acid comprising a nucleotide sequence encoding a functional muscle protein or precursor thereof, wherein the nucleic acid is present in a lumen of the exosome.
- nucleic acid comprises mRNA or modified mRNA (modRNA, e.g. S methyl cytosine, or N6 methyladenine) encoding for a protein set forth in Table 1 and/or Table 2 and/or Table 3.
- modified mRNA e.g. S methyl cytosine, or N6 methyladenine
- B6 The exosome according to any one of paragraphs B2 - B3.1, wherein the protein is encoded by a gene selected from Myotilin (MYOT), Lamin A/C (LMNA), Caveolin 3 (CAV3), DnaJ heat shock protein family (Hsp40) member B6 (DNAJB6), Spectrin repeat containing, nuclear envelope 1 (SYNE1 ), Spectrin repeat containing, nuclear envelope 2 (S YNE2), Desmin (DES), Crystallin alpha B (CRYAB), LIM domain binding 3 (LDB3), Filamin C (FLNC), BCL2 associated athanogene 3 (BAG3), Dystrophia myotonica protein kinase (DMPK), CCHC- type zinc finger, nucleic acid binding protein (CNBP), Poly(A) binding protein, nuclear 1 (PABPN1), Titin (TTN), Double homeobox 4 (DUX4), Structural maintenance of chromosomes flexible hinge domain
- VMA21 Laminin subunit alpha 2 (LAMA2), Integrin subunit alpha 7 (1TGA7), Selenoprotein N, 1 (SEPN1), Collagen type VI alpha 1 (COL6AI), Collagen type VI alpha 2 (COL6A2), Collagen type VI alpha 3 (COL6A3), Docking protein 7 (DOK7), Protein O- mannosyltransferase 1 (POMT1), Protein O-mannosyltransferase 2 (POMT2), Protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-) (POMGNT1), FKTN, FKRP, Like- glycosyltransferase (LARGE), Isoprenoid synthase domain containing (ISPD), Protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-) (POMGNT2), Transmembrane protein S
- exosome according to any one of paragraphs Al - AS or Bl, that comprises at least one fusion product comprising a skeletal muscle targeting sequence linked to an exosomal membrane marker.
- exosome according to paragraph B7 or B8, wherein the exosomal membrane marker is selected from the group consisting of CD9, CD37, CDS3, CD63, CD81, CD82, CD151, an integrin, ICAM-1, CDD31, an annexin, TSG101, ALIX, lysosome-associated membrane protein 1, lysosome-associated membrane protein 2, lysosomal integral membrane protein and a fragment of any exosomal membrane marker that comprises at least one intact transmembrane domain.
- the exosomal membrane marker is selected from the group consisting of CD9, CD37, CDS3, CD63, CD81, CD82, CD151, an integrin, ICAM-1, CDD31, an annexin, TSG101, ALIX, lysosome-associated membrane protein 1, lysosome-associated membrane protein 2, lysosomal integral membrane protein and a fragment of any exosomal membrane marker that comprises at least one intact transmembrane domain.
- composition comprising exosomes according to any one of paragraphs Al - A5, and a pharmaceutically acceptable carrier.
- composition according to paragraph CI wherein the composition is substantially free of vesicles having a diameter less than 20 nm.
- composition according to paragraph CI or C2 wherein the composition is substantially free of vesicles having a diameter greater than 140 nm or greater than 120nm.
- composition according to claim C4 which exhibits a zeta potential having a magnitude of up to 200 mV, or up to 175 mV, or up to 150 mV, or up to 140 mV, or up to 130 mV, or up to 120 mV, or up to 110 mV, or up to 100 mV.
- Dl A method of increasing the amount of a muscle protein in muscles in a mammal, comprising administering to the mammal an exosome according to any one of paragraphs A1 - B13, or a composition according to any one of paragraphs CI- C5.
- a method of treating a genetic myopathy in a mammal comprising administering to the mammal an exosome according to any one of paragraphs Al - B13, or a composition according to any one of paragraphs C1- C5.
- D4 Use of an exosome according to any one of paragraphs Al - B13, or a composition according to any one of paragraphs CI- C5, for treating a genetic myopathy in a mammal.
- D5. The method or use according to any one of paragraphs Dl - D4, wherein the mammal is human.
- D6 The method or use according to paragraph DS, wherein the human has a genetic myopathy selected from Muscular dystrophy, limb-girdle, type IA, Muscular dystrophy, limb-girdle, type IB, Muscular dystrophy, limb-girdle, type IC, Muscular dystrophy, limb-girdle, type IE, Emery-Dreifiiss muscular dystrophy 4, Emery-Dreifuss muscular dystrophy S, Myopathy, myofibrillar, 1, Myopathy, myofibrillar, 2, Myopathy, myofibrillar, 4, Myopathy, myofibrillar, 5, Myopathy, myofibrillar, 6, Myotonic dystrophy 1, Myotonic dystrophy 2, Oculopharyngeal muscular dystrophy, Tibial muscular dystrophy, tardive, Facioscapulohumeral muscular dystrophy 1, Facioscapulohumeral muscular dystrophy 2, digenic, Muscular dystrophy,
- Figure 1 graphically illustrates dystrophin protein content in primary dermal fibroblasts from control and DMD patients after treatment with exosomes loaded with dystrophin (Dmd) mRNA as determined by quantification of confocal microscopy images.
- Dmd dystrophin
- Figure 2 graphically illustrates dystrophin protein expression in primary dermal fibroblasts from control and DMD patients after treatment with exosomes loaded with dystrophin (Dmd) mRNA as determined by immunoblot analysis.
- Dmd dystrophin
- Figure 3 illustrates dystrophin content in tibialis anterior (TA) muscle (A), soleus (SOL) muscle (B), and heart (C) in dystrophin-deficient mdx mice after treatment with vehicle, empty exosomes and dystroph in-mRN A loaded exosomes.
- TA tibialis anterior
- SOL soleus
- C heart
- Figure 4 graphically illustrates body (A), fast-twitch muscle (tibialis anterior (TA) (B), extensor digitorum longus (EDL) (C)) and slow-twitch (soleus (SOL)) muscle (D) weights in mdx mice after treatment with vehicle, empty exosomes, dystrophin mRNA loaded exosomes and prednisolone.
- TA anterior
- EDL extensor digitorum longus
- SOL slow-twitch muscle
- Figure 5 graphically illustrates maximum grip strength relative to TA muscle weight in mdx mice after treatment with vehicle, empty exosomes, dystrophin mRNA loaded exosomes and prednisolone.
- Figure 6 graphically illustrates serum creatine kinase (CK) levels in mdx mice after treatment with vehicle, empty exosomes, dystrophin mRNA loaded exosomes and prednisolone.
- CK serum creatine kinase
- Figure 7 graphically illustrates acid alpha glucosidase (OAA) activity in primary myotubes isolated from GAA wild-type (GA A + ⁇ and knock-out (GA A" 7 ') mice treated with naked GAA protein, empty exosomes (exosome control) or GAA protein-loaded exosomes.
- OAA acid alpha glucosidase
- Figure 8 graphically illustrates GAPDH gene expression in muscle cells treated with GAPDH siRNA or scRNA (scrambled RN A; control for siRNA) by delivery of naked scRNA or siRNA, scRNA or siRNA transfected with lipofectamine 2000 (LF2000), scRNA- or siRNA- loaded non-targeting exosomes and scRNA- or siRNA-loaded skeletal muscle-targeting exosomes.
- GAPDH siRNA or scRNA scrambled RN A; control for siRNA
- Figure 9 graphically illustrates gene expression of PGC-1 alpha and of downstream targets of PGC-1 alpha (A) and cytochrome c oxidase function (B) in primary mouse muscle cells treated with PGC-1 alpha siRNA or scRNA delivered by naked scRNA or siRNA, scRNA or siRNA transfected with lipofectamine 2000 (LF2000), scRNA- or siRNA-loaded non-targeting exosomes and scRNA- or siRNA-loaded skeletal muscle targeting exosomes.
- LF2000 lipofectamine 2000
- a method of treating myopathy in a mammal comprising administering to the mammal exosomes genetically modified to incorporate a muscle protein useful to treat the myopathy or nucleic acid encoding the protein.
- exosomes which have been genetically engineered to incorporate a muscle protein, and/or nucleic acid encoding a muscle protein are also provided.
- exosome refers to cell-derived vesicles having a diameter of between about 20 and 140 nm, for example, a diameter of about 20-120 nm, or a diameter of about 40-100 nm, including exosomes of a diameter of about 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm and/or 120 nm.
- Exosomes may be isolated from any suitable biological sample from a mammal, including but not limited to, whole blood, serum, plasma, urine, saliva, breast milk, cerebrospinal fluid, amniotic fluid, ascitic fluid, bone marrow and cultured mammalian cells (e.g.
- immature dendritic cells wild-type or immortalized
- induced and non-induced pluripotent stem cells fibroblasts, platelets, immune cells, reticulocytes, tumour cells, mesenchymal stem cells, satellite cells, hematopoietic stem cells, pancreatic stem cells, white and beige pre-adipocytes and the like.
- cultured cell samples will be in the cell- appropriate culture media (using exosome-free serum).
- Exosomes may be identified by specific surface markers not present in other vesicles, including surface markers such as tetraspanins, e.g.
- Exosomes may also be obtained from a non-mammalian biological sample, including cultured non-mammalian cells.
- exosomes from non-mammalian sources include surface markers which are isoforms of mammalian surface markers, such as isoforms of CD9 and CD63, which distinguish them from other cellular vesicles.
- mammalian surface markers such as isoforms of CD9 and CD63, which distinguish them from other cellular vesicles.
- the term "mammal” is meant to encompass, without limitation, humans, domestic animals such as dogs, cats, horses, cattle, swine, sheep, goats and the like, as well as non-domesticated animals such as, but not limited to, mice, rats and rabbits.
- non-mammal is meant to encompass, for example, exosomes from microorganisms such as bacteria, flies, worms, plants, fruit/vegetables (e.g. corn, pomegranate) and yeast.
- Exosomes may be obtained from the appropriate biological sample using any protocol that yields exosomes useful for therapeutic use, e.g. sufficiently pure, intact exosomes with good stability.
- any protocol that yields exosomes useful for therapeutic use e.g. sufficiently pure, intact exosomes with good stability.
- isolation techniques may be employed: centrifugation, filtration, ultracentrifugation, ultrafiltration, immunoaffinity capture and solvent or polymer-based methodologies.
- the isolation protocol includes the steps of: i) exposing the biological sample to a first centrifugation to remove cellular debris greater than about 7-10 microns in size from the sample and obtaining the supernatant following centrifugation; ii) subjecting the supernatant from step i) to centrifugation to remove microvesicles therefrom; iii) microfiltering the supernatant from step ii) and collecting the microfiltered supernatant; iv) subjecting the microfiltered supernatant from step iii) to at least one round of ultracentrifugation to obtain an exosome pellet; and v) re-suspending the exosome pellet from step iv) in a physiological solution, conducting a second ultracentrifugation In a density gradient and removing the exosome pellet fraction therefrom.
- the process of isolating exosomes from a biological sample includes a first step of removing undesired large cellular debris from the sample, i.e. cells, cell components, apoptotic bodies and the like greater than about 7-10 microns in size.
- This step is generally conducted by centrifugation, for example, at 1000-4000x g for 10 to 60 minutes at 4°C, preferably at 1500-2SOOx g, e.g. 2000x g, for a selected period of time such as 10-30 minutes, 12-28 minutes, 14-24 minutes, 15-20 minutes or 16, 17, 18 or 19 minutes.
- a suitable commercially available laboratory centrifuge e.g.
- Thermo-ScientificTM or Cole- ParmerTM is employed to conduct this isolation step.
- the resulting supernatant is subjected to a second optional centrifugation step to further remove cellular debris and apoptotic bodies, such as debris that is at least about 7-10 microns in size, by repeating this first step of the process, i.e. centrifugation at 1000-4000x g for 10 to 60 minutes at 4°C, preferably at 1500-2500x g, e.g. 2000x g, for the selected period of time.
- the supernatant resulting from the first centrifugation step(s) is separated from the debris-containing pellet (by decanting or pipetting it off) and may then be subjected to an optional additional (second) centrifugation step, including spinning at 12,000-15,000x g for 30-90 minutes at 4°C to remove intermediate-sized debris, e.g. debris that is greater than 6 microns size.
- this centrifugation step is conducted at 14,000x g for 1 hour at 4°C .
- the resulting supernatant is again separated from the debris- containing pellet.
- the resulting supernatant is collected and subjected to a third centrifugation step, including spinning at between 40,000-60,000x g for 30-90 minutes at 4°C to further remove impurities such as medium to small-sized micro vesicles greater than 0.3 microns in size e.g. in the range of about 0.3-6 microns.
- the centrifugation step is conducted at 50,000x g for 1 hour.
- the resulting supernatant is separated from the pellet for further processing. If the second centrifugation step is conducted, the third centrifugation step is optional.
- the supernatant is then filtered to remove debris, such as bacteria and larger microvesicles, having a size of about 0.22 microns or greater, e.g. using microfiltration.
- the filtration may be conducted by one or more passes through filters of the same size, for example, a 0.22 micron filter.
- filters of the same or of decreasing sizes e.g. one or more passes through a 40-50 micron filter, one or more passes through a 20-30 micron filter, one or more passes through a 10-20 micron filter, one or more passes through a 0.22-10 micron filter, etc.
- Suitable filters for use in this step include the use of 0.45 and 0.22 micron filters.
- the microfiltered supernatant may then be combined with a suitable physiological solution, preferably sterile, for example, an aqueous solution, a saline solution or a carbohydrate-containing solution, in a 1:1 ratio, e.g. 10 mL of supernatant to lOmL of physiological solution, to prevent clumping of exosomes during the subsequent ultracentrifugation and to maintain the integrity of the exosomes.
- a suitable physiological solution preferably sterile, for example, an aqueous solution, a saline solution or a carbohydrate-containing solution, in a 1:1 ratio, e.g. 10 mL of supernatant to lOmL of physiological solution, to prevent clumping of exosomes during the subsequent ultracentrifugation and to maintain the integrity of the exosomes.
- the exosomal solution is then subjected to ultracentrifugation to pellet exosomes and any remaining contaminating microvesicles (between
- This ultracentrifugation step is conducted at 110,000- 170,000x g for 1-3 hours at 4 °C, for example, 144,000x g for 2 hours or 170,000x g for 3 hours.
- This ultracentrifugation step may optionally be repeated, e.g. 2 or more times, in order to enhance results.
- Any commercially available ultracentrifuge e.g. Thermo-ScientificTM or BeckmanTM, may be employed to conduct this step.
- the exosome-containing pellet is removed from the supernatant using established techniques and re-suspended in a suitable physiological solution.
- the re-suspended exosome-containing pellet is subjected to density gradient separation to separate contaminating microvesicles from exosomes based on their density.
- density gradients may be used, including, for example, a sucrose gradient, a colloidal silica density gradient, an iodixanol gradient, or any other density gradient sufficient to separate exosomes from contaminating microvesicles (e.g. a density gradient that functions similar to the 1.100-1.200 g/ml sucrose fraction of a sucrose gradient).
- density gradients include the use of a 0.25-2.5 M continuous sucrose density gradient separation, e.g.
- sucrose cushion centrifugation comprising 20-50% sucrose; a colloidal silica density gradient, e.g. PercollTM gradient separation (colloidal silica particles of 15-30 nm diameter, e.g. 30%/70% w/w in water (free of KNase and DNase), which have been coated with polyvinylpyrrolidone (PVP)); and an iodixanol gradient, e.g. 6-18% iodixanol.
- the resuspended exosome solution is added to the selected gradient and subjected to ultracentrifugation at a speed between 110,000- 170,000x g for 1-3 hours.
- the resulting essentially pure exosome pellet is removed and re- suspended in physiological solution.
- the re-suspended exosome pellet resulting from the density gradient separation may be ready for use.
- the density gradient used is a sucrose gradient
- the exosome pellet is removed from the appropriate sucrose gradient fraction, and is ready for use, or may preferably be subjected to an ultracentrifugation wash step at a speed of 110,000- 170,000x g for 1 -3 hours at 4°C.
- the density gradient used is, for example, a colloidal silica or a iodixanol density gradient
- the resuspended exosome pellet may be subjected to additional wash steps, e.g.
- the exosome pellet from any of the centrifugation or ultracentrifugation steps may be washed between centrifugation steps using an appropriate physiological solution, e.g. saline.
- the final pellet is removed from the supernatant and may be re- suspended in a physiologically acceptable solution for use.
- the exosome pellet may be stored for later use, for example, in cold storage at 4°C, in frozen form or in lyophilized form, prepared using well-established protocols.
- the exosome pellet may be stored in any physiological acceptable carrier, optionally including cryogenic stability and/or vitrification agents (e.g. DMSO, glycerol, trehalose, polyhydroxylated alcohols (e.g. methoxylated glycerol, propylene glycol), M22 and the like).
- cryogenic stability and/or vitrification agents e.g. DMSO, glycerol, trehalose, polyhydroxylated alcohols (e.g. methoxylated glycerol, propylene glycol), M22 and the like).
- an immunoaffinity method of isolating exosomes from a biological sample may be utilized.
- the method comprises the steps of: i) optionally exposing the biological sample to a method of pre-enrichment to remove cellular and other debris; and ii) subjecting the sample to immunoaffinity capture with an antibody cocktail comprising at least three different antibodies to different exosome surface proteins, wherein the exosomes bind to the antibodies which bind or are bound to a solid support to yield an exosome-solid support complex from which the exosome are removed to yield isolated exosomes.
- the optional pre-enrichment may include one or more centrifugation steps, microfiltration, and ultracentrifugation with or without a density gradient, as previously described to remove cellular debris, microvesicles and/or bacteria.
- Biological samples with a high protein concentration such as serum may also be immuno-depleted using methods well-established in the art to remove high abundance proteins that may interfere with exosome capture.
- exosomal markers include the following: CD9 molecule (CD9), programmed cell death 6 interacting protein/ Alix (PDCD6IP), heat shock protein family A (Hsp70) member 8 (HSPA8), glyceraldehyde-3- phosphate dehydrogenase (GAPDH), actin, beta (ACTB), annexin A2 (ANXA2), CD63 molecule (CD63), syndecan binding protein (SDCBP), enolase 1 , (alpha) (ENOl), heat shock protein 90kDa alpha family class A member 1 (HSP90AA1), tumor susceptibility 101 (TSG101), pyruvate kinase, muscle (PKM), lactate dehydrogenase A (LDH A), eukaryotic translation elongation factor 1 alpha 1 (EEF1A1), t
- the antibody cocktail comprises 3 or more antibodies each having a specificity for a different exosome marker selected from the following proteins: Alix, Flotillin 1, CD9, CD63, CD81, TSG101 and LAMP2.
- the antibody cocktail may comprise an antibody with specificity to each of Alix, Flotillin 1, CD9 and CD63, or an antibody to each of Flotillin 1, CD9, CD63, CD81 and TSG101, or an antibody to each of Flotillin 1, CD9, CD63, CD81, TSG101 and ALIX, or an antibody with specificity to each of ALIX, TSG101 and CD9, or an antibody with specificity to each of CD81, CD63 and CD9.
- immunoaffmity capture techniques that may be used to capture exosomes using a selected antibody cocktail include, but are not limited to, immunoprecipitation, column affinity chromatography, magnetic-activated cell sorting, fluorescence-activated cell sorting, adhesion-based sorting and microfluidic-based sorting.
- the antibodies in the antibody cocktail may be utilized together, in a single solution, or may be utilized in two or more solutions that are administered simultaneously or consecutively.
- exosome separation methods may be utilized in conjunction with one or more of centrifugation, microfiltration and ultracentrifugation steps, to isolate exosomes from a biological sample.
- protein organic solvent precipitation PROSPR
- PROSPR protein organic solvent precipitation
- a sample via solvent-based precipitation (e.g. acetone), leaving lipid-based microvesicles, including exosomes, in suspension within the sample, for further separation as above-described.
- solvent-based precipitation e.g. acetone
- polymer-based separation may be used in which suitable polymers such as polyethylene-glycol and variants thereof are mixed with an exosome-containing sample to separate exosomes from the sample into the polymer layer.
- exosome isolation protocols advantageously provide a means to obtain exosomes, such as mammalian exosomes, which are at least about 90% pure, and preferably at least about 95% or greater pure, i.e. referred to herein as "essentially free" from cellular debris, apoptotic bodies and microvesicles having a diameter less than 20 or greater than 140 nm, for example, free from particles having a diameter of less than 40 or greater than 120 nm (as measured, for example, by dynamic light scattering), and which are biologically intact, e.g. not clumped or in aggregate form, and not sheared, leaky or otherwise damaged.
- Exosomes isolated according to the methods described herein exhibit a high degree of stability, evidenced by the zeta potential of a mixture/solution of such exosomes, for example, a zeta potential of at least a magnitude of 30 mV, e.g. ⁇ -30 or > +30, and preferably, a magnitude of at least 40 mV, 50 mV, 60 mV, 70 mV, 80 mV, or greater.
- zeta potential refers to the electrokinetic potential of a colloidal dispersion, and the magnitude of the zeta potential indicates the degree of electrostatic repulsion between adjacent, similarly charged particles (exosomes) in a dispersion.
- exosomes For exosomes, a zeta potential of magnitude 30 mV or greater indicates moderate stability, i.e. the solution or dispersion will resist aggregation, while a zeta potential of magnitude 40-60 mV indicates good stability, and a magnitude of greater than 60 mV indicates excellent stability.
- high quantities of exosomes are achievable by the present isolation method, e.g. exosomes in an amount of about 100-2000 ⁇ g total protein can be obtained from 1-4 mL of mammalian serum or plasma, or from 15-20 mL of cell culture spent media (from at least about 2 x 10 6 cells).
- solutions comprising exosomes at a concentration of at least about S ⁇ g/ ⁇ L, and preferably at least about 10-25 ⁇ g/ ⁇ L, may readily be prepared due to the high exosome yields obtained by the present method.
- the term "about” as used herein with respect to any given value refers to a deviation from that value of up to 10%, either up to 10% greater, or up to 10% less.
- Exosomes isolated in accordance with the methods herein described which beneficially retain integrity, and exhibit a high degree of purity (being "essentially free” from entities having a diameter less than 20 nm and greater than 140 ran and/or greater than 120 nm), stability and biological activity both in vitro and in vivo, have not previously been achieved.
- tile present exosomes are uniquely useful, for example, diagnostically and/or therapeutically, e.g. for the in vivo delivery of protein and/or nucleic acid. They have also been determined to be non- allergenic/non-immunogenic, and thus, safe for autologous, allogenic, xenogenic and cross- kingdom use.
- Isolated exosomes may then be genetically engineered to incorporate an exogenous protein, e.g. an exogenous protein such as a muscle protein, or exogenous nucleic acid encoding a selected muscle protein, or both.
- exogenous protein e.g. an exogenous protein such as a muscle protein
- exogenous nucleic acid encoding a selected muscle protein, or both.
- muscle protein is used herein to refer to any protein that is expressed in, or active in, muscle, including skeletal, smooth and cardiac muscle.
- loaded exosome is used herein to refer to exosomes which have been genetically engineered to incorporate an exogenous protein, nucleic acid encoding a protein or other biological substances.
- exosome is used herein to refer to exosomes which have not been genetically engineered to incorporate an exogenous protein, nucleic acid encoding a protein or other biological substances.
- exogenous is used herein to refer to protein or nucleic acid originating from a source external to the exosomes.
- Nucleic acid encoding the protein may be produced using known synthetic techniques, incorporated into a suitable expression vector using well established methods to form a protein-encoding expression vector which is introduced into isolated exosomes using known techniques, e.g. electroporation, transfection using cationic lipid-based transfection reagents, and the like.
- the selected protein may be produced using recombinant techniques, or may be otherwise obtained, and then may be introduced directly into isolated exosomes by electroporation or transfection. More particularly, electroporation applying voltages in the range of about 20-1000 V/cm may be used to introduce nucleic acid or protein into exosomes.
- Transfection using cationic lipid-based transfection reagents such as, but not limited to, Lipofectamine® MessengerMAXTM Transfection Reagent, Lipofectamine® RNAiMAX Transfection Reagent, Lipofectamine® 3000 Transfection Reagent, or Lipofectamine® LTX Reagent with PLUSTM Reagent, may also be used.
- the amount of transfection reagent used may vary with the reagent, the sample and the cargo to be introduced.
- an amount in the range of about 0.15 uL to 10 uL may be used to load 100 ng to 2500 ng mRNA or protein into exosomes.
- Other methods may also be used to load protein into exosomes including, for example, the use of cell- penetrating peptides.
- Exosomes isolated in accordance with the methods herein described which beneficially retain integrity, and exhibit a high degree of purity and stability, readily permit loading of exogenous protein and/or nucleic acid in an amount of at least about 1 ng nucleic acid (e.g. mRNA) per 10 ug of exosomal protein or 30 ug protein per 10 ug of exosomal protein.
- nucleic acid e.g. mRNA
- a protein-encoding expression vector as above described may be introduced directly into exosome-producing cells, e.g. autologous, allogenic, or xenogenic cells, such as immature dendritic cells (wild-type or immortalized), induced and non-induced pluripotent stem cells, fibroblasts, platelets, immune cells, reticulocytes, tumour cells, mesenchymal stem cells, satellite cells, hematopoietic stem cells, pancreatic stem cells, white and beige pre-adipocytes and the like, by electroporation or transfection as described above. Following a sufficient period of time, e.g. 3-7 days to achieve stable expression of the protein, exosomes incorporating the expressed protein may be isolated from the exosome-producing cells as described herein.
- exosomes incorporating the expressed protein may be isolated from the exosome-producing cells as described herein.
- exosomes may be modified to express or incorporate a target-specific fusion product.
- target-specific fusion product is used herein to refer to exosomes which have been modified to express or incorporate a target-specific fusion product.
- non-targeting exosome is used herein to refer to exosomes which have not been modified to express or incorporate any target-specific fusion product.
- the target-specific fusion product comprises a muscle targeting sequence, linked to an exosomal membrane marker.
- exosomal membrane marker of the fusion product will localize the fusion product within the membrane of the exosome to enable the targeting sequence to direct the exosome to the intended target.
- exosome membrane markers include, but are not limited to: tetraspanins such as CD9, CD37, CD53, CD63, CD81, CD82 and CD151; targeting or adhesion markers such as integrins, ICAM-1 and CDD31; membrane fusion markers such as annexins, TSO101, ALIX; and other exosome transmembrane proteins such as LAMP (lysosome- associated membrane protein), e.g. LAMP 1 or 2, and LIMP (lysosomal integral membrane protein).
- LAMP lysosome- associated membrane protein
- LAMP 1 or 2 lysosomal integral membrane protein
- All or a fragment of an exosome membrane marker may be utilized in the fusion product provided that any fragment includes a sufficient portion of the membrane marker to enable it to localize within the exosome membrane, i.e. the fragment comprises at least one intact transmembrane domain to permit localization of the portion of the membrane marker into the exosomal membrane.
- the target-specific fusion product also includes a muscle targeting sequence, i.e. a protein or peptide sequence which facilitates the targeted uptake of the exosome into muscle.
- a muscle targeting sequence i.e. a protein or peptide sequence which facilitates the targeted uptake of the exosome into muscle.
- suitable skeletal muscle targeting sequences include, but are not limited to, muscle- binding peptides such as SERCA2, acetylcholine receptor epsilon, SCN4A, muscle specific creatine kinase (CK-MM) and fragments thereof, including the peptide sequence, TARGEHKEEELI (SEQ ID NO: 1).
- Cardiac muscle targeting sequences include sequences derived from cardiac troponin.
- Exosomes incorporating a muscle-specific fusion product may be produced using recombinant technology.
- an expression vector encoding the muscle-specific fusion product is introduced by electroporation or transfection into exosome-producing cells isolated from an appropriate biological sample.
- exosomes generated by the exosome-producing cells, and including the fusion product may be isolated as described.
- the desired muscle protein, nucleic acid encoding the protein or both may be introduced into isolated exosomes incorporating a muscle-targeting fusion product (muscle- targeting exosomes) as previously described, using electroporation or transfection methods. Addition to the exosome of both the desired muscle protein and nucleic acid encoding the same muscle protein may increase delivery efficiency of the protein.
- Exosomes genetically engineered to incorporate a muscle protein, and/or nucleic acid encoding the protein may be used to deliver the protein and/or nucleic acid to a mammal in vivo in the treatment of a pathological myopathy in which the protein is defective or absent (due to a genetic mutation in the gene encoding the protein) to upregulate the activity of the protein and thereby treat the myopathy.
- Exosomes either incorporating a muscle-targeting fusion product or not including such a targeting fusion product may be used to deliver the muscle protein (and/or nucleic acid encoding the protein) to muscle tissue in vivo in the treatment of a myopathy.
- AR autosomal recessive
- AD autosomal dominant
- XLR X-Hnked recessive
- Table 1 identifies the disease, the affected protein and affected or mutated gene involved in each disease, the type of mutation, the mRNA transcript sequence information (via NCBI (National Centre for Biotechnology Information) GenBank accession numbers) for the functional gene (which could be incorporated into the exosomes to treat a disease), and the corresponding protein sequence information for the proteins useful to treat each disease.
- Examples of congenital and other myopathies that are caused by genetic mutations and that may be treated using the present engineered exosomes are set out in Table 2 below.
- Table 2 identifies the disease, the affected protein and affected or mutated gene involved in each disease, the type of mutation (Mut), the mRNA transcript sequence information (via NCBI GenBank accession numbers) for the functional gene (which could be incorporated into the exosomes to treat a disease), and the corresponding protein sequence information for the proteins useful to treat each disease.
- Examples of metabolic myopathies that are caused by genetic mutations and that may be treated using the present engineered exosomes are set out in Table 3 below.
- Table 3 identifies the disease, the affected protein and affected or mutated gene involved in each disease, the type of mutation, the mRNA transcript sequence information (via the NCBI GenBank accession numbers) for the functional gene (which could be incorporated into the exosomes to treat a disease), and the corresponding protein sequence information for the proteins useful to treat each disease.
- a muscle protein or nucleic acid encoding the muscle protein for incorporation into exosomes may be a functional native mammalian protein or nucleic acid, including for example, a protein or nucleic acid from human and non-human mammals, or a functionally equivalent protein or nucleic acid.
- the term "functionally equivalent” is used herein to refer to a protein which exhibits the same or similar function to the native protein (retains at least about 30% of the activity of native protein), and includes all isoforms, variants, recombinant produced forms, and naturally-occurring or artificially modified forms, i.e.
- the term “functionally equivalent” also refers to nucleic acid, e.g. mRNA, DNA or cDNA, encoding a muscle protein, and is meant to include any nucleic acid sequence which encodes a functional muscle protein, including all transcript variants, variants that encode protein isoforms, variants due to degeneracy of the genetic code, artificially modified variants, and the like. Protein modifications may include, but are not limited to, one or more amino acid substitutions (for example, with a similarly charged amino acid, e.g.
- substitution of one amino acid with another each having non-polar side chains such as valine, leucine, alanine, isoleucine, glycine, methionine, phenylalanine, tryptophan, proline
- substitution of one amino acid with another each having basic side chains such as histidine, lysine, arginine
- substitution of one amino acid with another each having acidic side chains such as aspartic acid and glutamic acid
- substitution of one amino acid with another each having polar side chains such as cysteine, serine, threonine, tyrosine, asparagine, glutamine), additions or deletions
- modifications to amino acid side chains addition of a protecting group at the N- or C- terminal ends of the protein, fusion products (e.g.
- Suitable modifications will generally maintain at least about 70% sequence similarity with the active site and other conserved domains of a native muscle protein, and preferably at least about 80%, 90%, 95% or greater sequence similarity.
- Nucleic acid modifications may include one or more base substitutions or alterations, addition of 5' or 3' protecting groups, and the like, preferably maintaining significant sequence similarity, e.g. at least about 70%, and preferably, 80%, 90%, 95% or greater.
- Targeting and non-targeting exosomes including a selected protein, such as a muscle protein, or nucleic acid encoding the protein in accordance with the invention may be formulated for therapeutic use by combination with a pharmaceutically or physiologically acceptable carrier.
- pharmaceutically acceptable or physiologically acceptable mean acceptable for use in the pharmaceutical and veterinary arts, i.e. not being unacceptably toxic or otherwise unsuitable for physiological use.
- the selected carrier will vary with the intended utility of the exosome formulation.
- exosomes are formulated for administration by infusion or injection, e.g.
- a medical-grade, physiologically acceptable carrier such as an aqueous solution in sterile and pyrogen-free form, optionally, buffered or made isotonic.
- the carrier may be distilled water (DNase- and RNase-free), a sterile carbohydrate-containing solution (e.g. sucrose or dextrose) or a sterile saline solution comprising sodium chloride and optionally buffered.
- Suitable sterile saline solutions may include varying concentrations of sodium chloride, for example, normal saline (0.9%), half-normal saline (0.45%), quarter-normal saline (0.22%), and solutions comprising greater amounts of sodium chloride (e.g. 3%-7%, or greater).
- Saline solutions may optionally include additional components, e.g. carbohydrates such as dextrose and the like. Examples of saline solutions including additional components, include Ringer's solution, e.g.
- PBS phosphate buffered saline
- TRIS hydroxymethyl) aminomethane hydroxymethyl) aminomethane
- TBS TRIS-buffered saline
- HBSS Hank's balanced salt solution
- EBSS Earle's balanced solution
- SSC standard saline citrate
- HBS HEPES- buffered saline
- GBSS Gey's balanced salt solution
- the present exosomes are formulated for administration by routes including, but not limited to, oral, intranasal, enteral, topical, sublingual, intra-arterial, intramedullary, intrauterine, intrathecal, inhalation, ocular, transdermal, vaginal or rectal routes, and will include appropriate carriers in each case.
- exosomes may be formulated in normal saline, complexed with food, in a capsule or in a liquid formulation with an emulsifying agent (honey, egg yolk, soy lecithin, and the like).
- Oral compositions may additionally comprise adjuvants including sugars, such as lactose, trehalose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and derivatives thereof, such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetates; powdered tragancanth; malt; gelatin; talc; stearic acids; magnesium stearate; calcium sulfate; vegetable oils, such as peanut oils, cotton seed oil, sesame oil, olive oil and corn oil; polyols such as propylene glycol, glycerine, sorbital, mannitol and polyethylene glycol; agar; alginic acids; water; isotonic saline and phosphate buffer solutions.
- sugars such as lactose, trehalose, glucose and sucrose
- starches such as corn starch and potato starch
- Exosome compositions for topical application may be prepared including appropriate carriers. Creams, lotions and ointments may be prepared for topical application using an appropriate base such as a triglyceride base. Such creams, lotions and ointments may also contain a surface active agent. Aerosol formulations may also be prepared in which suitable propellent adjuvants are used. Other adjuvants may also be added to the composition regardless of how it is to be administered, for example, anti-microbial agents, antioxidants and other preservatives may be added to the composition to prevent microbial growth and/or degradation over prolonged storage periods.
- Targeting and non-targeting exosomes according to the present invention are useful in a method to treat myopathies involving a defective/missing muscle protein, or a condition involving lack of expression of a muscle protein.
- the terms 'treat", “treating” or 't reatment” are used herein to refer to methods that favorably alter a myopathy, including those that moderate, reverse, reduce the severity of, or protect against, the progression of the myopathy.
- a therapeutically effective amount of exosomes (targeting or non- targeting) loaded with a selected muscle protein, and/or nucleic acid encoding a muscle protein are administered to a mammal.
- terapéuticaally effective amount is an amount of exosome required to treat the myopathy, while not exceeding an amount which may cause significant adverse effects.
- Exosome dosages that are therapeutically effective will vary on many factors including the nature of the condition to be treated as well as the particular individual being treated.
- Appropriate exosome dosages for use include dosages sufficient to result in an increase in activity or amount of the target muscle protein in the patient by at least about 10%, and preferably an increase in activity of the protein or amount of the target muscle protein of greater than 10%, for example, at least 20%, 30%, 40%, 50% or greater.
- the dosage may be a dosage of exosome that delivers from about 0.1 mg/kg to about 100 mg/kg, such as 0.1- 50 mg/kg, or 0.1-10 mg/kg, of the desired protein, or an exosome dosage that delivers a sufficient amount of nucleic acid to yield about 0.1 mg/kg to about 100 mg/kg, such as 0.1 -50 mg/kg, or 0.1 - 10 mg/kg, of the desired protein.
- the dosage of mRNA encoding a particular protein may be in the range of about 1 ug/kg to 1 mg/kg to treat a given myopathy.
- the dosage may be a dosage of exosomes sufficient to deliver about lng/kg to about lOOmg/kg of gene-editing protein or nucleic acid.
- the term "about” is used herein to mean an amount that may differ somewhat from the given value, by an amount that would not be expected to significantly affect activity or outcome as appreciated by one of skill in the art, for example, a variance of from 1-10% from the given value.
- exosomes comprising a muscle protein, and/or nucleic acid encoding the protein, for example, to treat a myopathy, may be used in conjunction with (at different times or simultaneously, either in combination or separately) one or more additional therapies to facilitate treatment, including but not limited to, exercise, physiotherapy, stretching, high protein and/or carbohydrate diet, creatine monohydrate supplementation and corticosteroid treatment.
- the present method of treating myopathy in a mammal may include administration to the mammal of exosomes (for example, isolated as described above), genetically modified to incorporate gene-silencing systems (e.g., siRNA) to reduce the expression of a mutated gene followed by administration to the mammal of exosomes genetically modified to incorporate a protein useful to treat the myopathy and/or nucleic acid encoding the protein.
- siRNA suitable to target a mutated gene that expresses a product that causes or amplifies the myopathy.
- mutations that may be targeted with siRNA include, but are not limited to, mutations that result in myotonic muscular dystrophy type 1 and 2, occulopharyngeal muscular dystrophy, malignant hyperthermia (RYR1 and CACNA1S mutations), and other dominant-negative myopathies due to mutations in TPM3, COL6A1, COL6A2, COL6A3, ⁇ B-crystalin, and filamin.
- a method of treating myopathy in a mammal may include administering to the mammal exosomes genetically modified to incorporate genome- editing systems to correct the inherent primary mutation leading to the myopathy.
- Genome editing may include gene insertions, deletions, modifications (e.g. nucleotide transitions, transversions, insertions or deletions of one or more nucleotides or duplications of any nucleotide sequence), gene activation and gene silencing.
- genome editing may be for the purpose of correcting an undesirable gene mutation, introducing a gene mutation (e.g. including gene mutations to yield a transgenic animal model), altering a gene sequence (e.g.
- nuclease genome editing systems include, but are not limited to, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) nuclease system, e.g. including a targeting gRNA and a CRISPR-associated (Cas) gene, such as CRISPR-Cas9, Transcription Activator-Like Effector Nucleases (TALEN) and mito-TALEN, Zinc-Finger Nucleases (ZFN) and aptamer-guided delivery of therapeutic nucleic acids, e.g. small interfering RNA, micro RNA, anti-microKNA, antagonist RNA, small hairpin RNA and other RNA, DNA or peptide (including affuners) based aptamers.
- CRISPR Clustered Regularly Interspaced Short Palindromic Repeats
- Cas CRISPR-associated gene
- TALEN Transcription Activator-Like Effector Nucleases
- ZFN Zinc-Finger Nucleases
- the exosome is genetically modified to express or incorporate a CRISPR nuclease system, such as a CRISPR/Cas9 Type II genome editing system, including a Cas 9 nuclease, and a guide RNA (gRNA), which comprises a fusion of crRNA (CRISPR RNA) and a trans-activating RNA (tracrRNA).
- CRISPR RNA includes a targeting RNA sequence and a distinctive array of non-coding direct RNA repeats.
- the crRNA and tracrRNA are related to a selected Cas nuclease.
- the crRNA and tracrRNA components of the gRNA
- the Cas nuclease are indicated to be “related" which means that the crRNA and tracrRNA are specific for and recognized by one or more particular Cas nucleases.
- the targeting sequence of the guide RNA is a strand of RNA that is homologous to a region on a target gene, i.e. a gene to be edited or silenced, associated with a myopathy.
- Target genes may be genes associated with genetic disease, including hereditary disease such as autosomal dominant, autosomal recessive and X-linked myopathies.
- the targeting RNA may comprise from 10-30 nucleotides, e.g. from 15-25 nucleotides, such as 20 nucleotides, and may comprise a OC content of about 40-80%.
- the CRISPR system may be utilized to disrupt expression of a gene by insertion or deletion of nucleotides to disrupt the Open Reading Frame (ORF) of a target gene, or to introduce a premature stop codon therein.
- ORF Open Reading Frame
- NHEJ Non-Homologous End Joining
- the CRISPR system may also be used to edit (e.g. to correct a gene mutation) by utilizing homology directed repair, in which an editing region (also known as a repair template) is included in the CRISPR system.
- the editing region or repair template incorporates an edit (e.g.
- the size of the editing region or repair template is not particularly restricted, and may include a single nucleotide edit, or edits of up to 100 nucleotides or more.
- the targeting sequence of the gRNA is selected such that it targets a site within the target gene that is proximal (e.g. within about 2-5 nucleotides or more) to a protospacer adjacent motif (PAM) located within the target gene.
- the PAM is recognized by the Cas nuclease and permits Cas nuclease binding.
- the homologous arms will generally increase in size with the size of the editing region or repair template, for example, for edits of less than about 50 nucleotides, the homologous arms may be in the range of about 100- 150 nucleotides in length, while larger editing regions may incorporate homologous arms of about 200-800 nucleotides, or more. Edits may also be introduced using CRISPR which facilitate expression of a target gene, e.g. edits which introduce a transcription factor that promote gene expression.
- the gRNA additionally incorporates related crRNA and a tracrRNA sequences, which interact with and function to direct the Cas nuclease to the target gene to catalyze cleavage of the target gene by the Cas nuclease.
- crRNA, tracrRNA, and Cas nuclease sequences are related, these sequences may be native or mutated sequences, provided that any mutations thereof do not have an adverse impact on function.
- Selection of suitable gRNA sequences can be achieved using methods known in the art, such as using programs for this purpose (e.g. CRISPR-MIT (http://crispr.mit.edu/), CHOPCHOP (https://chopchop.rc.fas.harvard.edu/index.php), or E-CRISP (http://www.e-crisp.org/E- CRISP/index.html).
- the Cas nuclease may, for example, be a Cas 9 -based nuclease.
- a Cas 9 nuclease examples include wild-type Cas 9 (a double nickase) from Streptococcus pyogenes (SP), Staphylococcus aureus (SA), Neisseria meningitidis (NM), Streptococcus thermophilus (ST), and Treponema denticola (TD), as well as mutated recombinant Cas 9, e.g.
- Wild-type and single nickase Cas 9 may be used to edit genes, for example, that result in autosomal recessive, X-linked recessive or autosomal dominant myopathies, in order to correct the mutation.
- the mutated Cas 9 may also be a nuclease-deficient Cas (for example, incorporating both D10A and H840A to inactivate nuclease function) which binds but does not cleave and thereby silences a gene.
- Nuclease-deficient Cas 9 may be used to treat an autosomal recessive myopathy, to prevent or minimize expression of a dysfunctional mutated protein, which may interfere with the activity of the desired functional protein.
- the targeting RNA is an RNA strand complementary to a site on the target gene which is 3-4 nucleotides upstream of a PAM sequence recognized by the Cas nuclease.
- the targeting RNA does not itself include a PAM sequence.
- nucleic acid encoding a nuclease genome editing system such as a selected CRISPR nuclease system including gRNA, DNA repair template and a Cas nuclease
- a nuclease genome editing system such as a selected CRISPR nuclease system including gRNA, DNA repair template and a Cas nuclease
- a selected CRISPR nuclease system including gRNA, DNA repair template and a Cas nuclease may be produced using known synthetic techniques and then incorporated into the same or different expression vectors under the control of an appropriate promoter. Suitable vectors for such expression are known in the art.
- expression vectors incorporating the selected nuclease genome editing system may be obtained commercially.
- Expression vectors incorporating the nuclease genome editing system may be introduced into exosomes using electroporation or transfection using cationic lipid-based transfection reagents.
- the components of the nuclease editing system may be introduced directly into exosomes as single- stranded (ss) DNA using similar introduction techniques.
- the DNA repair template may be introduced into exosomes as ssDNA
- the gRNA and Cas nuclease may be introduced into exosomes as oligonucleotides/mRNA
- the Cas nuclease may be introduced into exosomes as a protein (produced using recombinant techniques, or otherwise obtained).
- the different components of the nuclease editing system may be introduced into exosomes in various forms and/or combinations of nucleic acid, protein and expression vector incorporating DNA.
- Class 2 CRISPR technology (such as CRISPR-spCAS9- HF) can be incorporated into exosomes and used as a gene editing system.
- exosomes of the present invention provide many advantages over current treatment methods.
- exosomes represent a physiological treatment method since they are an entity that naturally exists within a mammal.
- the present exosomes provide stability and protection from degradation and denaturation to the proteins/enzymes and/or nucleic acid that they deliver. This in turn facilitates the delivery of higher levels of protein or nucleic acid than is achieved by many other modes of delivery.
- the use of exosomes to deliver protein/nucleic acid results in a minimal immune reaction to the protein or nucleic acid being delivered because exosomes may be obtained from cells that do not induce any significant immunogenic response or which are not toxic (e.g.
- exosomes from immature dendritic cells may be tailored to incorporate a targeting sequence that results in enhanced recognition and fusion with the target tissue, e.g. muscle, to result in increased specificity with respect to targeted protein/nucleic acid delivery.
- Example 1 Dystrophin rescue in fibroblasts from Duchenne Muscular Dystrophy patients
- Exosome isolation - Dendritic cells were isolated from mouse bone marrow progenitor cells and from human peripheral blood mononuclear cells (collected using Ficoll gradient separation of human blood). Briefly, femur and tibia were carefully harvested from mice and were flushed with HBSS media to collect bone marrow progenitor cells. The bone marrow progenitor cells were cultured in OlutaMAX-DMEM media (Life Technologies) containing 10% FBS, ImM sodium pyruvate, 0.5% penicillin-streptomycin, and mouse recombinant granulocyte/macrophage colony-stimulating factor (R&D Systems).
- Both human and mouse dendritic cells were further purified using EasySepTM Mouse and Human Pan-DC Enrichment Kit (Stem Cell Technologies). Dendritic cells were then cultured with the aforementioned media (GlutaMAX-DMEM media for mouse DC and IMDB media for human DC). Media was pre-spun at 170,000x g for 2 hours at 37 °C for 4 days to ensure that the subsequent exosome pellet would not be contaminated with bovine microvesicles and/or exogenous exosomes.
- the dendritic cells were then grown to about 80% confluency in alpha minimum essential medium supplemented with ribonucleosides, deoxyribonucleosides, 4 mM L-glutamine, 1 mM sodium pyruvate, 5 ng/mL murine GM-CSF, and 20% fetal bovine serum.
- alpha minimum essential medium supplemented with ribonucleosides, deoxyribonucleosides, 4 mM L-glutamine, 1 mM sodium pyruvate, 5 ng/mL murine GM-CSF, and 20% fetal bovine serum.
- conditioned media collection cells were washed twice with sterile PBS (pH 7.4, Life Technologies) and the aforementioned media (with exosome-depleted fetal bovine serum) was added.
- Conditioned media from human and mouse immature dendritic cell culture was collected after 48 hours.
- the media (10 mL) was spun at 2,000x g for 15 min at 4°C to remove any cellular debris. This was followed by an optional 2000x g spin for 60 min at 4°C to further remove any contaminating nonadherent cells. The supernatant was then spun at 14,000x g for 60 min at 4°C. The resulting supernatant was optionally spun at S0,000x g for 60 min at 4°C. The supernatant was then filtered through a 40 ⁇ m filter, followed by filtration through a 0.22 um syringe filter (twice). The supernatant was then carefully transferred into ultracentrifuge tubes and diluted with an equal amount of sterile PBS (pH 7.4, Life Technologies).
- the exosomal pellet-containing fraction at the gradient interface was isolated carefully, diluted in 50 mL of sterile PBS (pH 7.4, Life Technologies), followed by a final spin for 90 minutes at 100,000x-170,000x g at 4°C to obtain purified exosomes.
- the resulting exosomal pellet was resuspended in sterile PBS or sterile 0.9% saline for downstream use.
- Exosomal fraction purity was confirmed by sizing using a Beckman DelsaMax dynamic light scattering analyzer showing minimal contamination outside of the 40-120 nm size range, and by immuno-gold labelling/Western blotting using the exosome membrane markers, CD9, CD63, TSG101 and ALIX.
- Exosomes were loaded with dystrophin mRNA using a cationic lipid-based transfection reagent (Lipofectamine® MessengerMAXTM Transfection Reagent, Life Technologies). After transfection, exosomes were spun for 2 hours at 170,000x g at 4°C followed by re-suspension in 5% (wt/vol) glucose in 0.9% sterile saline solution.
- a cationic lipid-based transfection reagent Lipofectamine® MessengerMAXTM Transfection Reagent, Life Technologies.
- Dmd mRNA-loaded exosomes Primary dermal fibroblasts isolated from four DMD patients, and two age/gender-matched controls, were treated with human Dmd mRNA (100 ng), empty exosomes (10 ug of total exosomal protein in 0.9% sterile saline), and with human Dmd mRNA-loaded exosomes (100 ng of mRNA packaged in 10 ug of total exosomal protein in 0.9% sterile saline) for 48 hours. Cells were then seeded on glass-bottom chamber slides, washed with PBS, fixed with 4% paraformaldehyde, and incubated with anti- dystrophin (Abeam) antibody.
- Abeam anti- dystrophin
- Results show almost complete rescue of dystrophin protein in fibroblasts treated with exosomes loaded with dystrophin (Dmd) mRNA as compared to those treated with either dystrophin (Dmd) mRNA or exosomes not loaded with dystrophin mRNA ( Figure 1).
- Results show complete rescue of dystrophin protein in fibroblasts treated with exosomes loaded with dystrophin (Dmd) mRNA as compared to those treated with either dystrophin (Dmd) mRNA or exosomes not loaded with dystrophin mRNA ( Figure 2).
- DMD Duchenne Muscular Dystrophy
- mice (lacking functional dystrophin gene) were obtained from Jackson Laboratories (Strain 001801), and housed at McMaster University's Central Animal Facility. Mice were bred in accordance with rules set by McMaster University's Animal Research and Ethics board, following guidelines set forth by the Canadian Council of Animal Care.
- prednisolone which is the gold-standard therapy for Duchenne muscular dystrophy (PRED; administered at a dosage of 2 mg/kg body weight/day, delivered as two bolus i.p.
- mice were sacrificed two days after the last injection by cervical dislocation. Blood was collected immediately after sacrifice in EDTA-coated microfuges, followed by centrifugation at 1500 g for 15 mins at 4°C, supernatant (plasma) collected and frozen at -80 °C Tissues (EDL, SOL, TA and diaphragm) were extracted, snap frozen, weighed and stored at -80 °C until further analysis.
- Plasma supernatant
- Tissues EDL, SOL, TA and diaphragm
- Membranes were then incubated with the appropriate anti-rabbit HRP-linked secondary antibody (1 : 10,000) and visualized with an enhanced chemiluminescence detection reagent (GE Healthcare, Cleveland, OH) and the ChemiDoc MP system (Biorad). Ponceau staining was used to ensure equal loading across all gels (not shown).
- Dystrophin mRNA-loaded exosome therapy restores dystrophin content and improves functional outcomes in mdx mice
- exosomes were engineered to incorporate alpha acid glucosidase (OAA) and deliver the protein to the muscle of OAA deficient mice.
- OAA alpha acid glucosidase
- OAA Mouse alpha acid glucosidase
- pOEX GST-fusion vector OE Healthcare Life Sciences
- the vector was maintained using the competent E. coli DHSalpha line (Life Technologies).
- the pGEX mammalian vector was then transfected into Chinese Hamster Ovary Cells (CHO; ATCC Cat. CCL-661) for mass production of active GAA enzyme.
- CHO cells transfected with G AA-pOEX vector were lysed and CHO cell lysate was cleared using ultra-performance resins for OST-tagged fusion protein purification (GE Healthcare Life Sciences). Over 80% of the recombinant protein was eluted after 3 washes. Elution #1 and Elution #2 were combined to obtain a high yield of protein. GST tag was removed from active GAA using PreScission Protease (GE Healthcare Life Sciences).
- Exosomes were produced as described in Example 1. Exosomes were loaded with GAA protein using cationic lipid-based transfection reagents (Lipofectamine® MessengerMAXTM Transfection Reagent, Life Technologies). After transfection, exosomes were spun for 2 hours at 170,000x g at 4°C followed by re-suspension in 5% (wt/vol) glucose in 0.9% sterile saline solution.
- cationic lipid-based transfection reagents Lipofectamine® MessengerMAXTM Transfection Reagent, Life Technologies. After transfection, exosomes were spun for 2 hours at 170,000x g at 4°C followed by re-suspension in 5% (wt/vol) glucose in 0.9% sterile saline solution.
- GAA heterozygous breeding pairs were obtained from Jackson Laboratories (Maine, USA) to generate homozygous GAA knock-outs (GAA-/-) and wild-type littermates (GAA+/+). Mice were genotyped at 1 month of age using a standard genotyping kit (REDExtract-N-Amp Tissue PCR Kit; Sigma Aldrich). The birth rate of homozygous mutants was 18%, and significant deficits in front-limb muscle strength were detected as early as 1.5 months of age. During breeding, all animals were housed three to five per cage in a 12-h light/dark cycle and were fed ad libitum (Harlan-Teklad 8640 22/5 rodent diet) after weaning. The study was approved by the McMaster University Animal Research and Ethics Board under the global Animal Utilization Protocol # 12-03-09, and the experimental protocol strictly followed guidelines put forth by Canadian Council of Animal Care.
- the artificial substrate (4-methyl-umbelliferyl a-d-gluco-pyranoside in 0.2 M sodium acetate [NaAc] buffer, pH 3.9, heated to 65 °C) in a 96 well black plate.
- Standards were prepared from a S mM 4-methylumbelHferone/50% ethanol stock by serial dilution in 0.2 M NaAc buffer (pH 3.9), loaded in 10 uL triplicates, and mixed with 20 uL 0.2 M NaAc buffer (pH 3.9). The samples were then incubated in the dark for 1 h at 37.S °C and the reaction was terminated by adding 200 uL of 0.S M sodium carbonate (pH 10.7).
- exosomes modified to incorporate functional protein were shown to effectively deliver protein to muscle cells.
- Example 4 Biogengineering Tangerine Exosomes Enhances Exosome Delivery to Muscle
- DC cells were grown to about 80% confluency before exosome collection as described above.
- DC were transfected with mammalian expression Lamp 1 -skeletal muscle targeting sequence (MTS) fusion plasmid 0.1-1 ug (depending on cell density) using Lipofectamine 2000 reagent (Life Technologies).
- the Lampl -MTS fusion plasmid was made using Gateway® technology and vectors (Life Technologies) with amplified mouse skeletal muscle cDNA that corresponds to the skeletal muscle targeting sequence (TARGEHKEEELI; SEQ ID NO: 1).
- the mouse LAMP1 cDNA exosome marker (NM_001317353.1) was amplified from mouse dendritic cell cDNA.
- the skeletal muscle targeting sequence and the exosome marker were linked via PCR, and then were incorporated into a mammalian expression vector.
- the dendritic cells were washed and combined with fresh growth media (GlutaMAX-DMEM, pre-spun at 170,000x g for 2 hours to generate media virtually free of contamination from bovine exosomes or microvesicles).
- GAPDH siRNA or scRNA scrambled RNA obtained from Sigma; control for siRNA
- scRNA scrambled RNA obtained from Sigma; control for siRNA
- l OOng of naked scRNA or siRNA scRNA or siRNA transfected with Lipofectamine 2000 (LF2000), scRNA- or siRNA-loaded non-targeting exosomes, and scRNA- or siRNA-loaded skeletal muscle targeting exosomes (100 ng of scRNA or siRNA packaged in 10 ug of total exosomal protein in 0.9% sterile saline).
- scRNA and GAPDH siRNA were purchased from Sigma.
- GAPDH qPCR was carried out to assess down-regulation of GAPDH mRNA.
- Treatment of myotubes with GAPDH siRNA-loaded skeletal muscle targeting exosomes exhibited greater down-regulation of GAPDH compared to GAPDH siRNA loaded non-targeting exosomes and conventional GAPDH siRNA transfected with LF2000 ( Figure 8).
- Example 5 - Muscle targetins exosomes efficiently deliver PGC-1 alpha siRNA to muscle cells
- Skeletal muscle-targeting exosomes prepared as described in Example 4 were transfected with PGC-1 alpha siRNA or scRNA.
- Primary mouse myotubes, obtained as described in Example 4, were treated with 100 ng of naked PGC-1 alpha siRNA or scRNA, scRNA or PGC- 1 alpha siRNA transfected with LF2000, 100 ng of scRNA- or PGC-1 alpha siRNA-loaded non- targeting exosomes and scRNA- or PGC-1 alpha siRNA-loaded skeletal muscle targeting exosomes (100 ng of scRNA or siRNA packaged in 10 ug of total exosomal protein in 0.9% sterile saline).
- PGC-1 alpha siRNA as purchased from Sigma.
- PGC-1 alpha siRNA-loaded skeletal muscle targeting exosomes and PGC-1 alpha siRNA loaded non-targeting exosomes were determined to down-regulate PGC-1 alpha expression, which resulted in the subsequent down-regulation of mitochondrial genes that are known to be regulated by PGC-1 alpha including: NRF-1, Tfam, COX-IV, COX-VIIa, and Cycs ( Figure 9A).
- This reduction in PGC-1 alpha mRNA and downstream mitochondrial genes also resulted in a reduction in mitochondrial electron transport chain complex IV (cytochrome c oxidase; COX) activity ( Figure 9B).
- the PGC-1 alpha siRNA had no effect on those genes which are not believed to be under the influence of PGC-1 alpha (being PGC-1 beta and PRC), demonstrating both the desired specificity and functionality of the siRNA administered via exosomes. Furthermore, the down-regulation in gene expression and reduction in mitochondrial biofunctional capacity was more effective in cells treated with PGC-1 alpha siRNA-loaded skeletal muscle targeting exosomes in comparison to cells treated with PGC-1 alpha siRNA-loaded non- targeting exosomes or PGC-1 alpha siRNA transfected with LF2000 ( Figure 9A-B). Thus, exosomes can be bioengineered to deliver cargo to skeletal muscle for the purpose of modulating cellular activity.
- conditioned media collection cells were washed twice with sterile phosphate buffered saline (PBS) (pH 7.4, Life Technologies) and the aforementioned media (with exosome-depleted fetal bovine serum) was added.
- PBS sterile phosphate buffered saline
- the aforementioned media with exosome-depleted fetal bovine serum
- Conditioned media from human immature dendritic cell culture was collected after 48 hours. From this point onwards, all samples (serum- lmL and IDC media- 10mL) were treated exactly the same. Debris was removed from the biological sample by centrifugation of the supernatant at 2000x g for 24 min at 4°C.
- the supernatant was then spun at 2000x g for 60 min at 4°C and the subsequent supernatant was spun at 14,000x g for 60 min at 4°C.
- the resulting supernatant was then filtered through a 0.22 ⁇ m syringe filter (twice). This resultant filtrate is ready for purification via immunoaffinity.
- Magnetic beads were prepared by vortexing magnetic bead-protein A solution (30 mg Dynabeads® suspension/mL in PBS, pH 7.4, with 0.01% Tween®-20 and 0.09% sodium azide) (Dynabeads®-Protein A; Cat. no. 10610D, Life Technologies) for 15-30 seconds to resuspend the beads. This sequence was repeated with the magnetic bead-protein O solution (30 mg Dynabeads® suspension/mL in PBS, pH 7.4, with 0.01% Tween®-20 and 0.09% sodium azide) (Dynabeads®-Protein O; Cat. no. 10612D, Life Technologies).
- magnetic bead-protein A/G 500 each ⁇ L of magnetic bead-protein A and magnetic bead-protein G (herein referred to as magnetic bead-protein A/G) were transferred into a microfuge tube.
- the tube was placed on a magnetic rack for 1 min at room temperature (RT) to separate the magnetic bead-protein A/O from the solution, and the supernatant was carefully removed without disturbing the magnetic beads.
- the tube was removed from the magnet.
- a selected antibody was then bound to the magnetic bead-protein A/O complex.
- the antibody solution was added to the magnetic bead-protein A/O.
- the resultant solution was men incubated at 4°C overnight using an end-over-end mixer.
- the tube was placed on the magnet for 1 min at RT and then the supernatant was removed carefully without disturbing the magnetic bead-protein A/G- antibody complex.
- the tube was removed from the magnet and the magnetic bead-protein A/G- antibody complex was resuspended in 0.1 mL of protease inhibitor solution.
- the magnetic bead- protein A/G-antibody complex was washed for 5 minutes with 1 mL of fresh protease inhibitor solution, using an end-over-end mixer. This was repeated three more times.
- the antibody was then crosslinked to the protein A/O affinity ligand. This involved the following.
- the magnetic bead-protein A/O-Antibody complex was resuspended in 500 ⁇ L of 5 mM Bis(sulfosuccinimidyl)suberate in antibody conjugation buffer (20 mM sodium phosphate, 0.1SM NaCl (pH 7.4,prepared fresh on day of use).
- the resultant solution was incubated at room temperature for 40 min with gentle mixing using an end-over-end mixer.
- 25 ⁇ L of quenching buffer (1M Tris HC1 (pH 7.4,prepared fresh on day of use) was then added and the solution was incubated at room temperature for 24 min with gentle mixing using an end-over-end mixer.
- the tube was placed on the magnet for 1 min and the supernatant carefully removed without disturbing the magnetic bead-protein A/G-antibody complex.
- the crosslinked magnetic bead-protein A/G- antibody complex was washed for 5 minutes with 1 mL of fresh protease inhibitor solution, using an end-over-end mixer. This was repeated three more times.
- exosomes were then isolated using the following steps. 1 mL of the exosome filtrate was resuspended in 400 uL of magnetic bead-protein A/G-antibody complex and incubated overnight at 4°C with gentle mixing using an end-over-end mixer. The magnetic bead-protein A/G-antibody-exosome complex was then washed for 5 minutes with 1 mL of fresh PBS (pH 7.4) with 0.1% Tween®-20 and protease inhibitor solution, using an end-over-end mixer. This wash was repeated three more times.
- exosomes were eluted by resuspending the magnetic bead- protein A/G-antibody-exosome complex in elution buffer (20 mMTris HC1 (pH 8), 137 mM NaCl, 1% Nonidet P-40, 2 mM EDTA).
- elution buffer 20 mMTris HC1 (pH 8), 137 mM NaCl, 1% Nonidet P-40, 2 mM EDTA.
- a BCA assay (PierceTM) was used to determine the yield of exosomes in each sample.
- Total protein yield obtained from human serum for the three-antibody cocktail was 5.2 ⁇ g/ ⁇ L for 3Ab-a and 11.9 ⁇ g/ ⁇ L for 3Ab-b, and for the six-antibody cocktail was 17.0 ⁇ g/ ⁇ L for 6Ab.
- the total protein yield obtained from human IDC cells was 4.0 ⁇ g/ ⁇ L for 3Ab-a and 5.7 ⁇ g/ ⁇ L, for 3Ab-b, and 8.7 ⁇ g/ ⁇ L for 6Ab. Since it is assumed that all exosomes bear certain standard exosomal markers (such as CD9, CD63, ALIX, etc.), it would be expected that immunoprecipitation using any antibody having specificity for these markers in isolation should be equally effective at immunocapturing all exosomes.
- standard exosomal markers such as CD9, CD63, ALIX, etc.
- exosome size distribution and stability of the exosomes was also determined using a Beckman DelsaMax dynamic light scattering analyzer.
- Exosomes isolated from human serum using the three antibody cocktail (3Ab) and six antibody cocktail (6Ab) were each within the established exosomal size range of 20-100nm, indicating a high degree of purity.
- the zeta potential of exosomes isolated from human serum using each antibody cocktail (3Ab and 6Ab) was determined to be between 102 to 164mV, indicating excellent stability.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Optics & Photonics (AREA)
- Diabetes (AREA)
- Nanotechnology (AREA)
- Botany (AREA)
Abstract
A method of treating myopathy in a mammal is provided. The method includes administering to the mammal exosomes genetically modified to incorporate a muscle protein useful to treat the myopathy or nucleic acid encoding the protein.
Description
TREATMENT OF GENETIC MYOPATHIES USING BIOENGINEERED EXOSOMES Field of the Invention
[0001] The present invention generally relates to the treatment of genetic myopathies (muscular dystrophy, congenital myopathy, and metabolic myopathies), and more particularly, relates to a method of treating genetic myopathies using bioengineered exosomes.
Background of the Invention
[0002] Myopathy refers to disease in muscle tissue, and generally results in dysfunctional muscle fibers. The myopathies represent a broad category of acquired and genetic entities. The genetic myopathies are broadly categorized as muscular dystrophy, congenital myopathy and metabolic myopathies. Muscular dystrophy is a broad term relating to muscle diseases that occur due to a gene mutation usually in a structural gene (e.g. dystrophin, sarcoglycan, dystroglycan) or other muscle protein (e.g. calpain 3). The muscle eventually shows evidence of centralized nuclei, fibrosis, necrosis and sarcolemmal damage as reflected by an elevation of creatine kinase (CK) in the serum. The congenital myopathies are genetic disorders that often present in the first few years of life, are often less progressive than the muscular dystrophies, may have a characteristic pattern on histology (e.g. central cores, central nuclear myopathy, inclusion bodies, abnormal protein accumulation), and may have a normal serum CK level. The metabolic myopathies include glycogen storage diseases (e.g. McArdle disease, Tarui disease), fatty acid oxidation defects (VLCAD deficiency, trifunctional protein deficiency, CPT2 deficiency) and the mitochondrial cytopatbies.
[0003] The defining hallmark of muscular dystrophy and the congenital myopathies is skeletal muscle weakness that can progress and require gait assistive devices (canes, walkers, wheelchairs), and may affect respiratory function leading to progressive respiratory failure and the need for assistive ventilation. In contrast, the metabolic myopathies often show no weakness or hyperCKemia between episodes (except McArdle disease), yet show episodes of muscle breakdown (rhabdomyolysis) during exercise and other metabolic stressors. During bouts of rhabdomyolysis, CK is elevated and there is often muscle pain, cramps and weakness.
[0004] Although the identification of the first dystrophin mutation associated with Duchenne muscular dystrophy was discovered in 1987 (nearly 30 years ago) the treatment of muscular dystrophies, congenital myopathies and the metabolic myopathies remain largely supportive. General supportive therapy for muscular dystrophies and the congenital myopathies include physiotherapy (bracing when needed), stretching (when needed for contractures), optimal nutrition, creatine monohydrate supplementation, therapeutic exercise and use of braces and mobility aids as needed. The mainstay of therapy for Duchenne muscular dystrophy has been the use of corticosteroids, although several case reports and case series have suggested mild improvements in other forms of muscular dystrophy. A variety of genetic manipulations including exon skipping, myoblast transfer, adeno-associated virus gene delivery, and stop codon read through have been tried predominately in Duchenne muscular dystrophy with no evidence of clinical benefits at this point and none of the genetic therapies are currently available clinically in North American or Europe. The treatment of the metabolic myopathies is primarily an avoidance of triggering episodes (high intensity activity for the glycogen storage disorders and fasting, concurring illness and prolonged endurance exercise for the fatty acid oxidation defects). Pre- activity carbohydrate supplementation has been shown to be a benefit for McArdle disease by improving exercise capacity. High protein diets have generally been recommended for the glycogen storage disorders but have not been proven to be effective. Variable symptomatic relief have been found using high carbohydrate intakes, MCT (medium chain triglyceride) supplementation, and triheptanoin for the fatty acid oxidation defects. Regular exercise is also helpful in all of the metabolic disorders and it is essential to avoid excessive and unaccustomed activity to avoid rhabdomyolysis.
[0005] Since all of the aforementioned therapies are supportive and may have only minimal functional impact on the life of the individual, there is a need to develop improved methods for treating myopathies.
Summary of the Invention
[0006] It has now been found that bioengineered exosomes are useful as a vehicle to deliver a protein and/or nucleic acid to muscle tissue to effectively treat myopathies such as muscular dystrophy, congenital myopathy and metabolic myopathies.
[0007] Thus, in one aspect of the invention, a method of treating myopathy in a mammal is provided comprising administering to the mammal exosomes genetically modified to incorporate a functional muscle protein useful to treat the myopathy and/or nucleic acid encoding the functional protein.
[0008] In another aspect of the invention, a method of increasing the level or amount of a functional muscle protein in mammalian muscle is provided, comprising administering to the mammal exosomes genetically modified to incorporate the functional muscle protein or nucleic acid encoding the muscle protein.
[0009] In another aspect, exosomes genetically modified to incorporate the functional muscle protein and/or nucleic acid encoding the muscle protein are provided.
[0010] In another aspect of the invention, a method of treating a myopathy in a mammal resulting from expression of a mutated gene is provided comprising administering to the mammal exosomes genetically modified to incorporate gene-silencing systems (e.g., siRNA) to reduce the expression of the mutated gene followed by administering to the mammal exosomes genetically modified to incorporate a functional muscle protein useful to treat the myopathy and/or nucleic acid encoding the muscle protein.
[0011] In another aspect of the invention, a method of treating myopathy in a mammal is provided comprising administering to the mammal exosomes genetically modified to incorporate gene-editing (e.g., CRISPR-Cas9, TALEN, zinc finger nucleases) systems to correct the inherent primary mutation leading to the myopathy.
[0012] In another aspect, a method of increasing the activity of a muscle protein in a mammal is provided, comprising administering to the mammal exosomes which are genetically modified to incorporate a functional muscle protein and/or nucleic acid encoding the muscle protein.
[0013] Additional aspects of the invention include aspects and variations set forth in the following lettered paragraphs:
[0014] A1. An exosome produced by a process that comprises: (a) isolating exosomes from a biological sample from an organism or from a conditioned medium from a cultured cell; and (b) introducing a modification into the exosome selected from the group consisting of: (i) at least one functional muscle protein or precursor thereof; (ii) at least one nucleic acid comprising a nucleotide sequence that encodes the functional muscle protein or precursor thereof; (iii) at least one fusion product comprising a skeletal muscle targeting sequence linked to an exosomal membrane marker; (iv) at least one nucleic acid comprising a nucleotide sequence that encodes the fusion product; and (v) two or more of (i), (ii,) (iii), and (iv).
[0015] A2. The exosome according to paragraph Al , wherein the isolating includes at least one density gradient centrifugation step ideally using Percoll or other colloidal silica product.
[0016] A2.1 The exosome according to paragraph Al or A2, wherein the isolating removes vesicles that are greater than 120 or 140 nm in diameter.
[0017] A3. The exosome according to paragraph Al or A2 or A2.1, wherein the biological sample is from a mammal, or the cell is from a mammal or a mammalian cell line.
[0018] A4. The exosome according to any one of paragraphs Al to A3, wherein the isolating removes vesicles and cellular debris less than 20 nm in diameter.
[0019] AS. An exosome that comprises a modification selected from the group consisting of: (i) at least one functional muscle protein or precursor thereof; (ii) at least one nucleic acid comprising a nucleotide sequence that encodes the functional muscle protein or precursor thereof;
(iii) at least one fusion product comprising a skeletal muscle targeting sequence linked to an exosomal membrane marker; (iv) at least one nucleic acid comprising a nucleotide sequence that encodes the fusion product; and (v) two or more of (i), (ii,) (iii), and (iv).
[0020] Bl . The exosome according to any of paragraphs Al - AS, having a diameter of 20-140 nm, e.g. 20-120 nm.
[0021] B2. The exosome according to any of paragraphs Al - AS, that comprises a functional muscle protein or precursor thereof, wherein the protein is present in a lumen of the exosome.
[0022] B3. The exosome according to any of paragraphs Al - AS, that comprises a nucleic acid comprising a nucleotide sequence encoding a functional muscle protein or precursor thereof, wherein the nucleic acid is present in a lumen of the exosome.
[0023] B3.1. The exosome according to paragraph B3, wherein the nucleic acid comprises mRNA or modified mRNA (modRNA, e.g. S methyl cytosine, or N6 methyladenine) encoding for a protein set forth in Table 1 and/or Table 2 and/or Table 3.
[0024] B4. The exosome according to paragraph B2 or B3 or B3.1, wherein the protein comprises one or more of the proteins set forth in Table 1 and/or Table 2 and/or Table 3.
[0025] B5. The exosome according to paragraph B4, wherein the protein is an enzyme.
[0026] B6. The exosome according to any one of paragraphs B2 - B3.1, wherein the protein is encoded by a gene selected from Myotilin (MYOT), Lamin A/C (LMNA), Caveolin 3 (CAV3), DnaJ heat shock protein family (Hsp40) member B6 (DNAJB6), Spectrin repeat containing, nuclear envelope 1 (SYNE1 ), Spectrin repeat containing, nuclear envelope 2 (S YNE2), Desmin (DES), Crystallin alpha B (CRYAB), LIM domain binding 3 (LDB3), Filamin C (FLNC), BCL2 associated athanogene 3 (BAG3), Dystrophia myotonica protein kinase (DMPK), CCHC- type zinc finger, nucleic acid binding protein (CNBP), Poly(A) binding protein, nuclear 1
(PABPN1), Titin (TTN), Double homeobox 4 (DUX4), Structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHDl), Calpain 3 (CAPN3), Dysferlin (DYSF), Sarcoglycan gamma (SGCG), Sarcoglycan alpha (SGCA), Sarcoglycan beta (SGCB), Sarcoglycan delta (SGCD), Titin-cap (TCAP), Tripartite motif containing 32 (TR1M32), Fukutin related protein (FKRP), TTN, Protein O-mannosyltransferase 1 (POMT1), Anoctamin 5, Fukutin (FKTN), Protein O-mannosyltransferase 2 (POMT2), Protein O-linked mannose N- acetylglucosaminyltransferase 1 (beta 1,2) (POMGnTl), Dystroglycan 1 (DAG1), Plectin (PLEC), DBS, Trafficking protein particle complex 11 (TRAPPCl 1), GDP-mannose pyrophosphorylase B (GMPPB), Tafazzin (TAZ), Dystrophin (DMD), Emerin (EMD), Four and a half LIM domains 1 Ly (FHL1), Lysosome-associated membrane protein 2 (LAMP-2), VMA21 vacuolar H+-ATPase homolog (S. cerevisiae) (VMA21), Laminin subunit alpha 2 (LAMA2), Integrin subunit alpha 7 (1TGA7), Selenoprotein N, 1 (SEPN1), Collagen type VI alpha 1 (COL6AI), Collagen type VI alpha 2 (COL6A2), Collagen type VI alpha 3 (COL6A3), Docking protein 7 (DOK7), Protein O- mannosyltransferase 1 (POMT1), Protein O-mannosyltransferase 2 (POMT2), Protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-) (POMGNT1), FKTN, FKRP, Like- glycosyltransferase (LARGE), Isoprenoid synthase domain containing (ISPD), Protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-) (POMGNT2), Transmembrane protein S (TMEM5), GDP-mannose pyrophosphorylase B (GMPPB), Choline kinase beta (CHKB), Ryanodine receptor 1 (RYR1), Collagen type VI alpha 1 (COL6A1), Collagen type VI alpha 2 (COL6A2), Collagen type VI alpha 3 (COL6A3), Selenoprotein N, 1 (SEPN1), DES, Myosin, heavy chain 2, skeletal muscle, adult (MYH2), Valosin containing protein (VCP), Heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1), Heterogeneous nuclear ribonucleoprotein Al (HNRNPAl), Glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase (GNE), Glucan (1,4-alpha-), branching enzyme 1 (GBE1), Amylo-alpha-1, 6-glucosidase, 4-alpha- glucanotransferase (AGL), Enolase 3 (beta, muscle) (EN03), Glycogen synthase 1 (GYS1), Glycogenin 1 (GYG1), Hexokinase 1 (HK1), Lactate dehydrogenase A (LDHA), Phosphofructokinase, muscle (PFKM), Phosphoglucomutase 1 (PGM1), Phosphoglyceratemutase 2 (PGAM2), Phosphorylase, glycogen, muscle (PYGM), LAMP2, Phosphoglycerate kinase 1 (PGK1), Phosphorylase kinase, alpha 2 (liver) (PHKA2), Phosphorylase kinase, alpha 1 (muscle) (PHKA1), Carnitine palmitoyltransferase 1A (CPT1A), Carnitine palmitoyltransferase 2 (CPT2), Acyl-CoA dehydrogenase, C-4 to C-12 straight chain (ACADM), Acyl-CoA dehydrogenase, very
long chain (ACADVL), Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit (HADHA), Hydroxyacyl-CoA dehydrogenase/3- ketoacyl-CoA thiolase/enoyl-CoA hydratase (triftmctional protein), beta subunit (HADHB), Electron transfer flavoprotein alpha subunit (ETFA), Solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 (SLC25A20), Solute carrier family 22 (organic cation/carnitine transporter), member 5 (SLC22A5) and Glucosidase, alpha; acid (OAA).
[0027] B7. The exosome according to any one of paragraphs B2 - B6, further comprising at least one fusion product comprising a skeletal muscle targeting sequence linked to an exosomal membrane marker.
[0028] B8. The exosome according to any one of paragraphs Al - AS or Bl, that comprises at least one fusion product comprising a skeletal muscle targeting sequence linked to an exosomal membrane marker.
[0029] B9. The exosome according to paragraph B7 or B8, wherein the exosomal membrane marker is selected from the group consisting of CD9, CD37, CDS3, CD63, CD81, CD82, CD151, an integrin, ICAM-1, CDD31, an annexin, TSG101, ALIX, lysosome-associated membrane protein 1, lysosome-associated membrane protein 2, lysosomal integral membrane protein and a fragment of any exosomal membrane marker that comprises at least one intact transmembrane domain.
[0030] B10. The exosome according to any one of paragraphs B7 - B9, wherein the skeletal muscle targeting sequence is selected from the group consisting of SERCA2, acetylcholine receptor epsilon, SCN4A, muscle specific creatine kinase (CK-MM) and fragments thereof, including the peptide sequence, TARGEHKEEELI (SEQ ID NO: 1).
[0031 ] B 11. The exosome according to any one of paragraphs B7 ~ B 10, wherein the fusion product is a fusion protein.
[0032] B12. The exosome according to paragraph Bl l, further wherein the fusion protein includes a peptide linker between the skeletal muscle targeting sequence and the exosomal membrane marker.
[0033] B13. The exosome according to any one of paragraphs B7-B12, wherein the exosomal membrane marker of the fusion product includes a transmembrane domain and localizes in a membrane of the exosome.
[0034] CI. A composition comprising exosomes according to any one of paragraphs Al - A5, and a pharmaceutically acceptable carrier.
[003S] C2. The composition according to paragraph CI, wherein the composition is substantially free of vesicles having a diameter less than 20 nm.
[0036] C3. The composition according to paragraph CI or C2, wherein the composition is substantially free of vesicles having a diameter greater than 140 nm or greater than 120nm.
[0037] C4. The composition according to any one of claims CI - C3, which exhibits a zeta potential having a magnitude of at least 30 mV, or at least 40 mV, or at least SO mV, or at least 60 mV, or at least 70 mV, or at least 80 mV, e.g. 30-80 mV, or -80 to -30 mV.
[0038] CS. The composition according to claim C4, which exhibits a zeta potential having a magnitude of up to 200 mV, or up to 175 mV, or up to 150 mV, or up to 140 mV, or up to 130 mV, or up to 120 mV, or up to 110 mV, or up to 100 mV.
[0039] Dl . A method of increasing the amount of a muscle protein in muscles in a mammal, comprising administering to the mammal an exosome according to any one of paragraphs A1 - B13, or a composition according to any one of paragraphs CI- C5.
[0040] D2. Use of an exosome according to any one of paragraphs Al - B13, or a composition according to any one of paragraphs CI- C5, for increasing the amount of a muscle protein in muscle in a mammal.
[0041] D3. A method of treating a genetic myopathy in a mammal comprising administering to the mammal an exosome according to any one of paragraphs Al - B13, or a composition according to any one of paragraphs C1- C5.
[0042] D4. Use of an exosome according to any one of paragraphs Al - B13, or a composition according to any one of paragraphs CI- C5, for treating a genetic myopathy in a mammal.
[0043] D5. The method or use according to any one of paragraphs Dl - D4, wherein the mammal is human.
[0044] D6. The method or use according to paragraph DS, wherein the human has a genetic myopathy selected from Muscular dystrophy, limb-girdle, type IA, Muscular dystrophy, limb-girdle, type IB, Muscular dystrophy, limb-girdle, type IC, Muscular dystrophy, limb-girdle, type IE, Emery-Dreifiiss muscular dystrophy 4, Emery-Dreifuss muscular dystrophy S, Myopathy, myofibrillar, 1, Myopathy, myofibrillar, 2, Myopathy, myofibrillar, 4, Myopathy, myofibrillar, 5, Myopathy, myofibrillar, 6, Myotonic dystrophy 1, Myotonic dystrophy 2, Oculopharyngeal muscular dystrophy, Tibial muscular dystrophy, tardive, Facioscapulohumeral muscular dystrophy 1, Facioscapulohumeral muscular dystrophy 2, digenic, Muscular dystrophy, limb-girdle, type 2A, Muscular dystrophy, limb-girdle, type 2B, Muscular dystrophy, limb-girdle, type 2C, Muscular dystrophy, limb-girdle, type 2D, Muscular dystrophy, limb-girdle, type 2E, Muscular dystrophy, limb-girdle, type 2F, Muscular dystrophy, limb-girdle, type 20, Muscular dystrophy, limb-girdle, type 2H, Muscular dystrophy, limb-girdle, type 21 / Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5, Muscular dystrophy, limb-girdle, type 2J, Muscular dystrophy, limb- girdle, type 2K / Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 1, Muscular dystrophy, limb-girdle, type 2L, Muscular dystrophy, limb-girdle, type 2M / Muscular dystrophy- dystroglycanopathy (limb-girdle), type C, 4, Muscular dystrophy, limb-girdle, type 2N / Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2, Muscular dystrophy, limb-girdle, type 20 / Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3, Muscular dystrophy, limb- girdle, type 2P / Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 9, Muscular dystrophy, limb-girdle, type 2Q, Muscular dystrophy, limb-girdle, type 2R, Muscular dystrophy, limb-girdle, type 2S, Muscular dystrophy, limb-girdle, type 2T / Muscular dystrophy- dystroglycanopathy (limb-girdle), type C, 14, Barth syndrome, Muscular dystrophy, duchenne type, Muscular dystrophy, becker type, Emery-Dreifuss muscular dystrophy 1, X-linked, Emery- Dreifuss muscular dystrophy 6, X-linked, Danon disease, Myopathy, X-linked, with excessive autophagy, Muscular dystrophy, congenital merosin-deficient, 1A, Muscular dystrophy,
congenital, due to ITOA7 deficiency, Myopathy, congenital, with fiber-type disproportion, Ullrich congenital muscular dystrophy 1, Ullrich congenital muscular dystrophy 1, Ullrich congenital muscular dystrophy 1, Myasthenic syndrome, congenital, 10, Muscular dystrophy- dystroglycanopathy (congenital with brain and eye anomalies), type A, 1 / Muscular dystrophy- dystroglycanopathy (congenital with mental retardation), type B, 1, Muscular dystrophy- dystroglycanopathy (congenital with brain and eye anomalies), type A, 2 / Muscular dystrophy- dystroglycanopathy (congenital with mental retardation), type B, 2, Muscular dystrophy- dystroglycanopathy (congenital with brain and eye anomalies), type A, 3 / Muscular dystrophy- dystroglycanopathy (congenital with mental retardation), type B, 3, Muscular dystrophy- dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 / Muscular dystrophy- dystroglycanopathy (congenital without mental retardation), type B, 4, Muscular dystrophy- dystroglycanopathy (congenital with brain and eye anomalies), type A, 5 / Muscular dystrophy- dystroglycanopathy (congenital with or without mental retardation), type B, 5, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 6, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 8, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 10, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14 / Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 14, Muscular dystrophy, congenital, megaconial type, Central core disease, Bethlem myopathy 1, Bethlem myopathy 1, Bethlem myopathy 1, Muscular dystrophy, rigid spine, 1, Inclusion body myopathy 1 / Myopathy, myofibrillar, 1, Inclusion body myopathy 3 / Proximal myopathy and ophthalmoplegia, Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1, Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2, Inclusion body myopathy with early-onset Paget disease without frontotemporal dementia 3, Inclusion body myopathy 2 / Nonaka myopathy, Glycogen storage disease IV, Glycogen storage disease Ilia / Illb, Glycogen storage disease XIII, Glycogen storage disease 0, muscle, Glycogen storage disease XV, Glycogen storage disease XI, Glycogen storage disease VII, Glycogen storage disease X, Glycogen storage disease V / McArdle disease, Danon disease, Phosphoglycerate kinase 1 deficiency, Glycogen storage disease, type IXal / Glycogen storage disease, type IXa2, Muscle glycogenosis, CPT deficiency, hepatic, type IA, CPT
deficiency, hepatic, type II, Acyl-CoA dehydrogenase, medium chain, deficiency of, VLCAD deficiency, Mitochondrial trifunctional protein deficiency, Mitochondrial Afunctional protein deficiency, Multiple acyl-CoA dehydrogenase deficiency (MADD) / Glutaric acidemia IIA, Carnitine-acylcarnitine translocase deficiency, Carnitine deficiency, systemic primary and Glycogen storage disease II.
[0045] D7. The method or use according to any one of paragraphs Dl - D4, wherein the mammal is human and has a disease set forth in Table 1 and/or Table 2 and/or Table 3, and the exosome contains the corresponding protein in Table 1 and/or Table 2 and/or Table 3, or a nucleic acid encoding said protein.
[0046] These and other aspects of the invention will be described by reference to the following figures.
Brief Description of the Figures
[0047] Figure 1 graphically illustrates dystrophin protein content in primary dermal fibroblasts from control and DMD patients after treatment with exosomes loaded with dystrophin (Dmd) mRNA as determined by quantification of confocal microscopy images.
[0048] Figure 2 graphically illustrates dystrophin protein expression in primary dermal fibroblasts from control and DMD patients after treatment with exosomes loaded with dystrophin (Dmd) mRNA as determined by immunoblot analysis.
[0049] Figure 3 illustrates dystrophin content in tibialis anterior (TA) muscle (A), soleus (SOL) muscle (B), and heart (C) in dystrophin-deficient mdx mice after treatment with vehicle, empty exosomes and dystroph in-mRN A loaded exosomes.
[0050] Figure 4 graphically illustrates body (A), fast-twitch muscle (tibialis anterior (TA) (B), extensor digitorum longus (EDL) (C)) and slow-twitch (soleus (SOL)) muscle (D) weights in mdx mice after treatment with vehicle, empty exosomes, dystrophin mRNA loaded exosomes and prednisolone.
[0051] Figure 5 graphically illustrates maximum grip strength relative to TA muscle weight in mdx mice after treatment with vehicle, empty exosomes, dystrophin mRNA loaded exosomes and prednisolone.
[0052] Figure 6 graphically illustrates serum creatine kinase (CK) levels in mdx mice after treatment with vehicle, empty exosomes, dystrophin mRNA loaded exosomes and prednisolone.
[0053] Figure 7 graphically illustrates acid alpha glucosidase (OAA) activity in primary myotubes isolated from GAA wild-type (GA A+^ and knock-out (GA A"7') mice treated with naked GAA protein, empty exosomes (exosome control) or GAA protein-loaded exosomes.
[0054] Figure 8 graphically illustrates GAPDH gene expression in muscle cells treated with GAPDH siRNA or scRNA (scrambled RN A; control for siRNA) by delivery of naked scRNA or siRNA, scRNA or siRNA transfected with lipofectamine 2000 (LF2000), scRNA- or siRNA- loaded non-targeting exosomes and scRNA- or siRNA-loaded skeletal muscle-targeting exosomes.
[0055] Figure 9 graphically illustrates gene expression of PGC-1 alpha and of downstream targets of PGC-1 alpha (A) and cytochrome c oxidase function (B) in primary mouse muscle cells treated with PGC-1 alpha siRNA or scRNA delivered by naked scRNA or siRNA, scRNA or siRNA transfected with lipofectamine 2000 (LF2000), scRNA- or siRNA-loaded non-targeting exosomes and scRNA- or siRNA-loaded skeletal muscle targeting exosomes.
Detailed Description of the Invention
[0056] A method of treating myopathy in a mammal is provided comprising administering to the mammal exosomes genetically modified to incorporate a muscle protein useful to treat the myopathy or nucleic acid encoding the protein. Thus, exosomes which have been genetically engineered to incorporate a muscle protein, and/or nucleic acid encoding a muscle protein are also provided.
[0057] The term "exosome" refers to cell-derived vesicles having a diameter of between about 20 and 140 nm, for example, a diameter of about 20-120 nm, or a diameter of about 40-100 nm, including exosomes of a diameter of about 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm and/or 120 nm. Exosomes may be isolated from any suitable biological sample from a mammal, including but not limited to, whole blood, serum, plasma, urine, saliva, breast milk, cerebrospinal fluid, amniotic fluid, ascitic fluid, bone marrow and cultured mammalian cells (e.g. immature dendritic cells (wild-type or immortalized), induced and non-induced pluripotent stem cells, fibroblasts, platelets, immune cells, reticulocytes, tumour cells, mesenchymal stem cells, satellite cells, hematopoietic stem cells, pancreatic stem cells, white and beige pre-adipocytes and the like). As one of skill in the art will appreciate, cultured cell samples will be in the cell-
appropriate culture media (using exosome-free serum). Exosomes may be identified by specific surface markers not present in other vesicles, including surface markers such as tetraspanins, e.g. CD9, CD37, CD44, CD53, CD63, CD81, CD82 and CD151; targeting or adhesion markers such as integrins, ICAM-1, EpCAM and CD31; membrane fusion markers such as annexins, TSG101, ALIX; and other exosome transmembrane proteins such as Rab5b, HLA-G, HSP70, LAMP2 (lysosome-associated membrane protein) and LIMP (lysosomal integral membrane protein). Exosomes may also be obtained from a non-mammalian biological sample, including cultured non-mammalian cells. As the molecular machinery involved in exosome biogenesis is believed to be evolutionarily conserved, exosomes from non-mammalian sources include surface markers which are isoforms of mammalian surface markers, such as isoforms of CD9 and CD63, which distinguish them from other cellular vesicles. As used herein, the term "mammal" is meant to encompass, without limitation, humans, domestic animals such as dogs, cats, horses, cattle, swine, sheep, goats and the like, as well as non-domesticated animals such as, but not limited to, mice, rats and rabbits. The term "non-mammal" is meant to encompass, for example, exosomes from microorganisms such as bacteria, flies, worms, plants, fruit/vegetables (e.g. corn, pomegranate) and yeast.
[0058] Exosomes may be obtained from the appropriate biological sample using any protocol that yields exosomes useful for therapeutic use, e.g. sufficiently pure, intact exosomes with good stability. For example, one or more of the following isolation techniques may be employed: centrifugation, filtration, ultracentrifugation, ultrafiltration, immunoaffinity capture and solvent or polymer-based methodologies.
[00S9] In one embodiment, the isolation protocol includes the steps of: i) exposing the biological sample to a first centrifugation to remove cellular debris greater than about 7-10 microns in size from the sample and obtaining the supernatant following centrifugation; ii) subjecting the supernatant from step i) to centrifugation to remove microvesicles therefrom; iii) microfiltering the supernatant from step ii) and collecting the microfiltered supernatant; iv) subjecting the microfiltered supernatant from step iii) to at least one round of ultracentrifugation to obtain an exosome pellet; and v) re-suspending the exosome pellet from step iv) in a physiological solution, conducting a second ultracentrifugation In a density gradient and removing the exosome pellet fraction therefrom.
[0060] Thus, the process of isolating exosomes from a biological sample includes a first step of removing undesired large cellular debris from the sample, i.e. cells, cell components, apoptotic bodies and the like greater than about 7-10 microns in size. This step is generally conducted by centrifugation, for example, at 1000-4000x g for 10 to 60 minutes at 4°C, preferably at 1500-2SOOx g, e.g. 2000x g, for a selected period of time such as 10-30 minutes, 12-28 minutes, 14-24 minutes, 15-20 minutes or 16, 17, 18 or 19 minutes. Asoneof skill in the art will appreciate, a suitable commercially available laboratory centrifuge, e.g. Thermo-Scientific™ or Cole- Parmer™, is employed to conduct this isolation step. To enhance exosome isolation, the resulting supernatant is subjected to a second optional centrifugation step to further remove cellular debris and apoptotic bodies, such as debris that is at least about 7-10 microns in size, by repeating this first step of the process, i.e. centrifugation at 1000-4000x g for 10 to 60 minutes at 4°C, preferably at 1500-2500x g, e.g. 2000x g, for the selected period of time.
[0061] Following removal of cell debris, the supernatant resulting from the first centrifugation step(s) is separated from the debris-containing pellet (by decanting or pipetting it off) and may then be subjected to an optional additional (second) centrifugation step, including spinning at 12,000-15,000x g for 30-90 minutes at 4°C to remove intermediate-sized debris, e.g. debris that is greater than 6 microns size. In one embodiment, this centrifugation step is conducted at 14,000x g for 1 hour at 4°C . The resulting supernatant is again separated from the debris- containing pellet.
[0062] Alternatively or additionally, the resulting supernatant is collected and subjected to a third centrifugation step, including spinning at between 40,000-60,000x g for 30-90 minutes at 4°C to further remove impurities such as medium to small-sized micro vesicles greater than 0.3 microns in size e.g. in the range of about 0.3-6 microns. In one embodiment, the centrifugation step is conducted at 50,000x g for 1 hour. The resulting supernatant is separated from the pellet for further processing. If the second centrifugation step is conducted, the third centrifugation step is optional.
[0063] The supernatant is then filtered to remove debris, such as bacteria and larger microvesicles, having a size of about 0.22 microns or greater, e.g. using microfiltration. The filtration may be conducted by one or more passes through filters of the same size, for example, a
0.22 micron filter. Alternatively, filtration using 2 or more filters may be conducted, using filters of the same or of decreasing sizes, e.g. one or more passes through a 40-50 micron filter, one or more passes through a 20-30 micron filter, one or more passes through a 10-20 micron filter, one or more passes through a 0.22-10 micron filter, etc. Suitable filters for use in this step include the use of 0.45 and 0.22 micron filters.
[0064] The microfiltered supernatant (filtrate) may then be combined with a suitable physiological solution, preferably sterile, for example, an aqueous solution, a saline solution or a carbohydrate-containing solution, in a 1:1 ratio, e.g. 10 mL of supernatant to lOmL of physiological solution, to prevent clumping of exosomes during the subsequent ultracentrifugation and to maintain the integrity of the exosomes. The exosomal solution is then subjected to ultracentrifugation to pellet exosomes and any remaining contaminating microvesicles (between 100-220 nm). This ultracentrifugation step is conducted at 110,000- 170,000x g for 1-3 hours at 4 °C, for example, 144,000x g for 2 hours or 170,000x g for 3 hours. This ultracentrifugation step may optionally be repeated, e.g. 2 or more times, in order to enhance results. Any commercially available ultracentrifuge, e.g. Thermo-Scientific™ or Beckman™, may be employed to conduct this step. The exosome-containing pellet is removed from the supernatant using established techniques and re-suspended in a suitable physiological solution.
[0065] Following ultracentrifugation, the re-suspended exosome-containing pellet is subjected to density gradient separation to separate contaminating microvesicles from exosomes based on their density. Various density gradients may be used, including, for example, a sucrose gradient, a colloidal silica density gradient, an iodixanol gradient, or any other density gradient sufficient to separate exosomes from contaminating microvesicles (e.g. a density gradient that functions similar to the 1.100-1.200 g/ml sucrose fraction of a sucrose gradient). Thus, examples of density gradients include the use of a 0.25-2.5 M continuous sucrose density gradient separation, e.g. sucrose cushion centrifugation, comprising 20-50% sucrose; a colloidal silica density gradient, e.g. Percoll™ gradient separation (colloidal silica particles of 15-30 nm diameter, e.g. 30%/70% w/w in water (free of KNase and DNase), which have been coated with polyvinylpyrrolidone (PVP)); and an iodixanol gradient, e.g. 6-18% iodixanol. The resuspended exosome solution is added to the selected gradient and subjected to ultracentrifugation at a speed between 110,000-
170,000x g for 1-3 hours. The resulting essentially pure exosome pellet is removed and re- suspended in physiological solution.
[0066] Depending on the density gradient used, the re-suspended exosome pellet resulting from the density gradient separation may be ready for use. For example, if the density gradient used is a sucrose gradient, the exosome pellet is removed from the appropriate sucrose gradient fraction, and is ready for use, or may preferably be subjected to an ultracentrifugation wash step at a speed of 110,000- 170,000x g for 1 -3 hours at 4°C. If the density gradient used is, for example, a colloidal silica or a iodixanol density gradient, then the resuspended exosome pellet may be subjected to additional wash steps, e.g. subjected to one to three ultracentrifugation steps at a speed of 110,000- 170,000x g for 1-3 hours each at 4°C, to yield an essentially pure exosome-containing pellet. As one of skill in the art will appreciate, the exosome pellet from any of the centrifugation or ultracentrifugation steps may be washed between centrifugation steps using an appropriate physiological solution, e.g. saline. The final pellet is removed from the supernatant and may be re- suspended in a physiologically acceptable solution for use. Alternatively, the exosome pellet may be stored for later use, for example, in cold storage at 4°C, in frozen form or in lyophilized form, prepared using well-established protocols. The exosome pellet may be stored in any physiological acceptable carrier, optionally including cryogenic stability and/or vitrification agents (e.g. DMSO, glycerol, trehalose, polyhydroxylated alcohols (e.g. methoxylated glycerol, propylene glycol), M22 and the like).
[0067] In another embodiment, an immunoaffinity method of isolating exosomes from a biological sample may be utilized. The method comprises the steps of: i) optionally exposing the biological sample to a method of pre-enrichment to remove cellular and other debris; and ii) subjecting the sample to immunoaffinity capture with an antibody cocktail comprising at least three different antibodies to different exosome surface proteins, wherein the exosomes bind to the antibodies which bind or are bound to a solid support to yield an exosome-solid support complex from which the exosome are removed to yield isolated exosomes.
[0068] The optional pre-enrichment may include one or more centrifugation steps, microfiltration, and ultracentrifugation with or without a density gradient, as previously described to remove cellular debris, microvesicles and/or bacteria. Biological samples with a high protein
concentration (such as serum) may also be immuno-depleted using methods well-established in the art to remove high abundance proteins that may interfere with exosome capture.
[0069] Following pre-enrichment, immunoaffinity exosome capture is conducted using antibodies having specificity for an exosomal marker. Examples of exosomal markers that may be used include the following: CD9 molecule (CD9), programmed cell death 6 interacting protein/ Alix (PDCD6IP), heat shock protein family A (Hsp70) member 8 (HSPA8), glyceraldehyde-3- phosphate dehydrogenase (GAPDH), actin, beta (ACTB), annexin A2 (ANXA2), CD63 molecule (CD63), syndecan binding protein (SDCBP), enolase 1 , (alpha) (ENOl), heat shock protein 90kDa alpha family class A member 1 (HSP90AA1), tumor susceptibility 101 (TSG101), pyruvate kinase, muscle (PKM), lactate dehydrogenase A (LDH A), eukaryotic translation elongation factor 1 alpha 1 (EEF1A1), tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta (YWHAZ), phosphoglycerate kinase 1 (PGK1), eukaryotic translation elongation factor 2 (EEF2), aldolase, fructose-bisphosphate A (ALDOA), heat shock protein 90kDa alpha family class B member 1 (HSP90AB1), annexin A5 (ANXA5), fatty acid synthase (FASN), tyrosine 3- monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon (YWHAE), clathrin, heavy chain (He) (CLTC), CD81 molecule (CD81), albumin (ALB), valosin containing protein (VCP), triosephosphate isomerase 1 (TPI1), peptidylprolyl isomerase A (cyclophilin A) (PPIA), moesin (MSN), cofilin 1 (CFL1), peroxiredoxin 1 (PRDX1), profilin 1 (PFN1), RAP IB, member of RAS oncogene family (RAP IB), integrin subunit beta 1 (ITGB1), heat shock protein family A (Hsp70) member 5 (HSPA5), solute carrier family 3 (amino acid transporter heavy chain), member 2 (SLC3A2), histone cluster 1, H4a (HIST1H4A), guanine nucleotide binding protein (G protein), beta polypeptide 2 (GNB2), ATPase, Na+/K+ transporting, alpha 1 polypeptide (ATP1A1), tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta (YWHAQ), flotillin 1 (FLOT1), filamin A, alpha (FLNA), chloride intracellular channel 1 (CLIC1), chaperonin containing TCP1, subunit 2 (CCT2), cell division cycle 42 (CDC42), tyrosine 3- monooxygenase/tryptophan 5-monooxygenase activation protein, gamma (YWHAG), alpha-2- macroglobulin (A2M), tubulin alpha lb (TUBA IB), ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Racl) (RAC1), lectin, galactoside-binding, soluble, 3 binding protein (LGALS3BP), heat shock protein family A (Hsp70) member 1A (HSPA1A), guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 (GNAI2), annexin Al (ANXA1), ras homolog family member A (RHOA), milk fat globule-EGF factor 8
protein (MFGE8), peroxiredoxin 2 (PRDX2), GDP dissociation inhibitor 2 (GDI2), EH domain containing 4 (EHD4), actinin, alpha 4 (ACTN4), tyrosine 3-monooxygenase/tryptophan 5- monooxygenase activation protein, beta (YWHAB), RAB7A, member RAS oncogene family (RAB7A), lactate dehydrogenase B (LDHB), GNAS complex locus (GNAS), RAB5C, member RAS oncogene family (RAB5C), ADP ribosylation factor 1 (ARFl), annexin A6 (ANXA6), annexin Al 1 (ANXA11), actin gamma 1 (ACTG1), karyopherin (importin) beta 1 (KPNB1), ezrin (EZR), annexin A4 (ANXA4), ATP citrate lyase (ACLY), tubulin alpha lc (TUBA1C), transferrin receptor (TFRC), RAB14, member RAS oncogene family (RAB14), histone cluster 2, H4a (HIST2H4A), guanine nucleotide binding protein (G protein), beta polypeptide 1 (GNB1), thrombospondin 1 (THBS1), RAN, member RAS oncogene family (RAN), RAB5A, member RAS oncogene family (RAB5 A), prostaglandin F2 receptor inhibitor (PTGFRN), chaperonin containing TCP1, subunit 5 (epsilon) (CCT5), chaperonin containing TCP1, subunit 3 (CCT3), adenosylhomocysteinase (AHCY), ubiquitin-like modifier activating enzyme 1 (UBA1), RAB5B, member RAS oncogene family (RABSB), RAB1A, member RAS oncogene family (RAB1A), lysosomal-associated membrane protein 2 (LAMP2), integrin subunit alpha 6 (ITGA6), histone cluster 1, H4b (HIST1H4B), basigin (Ok blood group) (BSG), tyrosine 3- monooxygenase/tryptophan S-monooxygenase activation protein, eta (YWHAH), tubulin alpha la (TUBA1A), transketolase (TKT), t-complex 1 (TCP1), stomatin (STOM), solute carrier family 16 (monocarboxylate transporter), member 1 (SLC16A1), RAB8A, member RAS oncogene family (RAB8A), myosin, heavy chain 9, non-muscle (MYH9) and major vault protein (MVP).
[0070] In one embodiment, the antibody cocktail comprises 3 or more antibodies each having a specificity for a different exosome marker selected from the following proteins: Alix, Flotillin 1, CD9, CD63, CD81, TSG101 and LAMP2. For example, the antibody cocktail may comprise an antibody with specificity to each of Alix, Flotillin 1, CD9 and CD63, or an antibody to each of Flotillin 1, CD9, CD63, CD81 and TSG101, or an antibody to each of Flotillin 1, CD9, CD63, CD81, TSG101 and ALIX, or an antibody with specificity to each of ALIX, TSG101 and CD9, or an antibody with specificity to each of CD81, CD63 and CD9.
[0071] Examples of immunoaffmity capture techniques that may be used to capture exosomes using a selected antibody cocktail include, but are not limited to, immunoprecipitation, column affinity chromatography, magnetic-activated cell sorting, fluorescence-activated cell
sorting, adhesion-based sorting and microfluidic-based sorting. The antibodies in the antibody cocktail may be utilized together, in a single solution, or may be utilized in two or more solutions that are administered simultaneously or consecutively.
[0072] In a further embodiment, exosome separation methods may be utilized in conjunction with one or more of centrifugation, microfiltration and ultracentrifugation steps, to isolate exosomes from a biological sample. For example, protein organic solvent precipitation (PROSPR) may be used. Briefly, PROSPR, as described in Gallart-Palau et al., Scientific Reports, 2016, Sept. 30,5: 14664 (the contents of which are incorporated herein by reference) is rapid three- step protocol to remove soluble proteins from a sample via solvent-based precipitation (e.g. acetone), leaving lipid-based microvesicles, including exosomes, in suspension within the sample, for further separation as above-described. Similarly, polymer-based separation may be used in which suitable polymers such as polyethylene-glycol and variants thereof are mixed with an exosome-containing sample to separate exosomes from the sample into the polymer layer.
[0073] The described exosome isolation protocols advantageously provide a means to obtain exosomes, such as mammalian exosomes, which are at least about 90% pure, and preferably at least about 95% or greater pure, i.e. referred to herein as "essentially free" from cellular debris, apoptotic bodies and microvesicles having a diameter less than 20 or greater than 140 nm, for example, free from particles having a diameter of less than 40 or greater than 120 nm (as measured, for example, by dynamic light scattering), and which are biologically intact, e.g. not clumped or in aggregate form, and not sheared, leaky or otherwise damaged. Exosomes isolated according to the methods described herein exhibit a high degree of stability, evidenced by the zeta potential of a mixture/solution of such exosomes, for example, a zeta potential of at least a magnitude of 30 mV, e.g. < -30 or > +30, and preferably, a magnitude of at least 40 mV, 50 mV, 60 mV, 70 mV, 80 mV, or greater. The term "zeta potential" refers to the electrokinetic potential of a colloidal dispersion, and the magnitude of the zeta potential indicates the degree of electrostatic repulsion between adjacent, similarly charged particles (exosomes) in a dispersion. For exosomes, a zeta potential of magnitude 30 mV or greater indicates moderate stability, i.e. the solution or dispersion will resist aggregation, while a zeta potential of magnitude 40-60 mV indicates good stability, and a magnitude of greater than 60 mV indicates excellent stability.
[0074] Moreover, high quantities of exosomes are achievable by the present isolation method, e.g. exosomes in an amount of about 100-2000 μg total protein can be obtained from 1-4 mL of mammalian serum or plasma, or from 15-20 mL of cell culture spent media (from at least about 2 x 106 cells). Thus, solutions comprising exosomes at a concentration of at least about S μg/μL, and preferably at least about 10-25 μg/μL, may readily be prepared due to the high exosome yields obtained by the present method. The term "about" as used herein with respect to any given value refers to a deviation from that value of up to 10%, either up to 10% greater, or up to 10% less.
[0075] Exosomes isolated in accordance with the methods herein described, which beneficially retain integrity, and exhibit a high degree of purity (being "essentially free" from entities having a diameter less than 20 nm and greater than 140 ran and/or greater than 120 nm), stability and biological activity both in vitro and in vivo, have not previously been achieved. Thus, tile present exosomes are uniquely useful, for example, diagnostically and/or therapeutically, e.g. for the in vivo delivery of protein and/or nucleic acid. They have also been determined to be non- allergenic/non-immunogenic, and thus, safe for autologous, allogenic, xenogenic and cross- kingdom use.
[0076] Isolated exosomes may then be genetically engineered to incorporate an exogenous protein, e.g. an exogenous protein such as a muscle protein, or exogenous nucleic acid encoding a selected muscle protein, or both. The term "muscle protein" is used herein to refer to any protein that is expressed in, or active in, muscle, including skeletal, smooth and cardiac muscle. The term "loaded exosome" is used herein to refer to exosomes which have been genetically engineered to incorporate an exogenous protein, nucleic acid encoding a protein or other biological substances. The term "empty exosome" is used herein to refer to exosomes which have not been genetically engineered to incorporate an exogenous protein, nucleic acid encoding a protein or other biological substances. The term "exogenous" is used herein to refer to protein or nucleic acid originating from a source external to the exosomes. Nucleic acid encoding the protein may be produced using known synthetic techniques, incorporated into a suitable expression vector using well established methods to form a protein-encoding expression vector which is introduced into isolated exosomes using known techniques, e.g. electroporation, transfection using cationic lipid-based transfection reagents, and the like. Similarly, the selected protein may be produced using recombinant
techniques, or may be otherwise obtained, and then may be introduced directly into isolated exosomes by electroporation or transfection. More particularly, electroporation applying voltages in the range of about 20-1000 V/cm may be used to introduce nucleic acid or protein into exosomes. Transfection using cationic lipid-based transfection reagents such as, but not limited to, Lipofectamine® MessengerMAX™ Transfection Reagent, Lipofectamine® RNAiMAX Transfection Reagent, Lipofectamine® 3000 Transfection Reagent, or Lipofectamine® LTX Reagent with PLUS™ Reagent, may also be used. The amount of transfection reagent used may vary with the reagent, the sample and the cargo to be introduced. For example, using Lipofectamine® MessengerMAX™ Transfection Reagent, an amount in the range of about 0.15 uL to 10 uL may be used to load 100 ng to 2500 ng mRNA or protein into exosomes. Other methods may also be used to load protein into exosomes including, for example, the use of cell- penetrating peptides.
[0077] Exosomes isolated in accordance with the methods herein described, which beneficially retain integrity, and exhibit a high degree of purity and stability, readily permit loading of exogenous protein and/or nucleic acid in an amount of at least about 1 ng nucleic acid (e.g. mRNA) per 10 ug of exosomal protein or 30 ug protein per 10 ug of exosomal protein.
[0078] In another embodiment, a protein-encoding expression vector as above described, may be introduced directly into exosome-producing cells, e.g. autologous, allogenic, or xenogenic cells, such as immature dendritic cells (wild-type or immortalized), induced and non-induced pluripotent stem cells, fibroblasts, platelets, immune cells, reticulocytes, tumour cells, mesenchymal stem cells, satellite cells, hematopoietic stem cells, pancreatic stem cells, white and beige pre-adipocytes and the like, by electroporation or transfection as described above. Following a sufficient period of time, e.g. 3-7 days to achieve stable expression of the protein, exosomes incorporating the expressed protein may be isolated from the exosome-producing cells as described herein.
[0079] Alternatively, prior to incorporation into exosomes of a selected muscle protein, and/or nucleic acid encoding the protein, exosomes may be modified to express or incorporate a target-specific fusion product. The term "targeting exosome" is used herein to refer to exosomes which have been modified to express or incorporate a target-specific fusion product. The term
"non-targeting exosome" is used herein to refer to exosomes which have not been modified to express or incorporate any target-specific fusion product. For the delivery of muscle proteins, the target-specific fusion product comprises a muscle targeting sequence, linked to an exosomal membrane marker. The exosomal membrane marker of the fusion product will localize the fusion product within the membrane of the exosome to enable the targeting sequence to direct the exosome to the intended target. Examples of exosome membrane markers include, but are not limited to: tetraspanins such as CD9, CD37, CD53, CD63, CD81, CD82 and CD151; targeting or adhesion markers such as integrins, ICAM-1 and CDD31; membrane fusion markers such as annexins, TSO101, ALIX; and other exosome transmembrane proteins such as LAMP (lysosome- associated membrane protein), e.g. LAMP 1 or 2, and LIMP (lysosomal integral membrane protein). All or a fragment of an exosome membrane marker may be utilized in the fusion product provided that any fragment includes a sufficient portion of the membrane marker to enable it to localize within the exosome membrane, i.e. the fragment comprises at least one intact transmembrane domain to permit localization of the portion of the membrane marker into the exosomal membrane.
[0080] The target-specific fusion product also includes a muscle targeting sequence, i.e. a protein or peptide sequence which facilitates the targeted uptake of the exosome into muscle. Examples of suitable skeletal muscle targeting sequences include, but are not limited to, muscle- binding peptides such as SERCA2, acetylcholine receptor epsilon, SCN4A, muscle specific creatine kinase (CK-MM) and fragments thereof, including the peptide sequence, TARGEHKEEELI (SEQ ID NO: 1). Cardiac muscle targeting sequences include sequences derived from cardiac troponin.
[0081] Exosomes incorporating a muscle-specific fusion product may be produced using recombinant technology. In this regard, an expression vector encoding the muscle-specific fusion product is introduced by electroporation or transfection into exosome-producing cells isolated from an appropriate biological sample. As one of skill in the art will appreciate, it is also possible to produce the fusion product using recombinant techniques, and then introduce the fusion product directly into exosome-producing cells using similar techniques, e.g. electroporation, transfection using cationic lipid-based transfection reagents, and the like. Following a sufficient period of time,
exosomes generated by the exosome-producing cells, and including the fusion product, may be isolated as described.
[0082] The desired muscle protein, nucleic acid encoding the protein or both may be introduced into isolated exosomes incorporating a muscle-targeting fusion product (muscle- targeting exosomes) as previously described, using electroporation or transfection methods. Addition to the exosome of both the desired muscle protein and nucleic acid encoding the same muscle protein may increase delivery efficiency of the protein.
[0083] Exosomes genetically engineered to incorporate a muscle protein, and/or nucleic acid encoding the protein, may be used to deliver the protein and/or nucleic acid to a mammal in vivo in the treatment of a pathological myopathy in which the protein is defective or absent (due to a genetic mutation in the gene encoding the protein) to upregulate the activity of the protein and thereby treat the myopathy. Exosomes either incorporating a muscle-targeting fusion product or not including such a targeting fusion product may be used to deliver the muscle protein (and/or nucleic acid encoding the protein) to muscle tissue in vivo in the treatment of a myopathy. Examples of myopathies that may be treated using the present engineered exosomes include, genetic myopathies including muscular dystrophy, congenital myopathy and metabolic myopathies. At the genetic level, myopathies include disease inherited in an autosomal recessive (AR), autosomal dominant (AD) or X-Hnked recessive (XLR) manner. Examples of muscular dystrophy that are caused by genetic mutations and that may be treated using the present engineered exosomes are set out in Table 1 below. Table 1 identifies the disease, the affected protein and affected or mutated gene involved in each disease, the type of mutation, the mRNA transcript sequence information (via NCBI (National Centre for Biotechnology Information) GenBank accession numbers) for the functional gene (which could be incorporated into the exosomes to treat a disease), and the corresponding protein sequence information for the proteins useful to treat each disease.
[0084] Examples of congenital and other myopathies that are caused by genetic mutations and that may be treated using the present engineered exosomes are set out in Table 2 below. Table 2 identifies the disease, the affected protein and affected or mutated gene involved in each disease, the type of mutation (Mut), the mRNA transcript sequence information (via NCBI GenBank accession numbers) for the functional gene (which could be incorporated into the exosomes to treat a disease), and the corresponding protein sequence information for the proteins useful to treat each disease.
[0085] Examples of metabolic myopathies that are caused by genetic mutations and that may be treated using the present engineered exosomes are set out in Table 3 below. Table 3 identifies the disease, the affected protein and affected or mutated gene involved in each disease, the type of mutation, the mRNA transcript sequence information (via the NCBI GenBank accession numbers) for the functional gene (which could be incorporated into the exosomes to treat a disease), and the corresponding protein sequence information for the proteins useful to treat each disease.
[0086] As one of skill in the art will appreciate, a muscle protein or nucleic acid encoding the muscle protein for incorporation into exosomes according to the invention may be a functional native mammalian protein or nucleic acid, including for example, a protein or nucleic acid from human and non-human mammals, or a functionally equivalent protein or nucleic acid. The term "functionally equivalent" is used herein to refer to a protein which exhibits the same or similar
function to the native protein (retains at least about 30% of the activity of native protein), and includes all isoforms, variants, recombinant produced forms, and naturally-occurring or artificially modified forms, i.e. including modifications that do not adversely affect activity and which may increase cell uptake, stability, activity and/or therapeutic efficacy. The term "functionally equivalent" also refers to nucleic acid, e.g. mRNA, DNA or cDNA, encoding a muscle protein, and is meant to include any nucleic acid sequence which encodes a functional muscle protein, including all transcript variants, variants that encode protein isoforms, variants due to degeneracy of the genetic code, artificially modified variants, and the like. Protein modifications may include, but are not limited to, one or more amino acid substitutions (for example, with a similarly charged amino acid, e.g. substitution of one amino acid with another each having non-polar side chains such as valine, leucine, alanine, isoleucine, glycine, methionine, phenylalanine, tryptophan, proline; substitution of one amino acid with another each having basic side chains such as histidine, lysine, arginine; substitution of one amino acid with another each having acidic side chains such as aspartic acid and glutamic acid; and substitution of one amino acid with another each having polar side chains such as cysteine, serine, threonine, tyrosine, asparagine, glutamine), additions or deletions; modifications to amino acid side chains, addition of a protecting group at the N- or C- terminal ends of the protein, fusion products (e.g. with Fc peptide), and the like. Suitable modifications will generally maintain at least about 70% sequence similarity with the active site and other conserved domains of a native muscle protein, and preferably at least about 80%, 90%, 95% or greater sequence similarity. Nucleic acid modifications may include one or more base substitutions or alterations, addition of 5' or 3' protecting groups, and the like, preferably maintaining significant sequence similarity, e.g. at least about 70%, and preferably, 80%, 90%, 95% or greater.
[0087] Targeting and non-targeting exosomes including a selected protein, such as a muscle protein, or nucleic acid encoding the protein in accordance with the invention, may be formulated for therapeutic use by combination with a pharmaceutically or physiologically acceptable carrier. The expressions "pharmaceutically acceptable" or "physiologically acceptable" mean acceptable for use in the pharmaceutical and veterinary arts, i.e. not being unacceptably toxic or otherwise unsuitable for physiological use. As one of skill in the art will appreciate, the selected carrier will vary with the intended utility of the exosome formulation. In one embodiment, exosomes are formulated for administration by infusion or injection, e.g. subcutaneously,
intraperitoneally, intramuscularly or intravenously, and thus, are formulated as a suspension in a medical-grade, physiologically acceptable carrier, such as an aqueous solution in sterile and pyrogen-free form, optionally, buffered or made isotonic. The carrier may be distilled water (DNase- and RNase-free), a sterile carbohydrate-containing solution (e.g. sucrose or dextrose) or a sterile saline solution comprising sodium chloride and optionally buffered. Suitable sterile saline solutions may include varying concentrations of sodium chloride, for example, normal saline (0.9%), half-normal saline (0.45%), quarter-normal saline (0.22%), and solutions comprising greater amounts of sodium chloride (e.g. 3%-7%, or greater). Saline solutions may optionally include additional components, e.g. carbohydrates such as dextrose and the like. Examples of saline solutions including additional components, include Ringer's solution, e.g. lactated or acetated Ringer's solution, phosphate buffered saline (PBS), TRIS (hydroxymethyl) aminomethane hydroxymethyl) aminomethane)-buffered saline (TBS), Hank's balanced salt solution (HBSS), Earle's balanced solution (EBSS), standard saline citrate (SSC), HEPES- buffered saline (HBS) and Gey's balanced salt solution (GBSS).
[0088] In other embodiments, the present exosomes are formulated for administration by routes including, but not limited to, oral, intranasal, enteral, topical, sublingual, intra-arterial, intramedullary, intrauterine, intrathecal, inhalation, ocular, transdermal, vaginal or rectal routes, and will include appropriate carriers in each case. For oral administration, exosomes may be formulated in normal saline, complexed with food, in a capsule or in a liquid formulation with an emulsifying agent (honey, egg yolk, soy lecithin, and the like). Oral compositions may additionally comprise adjuvants including sugars, such as lactose, trehalose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and derivatives thereof, such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetates; powdered tragancanth; malt; gelatin; talc; stearic acids; magnesium stearate; calcium sulfate; vegetable oils, such as peanut oils, cotton seed oil, sesame oil, olive oil and corn oil; polyols such as propylene glycol, glycerine, sorbital, mannitol and polyethylene glycol; agar; alginic acids; water; isotonic saline and phosphate buffer solutions. Wetting agents, lubricants such as sodium lauryl sulfate, stabilizers, colouring agents and flavouring agents may also be present Exosome compositions for topical application may be prepared including appropriate carriers. Creams, lotions and ointments may be prepared for topical application using an appropriate base such as a triglyceride base. Such creams, lotions and ointments may also contain a surface active agent. Aerosol formulations may also be prepared
in which suitable propellent adjuvants are used. Other adjuvants may also be added to the composition regardless of how it is to be administered, for example, anti-microbial agents, antioxidants and other preservatives may be added to the composition to prevent microbial growth and/or degradation over prolonged storage periods.
[0089] Targeting and non-targeting exosomes according to the present invention are useful in a method to treat myopathies involving a defective/missing muscle protein, or a condition involving lack of expression of a muscle protein. The terms 'treat", "treating" or 't reatment" are used herein to refer to methods that favorably alter a myopathy, including those that moderate, reverse, reduce the severity of, or protect against, the progression of the myopathy. Thus, for use to treat a pathological myopathy, a therapeutically effective amount of exosomes (targeting or non- targeting) loaded with a selected muscle protein, and/or nucleic acid encoding a muscle protein, are administered to a mammal. The term "therapeutically effective amount" is an amount of exosome required to treat the myopathy, while not exceeding an amount which may cause significant adverse effects. Exosome dosages that are therapeutically effective will vary on many factors including the nature of the condition to be treated as well as the particular individual being treated. Appropriate exosome dosages for use include dosages sufficient to result in an increase in activity or amount of the target muscle protein in the patient by at least about 10%, and preferably an increase in activity of the protein or amount of the target muscle protein of greater than 10%, for example, at least 20%, 30%, 40%, 50% or greater. In one embodiment, the dosage may be a dosage of exosome that delivers from about 0.1 mg/kg to about 100 mg/kg, such as 0.1- 50 mg/kg, or 0.1-10 mg/kg, of the desired protein, or an exosome dosage that delivers a sufficient amount of nucleic acid to yield about 0.1 mg/kg to about 100 mg/kg, such as 0.1 -50 mg/kg, or 0.1 - 10 mg/kg, of the desired protein. For example, the dosage of mRNA encoding a particular protein may be in the range of about 1 ug/kg to 1 mg/kg to treat a given myopathy. In another embodiment, for the delivery of a gene-editing system, the dosage may be a dosage of exosomes sufficient to deliver about lng/kg to about lOOmg/kg of gene-editing protein or nucleic acid. The term "about" is used herein to mean an amount that may differ somewhat from the given value, by an amount that would not be expected to significantly affect activity or outcome as appreciated by one of skill in the art, for example, a variance of from 1-10% from the given value.
[0090] As will be appreciated by one of skill in the art, exosomes comprising a muscle protein, and/or nucleic acid encoding the protein, for example, to treat a myopathy, may be used in conjunction with (at different times or simultaneously, either in combination or separately) one or more additional therapies to facilitate treatment, including but not limited to, exercise, physiotherapy, stretching, high protein and/or carbohydrate diet, creatine monohydrate supplementation and corticosteroid treatment.
[0091] In another embodiment, the present method of treating myopathy in a mammal may include administration to the mammal of exosomes (for example, isolated as described above), genetically modified to incorporate gene-silencing systems (e.g., siRNA) to reduce the expression of a mutated gene followed by administration to the mammal of exosomes genetically modified to incorporate a protein useful to treat the myopathy and/or nucleic acid encoding the protein. In one embodiment, siRNA suitable to target a mutated gene that expresses a product that causes or amplifies the myopathy. Examples of mutations that may be targeted with siRNA include, but are not limited to, mutations that result in myotonic muscular dystrophy type 1 and 2, occulopharyngeal muscular dystrophy, malignant hyperthermia (RYR1 and CACNA1S mutations), and other dominant-negative myopathies due to mutations in TPM3, COL6A1, COL6A2, COL6A3, αB-crystalin, and filamin.
[0092] In another aspect of the invention, a method of treating myopathy in a mammal may include administering to the mammal exosomes genetically modified to incorporate genome- editing systems to correct the inherent primary mutation leading to the myopathy. Genome editing may include gene insertions, deletions, modifications (e.g. nucleotide transitions, transversions, insertions or deletions of one or more nucleotides or duplications of any nucleotide sequence), gene activation and gene silencing. As will be appreciated by one of skill in the art, genome editing may be for the purpose of correcting an undesirable gene mutation, introducing a gene mutation (e.g. including gene mutations to yield a transgenic animal model), altering a gene sequence (e.g. to improve, enhance or inhibit gene function), inserting a gene sequence (e.g. to activate or inhibit gene expression), and the like. Examples of nuclease genome editing systems include, but are not limited to, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) nuclease system, e.g. including a targeting gRNA and a CRISPR-associated (Cas) gene, such as CRISPR-Cas9, Transcription Activator-Like Effector Nucleases (TALEN) and mito-TALEN, Zinc-Finger
Nucleases (ZFN) and aptamer-guided delivery of therapeutic nucleic acids, e.g. small interfering RNA, micro RNA, anti-microKNA, antagonist RNA, small hairpin RNA and other RNA, DNA or peptide (including affuners) based aptamers.
[0093] In one embodiment, the exosome is genetically modified to express or incorporate a CRISPR nuclease system, such as a CRISPR/Cas9 Type II genome editing system, including a Cas 9 nuclease, and a guide RNA (gRNA), which comprises a fusion of crRNA (CRISPR RNA) and a trans-activating RNA (tracrRNA). CRISPR RNA includes a targeting RNA sequence and a distinctive array of non-coding direct RNA repeats. The crRNA and tracrRNA are related to a selected Cas nuclease. As one of skill in the art will appreciate, the crRNA and tracrRNA (components of the gRNA) and the Cas nuclease are indicated to be "related" which means that the crRNA and tracrRNA are specific for and recognized by one or more particular Cas nucleases.
[0094] [0087] The targeting sequence of the guide RNA (gRNA) is a strand of RNA that is homologous to a region on a target gene, i.e. a gene to be edited or silenced, associated with a myopathy. Target genes may be genes associated with genetic disease, including hereditary disease such as autosomal dominant, autosomal recessive and X-linked myopathies. The targeting RNA may comprise from 10-30 nucleotides, e.g. from 15-25 nucleotides, such as 20 nucleotides, and may comprise a OC content of about 40-80%. The CRISPR system may be utilized to disrupt expression of a gene by insertion or deletion of nucleotides to disrupt the Open Reading Frame (ORF) of a target gene, or to introduce a premature stop codon therein. Non-Homologous End Joining (NHEJ) DNA repair may be used in this instance. The CRISPR system may also be used to edit (e.g. to correct a gene mutation) by utilizing homology directed repair, in which an editing region (also known as a repair template) is included in the CRISPR system. The editing region or repair template incorporates an edit (e.g. a healthy or wild-type DNA sequence to replace an undesirable DNA mutation in a target gene or any other edit as above), flanked by a region of homology (homologous arms) on either side thereof. The size of the editing region or repair template is not particularly restricted, and may include a single nucleotide edit, or edits of up to 100 nucleotides or more. The targeting sequence of the gRNA is selected such that it targets a site within the target gene that is proximal (e.g. within about 2-5 nucleotides or more) to a protospacer adjacent motif (PAM) located within the target gene. The PAM is recognized by the Cas nuclease and permits Cas nuclease binding. The homologous arms will generally increase in size with the
size of the editing region or repair template, for example, for edits of less than about 50 nucleotides, the homologous arms may be in the range of about 100- 150 nucleotides in length, while larger editing regions may incorporate homologous arms of about 200-800 nucleotides, or more. Edits may also be introduced using CRISPR which facilitate expression of a target gene, e.g. edits which introduce a transcription factor that promote gene expression. The gRNA additionally incorporates related crRNA and a tracrRNA sequences, which interact with and function to direct the Cas nuclease to the target gene to catalyze cleavage of the target gene by the Cas nuclease. As will be understood by one of skill in the art, while each of the crRNA, tracrRNA, and Cas nuclease sequences are related, these sequences may be native or mutated sequences, provided that any mutations thereof do not have an adverse impact on function. Selection of suitable gRNA sequences can be achieved using methods known in the art, such as using programs for this purpose (e.g. CRISPR-MIT (http://crispr.mit.edu/), CHOPCHOP (https://chopchop.rc.fas.harvard.edu/index.php), or E-CRISP (http://www.e-crisp.org/E- CRISP/index.html).
[009S] The Cas nuclease may, for example, be a Cas 9 -based nuclease. Examples of a Cas 9 nuclease include wild-type Cas 9 (a double nickase) from Streptococcus pyogenes (SP), Staphylococcus aureus (SA), Neisseria meningitidis (NM), Streptococcus thermophilus (ST), and Treponema denticola (TD), as well as mutated recombinant Cas 9, e.g. mutated to function as a single nickase such as Cas9 D10A and Cas9 H840A, which may be used with 2 or more gRNAs to achieve a genome edit with increasing targeting efficiency that prevents non-specific genomic editing. Wild-type and single nickase Cas 9 may be used to edit genes, for example, that result in autosomal recessive, X-linked recessive or autosomal dominant myopathies, in order to correct the mutation. The mutated Cas 9 may also be a nuclease-deficient Cas (for example, incorporating both D10A and H840A to inactivate nuclease function) which binds but does not cleave and thereby silences a gene. Nuclease-deficient Cas 9 may be used to treat an autosomal recessive myopathy, to prevent or minimize expression of a dysfunctional mutated protein, which may interfere with the activity of the desired functional protein.
[0096] The targeting RNA is an RNA strand complementary to a site on the target gene which is 3-4 nucleotides upstream of a PAM sequence recognized by the Cas nuclease. The targeting RNA does not itself include a PAM sequence. PAM sequences differ for various Cas
nucleases. For example, for Streptococcus pyogenes (SP), the PAM sequence is NGG; for S. aureus, the PAM sequence is NNORRT or NNGRR(N); for Neisseria meningitides, the PAM sequence is NNNNGATT; for Streptococcus (hemophilus, the PAM sequence is NNAGAAW; for Treponema denticola (TD), the PAM sequence is NAAAAC. "N" represents any nucleotide, W = weak (A or T) and R = A or G.
[0097] For introduction into exosomes, nucleic acid encoding a nuclease genome editing system, such as a selected CRISPR nuclease system including gRNA, DNA repair template and a Cas nuclease, may be produced using known synthetic techniques and then incorporated into the same or different expression vectors under the control of an appropriate promoter. Suitable vectors for such expression are known in the art. Alternatively, expression vectors incorporating the selected nuclease genome editing system may be obtained commercially. Expression vectors incorporating the nuclease genome editing system may be introduced into exosomes using electroporation or transfection using cationic lipid-based transfection reagents. Alternatively, the components of the nuclease editing system may be introduced directly into exosomes as single- stranded (ss) DNA using similar introduction techniques. For example, the DNA repair template may be introduced into exosomes as ssDNA, the gRNA and Cas nuclease may be introduced into exosomes as oligonucleotides/mRNA, or the Cas nuclease may be introduced into exosomes as a protein (produced using recombinant techniques, or otherwise obtained). Thus, as would be recognized by one of skill in the art, the different components of the nuclease editing system may be introduced into exosomes in various forms and/or combinations of nucleic acid, protein and expression vector incorporating DNA.
[0098] In another embodiment, Class 2 CRISPR technology (such as CRISPR-spCAS9- HF) can be incorporated into exosomes and used as a gene editing system.
[0099] The exosomes of the present invention provide many advantages over current treatment methods. At the outset, exosomes represent a physiological treatment method since they are an entity that naturally exists within a mammal. In addition, the present exosomes provide stability and protection from degradation and denaturation to the proteins/enzymes and/or nucleic acid that they deliver. This in turn facilitates the delivery of higher levels of protein or nucleic acid than is achieved by many other modes of delivery. Further, the use of exosomes to deliver
protein/nucleic acid results in a minimal immune reaction to the protein or nucleic acid being delivered because exosomes may be obtained from cells that do not induce any significant immunogenic response or which are not toxic (e.g. exosomes from immature dendritic cells). Moreover, the present exosomes may be tailored to incorporate a targeting sequence that results in enhanced recognition and fusion with the target tissue, e.g. muscle, to result in increased specificity with respect to targeted protein/nucleic acid delivery.
[00100] Embodiments of the invention are described in the following specific examples which are not to be construed as limiting.
Example 1 - Dystrophin rescue in fibroblasts from Duchenne Muscular Dystrophy patients
[00101] To determine if dystrophin could be delivered to cells using genetically modified exosomes, the following experiment was conducted.
[00102] Exosome isolation - Dendritic cells (DC) were isolated from mouse bone marrow progenitor cells and from human peripheral blood mononuclear cells (collected using Ficoll gradient separation of human blood). Briefly, femur and tibia were carefully harvested from mice and were flushed with HBSS media to collect bone marrow progenitor cells. The bone marrow progenitor cells were cultured in OlutaMAX-DMEM media (Life Technologies) containing 10% FBS, ImM sodium pyruvate, 0.5% penicillin-streptomycin, and mouse recombinant granulocyte/macrophage colony-stimulating factor (R&D Systems). For human dendritic cell isolation, blood was collected in EDTA-lavender tubes followed by dilution of blood with 4x PBS buffer (pH 7.2 and 2 mM EDTA). 40 mL of diluted cell suspension was carefully layered over 20 mL of Ficoll gradient. The gradient was centrifuged at 400x g for 60 minutes followed by collection of the interphase layer containing the mononuclear cells. The mononuclear cells were cultured in IMDM media (BD Biosciences) containing 10% FBS, 1% glutamine, 0.5% penicillin- streptomycin, and human recombinant granulocyte/macrophage colony-stimulating factor (R&D Systems). Both human and mouse dendritic cells were further purified using EasySep™ Mouse and Human Pan-DC Enrichment Kit (Stem Cell Technologies). Dendritic cells were then cultured with the aforementioned media (GlutaMAX-DMEM media for mouse DC and IMDB media for human DC). Media was pre-spun at 170,000x g for 2 hours at 37 °C for 4 days to ensure that the
subsequent exosome pellet would not be contaminated with bovine microvesicles and/or exogenous exosomes.
[00103] The dendritic cells were then grown to about 80% confluency in alpha minimum essential medium supplemented with ribonucleosides, deoxyribonucleosides, 4 mM L-glutamine, 1 mM sodium pyruvate, 5 ng/mL murine GM-CSF, and 20% fetal bovine serum. For conditioned media collection, cells were washed twice with sterile PBS (pH 7.4, Life Technologies) and the aforementioned media (with exosome-depleted fetal bovine serum) was added. Conditioned media from human and mouse immature dendritic cell culture was collected after 48 hours. The media (10 mL) was spun at 2,000x g for 15 min at 4°C to remove any cellular debris. This was followed by an optional 2000x g spin for 60 min at 4°C to further remove any contaminating nonadherent cells. The supernatant was then spun at 14,000x g for 60 min at 4°C. The resulting supernatant was optionally spun at S0,000x g for 60 min at 4°C. The supernatant was then filtered through a 40 μm filter, followed by filtration through a 0.22 um syringe filter (twice). The supernatant was then carefully transferred into ultracentrifuge tubes and diluted with an equal amount of sterile PBS (pH 7.4, Life Technologies). This mixture was then subjected to ultracentrifugation at 100,000x-170,000x g for 2 hours at 4°C using a fixed-angle rotor. The resulting pellet was re-suspended in PBS and re-centrifuged at 100,000x-170,000x g for 2 hours at 4°C. The pellet was resuspended carefully with 25 mL of sterile PBS (pH 7.4, Life Technologies) and then added gently on top of 4 mL of 30%/70% Percoll™ gradient cushion (made with 0.22 μm filter sterilized water) in an ultracentrifuge tube. This mixture was spun at 100,000x-170,000x g for 90 minutes at 4°C. With a syringe, the exosomal pellet-containing fraction at the gradient interface was isolated carefully, diluted in 50 mL of sterile PBS (pH 7.4, Life Technologies), followed by a final spin for 90 minutes at 100,000x-170,000x g at 4°C to obtain purified exosomes. The resulting exosomal pellet was resuspended in sterile PBS or sterile 0.9% saline for downstream use. Exosomal fraction purity was confirmed by sizing using a Beckman DelsaMax dynamic light scattering analyzer showing minimal contamination outside of the 40-120 nm size range, and by immuno-gold labelling/Western blotting using the exosome membrane markers, CD9, CD63, TSG101 and ALIX.
[00104] Exosomes were loaded with dystrophin mRNA using a cationic lipid-based transfection reagent (Lipofectamine® MessengerMAX™ Transfection Reagent, Life
Technologies). After transfection, exosomes were spun for 2 hours at 170,000x g at 4°C followed by re-suspension in 5% (wt/vol) glucose in 0.9% sterile saline solution.
[00105] Treatment with Dmd mRNA-loaded exosomes - Primary dermal fibroblasts isolated from four DMD patients, and two age/gender-matched controls, were treated with human Dmd mRNA (100 ng), empty exosomes (10 ug of total exosomal protein in 0.9% sterile saline), and with human Dmd mRNA-loaded exosomes (100 ng of mRNA packaged in 10 ug of total exosomal protein in 0.9% sterile saline) for 48 hours. Cells were then seeded on glass-bottom chamber slides, washed with PBS, fixed with 4% paraformaldehyde, and incubated with anti- dystrophin (Abeam) antibody. Subsequent to a secondary incubation with an Alexa-fluor 568 conjugated anti-Rabbit antibody, cells were washed with phosphate buffered saline (PBS) and mounted with DNA-specific fluorescent dye, 4'-6-diamidino-2-phenylindole (DAPI)-containing hardset Vecta shield mounting fluid (Vector Laboratories, Inc.). Representative 3D z-stack images were taken using an Olympus laser scanning confocal microscope, which were then rendered into 2D images using the NIH Image J, Version 1.37, analysis software (Scion Image, NIH). The images confirm that bioengineered exosomes loaded with dystrophin {Dmd) mRNA rescue dystrophin deficiency in primary dermal fibroblasts isolated from Duchenne Muscular Dystrophy (DMD) patients. Quantification of confocal microscopy images to determine dystrophin protein content in primary dermal fibroblasts from control and DMD patients after treatment with exosomes loaded with dystrophin (Dmd) mRNA was then conducted. Total fluorescence per image was analyzed using the NIH Image J, Version 1.37, analysis software (Scion Image, NIH), and the data are represented as a bar graph. N=2 Controls (Con) and N=4 DMD patients. Results show almost complete rescue of dystrophin protein in fibroblasts treated with exosomes loaded with dystrophin (Dmd) mRNA as compared to those treated with either dystrophin (Dmd) mRNA or exosomes not loaded with dystrophin mRNA (Figure 1).
[00106] Immunoblot analysis of dystrophin protein expression in primary dermal fibroblasts was then conducted. Cells were washed with cold PBS, scraped, solubilized in radioimmuno-precipitation assay (RIP A) buffer and were resolved on 4-15% Criterion™ gradient gels (Biorad). The gels were transferred onto PVDF membranes using Trans-Blot® Turbo™ Transfer Starter System (Biorad), followed by blocking with 3% milk in TBS-Tween at room temperature. Immunoblotting was carried out using anti-dystrophin (Abeam) overnight at 4°C .
Membranes were then incubated with anti-mouse horseradish peroxidase-linked secondary antibody (OE Healthcare) and were visualized by enhanced chemiluminescence detection reagent (Amersham Biosciences). Relative intensities of the protein bands were digitally quantified by using NIH Image J, Version 1.37, analysis software (Scion Image, NIH). Data were analyzed using an unpaired /-test and are presented as mean ± SEM, *P<0.05, N=3 Control (Con), N=4 dystrophin (DMD). Results show complete rescue of dystrophin protein in fibroblasts treated with exosomes loaded with dystrophin (Dmd) mRNA as compared to those treated with either dystrophin (Dmd) mRNA or exosomes not loaded with dystrophin mRNA (Figure 2).
Example 2 - Treatment of a Genetic Myopathy In Vivo with Dystrophin mRNA loaded Exosomes
[00107] Genetically engineered exosomes comprising dystrophin mRNA as described in Example 1 were used for the in vivo treatment of a myopathy resulting from genetic mutation, namely, one of the most common and representative muscular dystrophy disorders: Duchenne Muscular Dystrophy (DMD).
In vivo experiments
[00108] Hemizygous male CS7BL/10ScSn-Dmdmdx (mdx+Iy or mdx) mice (lacking functional dystrophin gene) were obtained from Jackson Laboratories (Strain 001801), and housed at McMaster University's Central Animal Facility. Mice were bred in accordance with rules set by McMaster University's Animal Research and Ethics board, following guidelines set forth by the Canadian Council of Animal Care. Twelve male mdx mice, ~100 days old, were randomly divided into various treatment groups as follows: VEH (vehicle, 150 uL of sterile 0.9% saline injection per animal per week, n=4), EXO (empty exosomes, 10 μg of total exosomal protein in 150 μL of sterile 0.9% saline per mouse per week, n=4), EXO-mRNA (exosomes loaded with mRNA, 100 ng of human dystrophin mRNA packaged in 10 ug of total exosomal protein in 150 μL of sterile 0.9% saline per animal per week, n=4) and prednisolone, which is the gold-standard therapy for Duchenne muscular dystrophy (PRED; administered at a dosage of 2 mg/kg body weight/day, delivered as two bolus i.p. injections per week, n=4). All animals were treated for six weeks via intravenous tail vein injections. WT mouse values were used as controls and indicated with a dashed line. Data is represented as mean ± SEM. *P < 0.0S. Data were analyzed using an unpaired t-test. Exosomes used were isolated and loaded with Dmd mRNA as described in Example 1.
[00109] Maximum grip strength was measured by placing mice on a level wire mesh connected to a force transducer. The mouse was gently pulled away from the mesh by the base of the tail until release, while the transducer recorded the peak force (N). Trials were performed in triplicate, and mice were allowed time between trials to rest. The maximum grip strength was recorded, and corrected for muscle mass.
[00110] Mice were sacrificed two days after the last injection by cervical dislocation. Blood was collected immediately after sacrifice in EDTA-coated microfuges, followed by centrifugation at 1500 g for 15 mins at 4°C, supernatant (plasma) collected and frozen at -80 °C Tissues (EDL, SOL, TA and diaphragm) were extracted, snap frozen, weighed and stored at -80 °C until further analysis.
Measurement of dystrophin content
[00111] Whole tissue R1PA lysates were prepared from the TA, EDL, SOL and diaphragm muscle groups using established methods. Protein concentrations of whole tissue lysates were determined using a commercial assay (BCA Protein Assay; Pierce). Muscle extracts were separated on a 4-15% gradient SDS-PAGE, and subsequently transferred onto PVDF membranes (Biorad). Membranes were then blocked with 3% skim milk in lx TBS-Tween20 solution (Tris- buffered saline-Tween-20: 25 mM Tris-HCl, pH 7.5, 1 mM NaCl and 0.1% Tween-20) at room temperature, followed by overnight incubation in blocking solution with an antibody directed towards dystrophin (Abeam). Membranes were then incubated with the appropriate anti-rabbit HRP-linked secondary antibody (1 : 10,000) and visualized with an enhanced chemiluminescence detection reagent (GE Healthcare, Cleveland, OH) and the ChemiDoc MP system (Biorad). Ponceau staining was used to ensure equal loading across all gels (not shown).
Dystrophin mRNA-loaded exosome therapy restores dystrophin content and improves functional outcomes in mdx mice
[00112] Treatment with dystrophin mRNA-loaded exosomes restored dystrophin protein content in the Extensor digitorum longus (EDL) muscle (A), soleus (SOL) muscle (B), heart (C) (Figure 3) and diaphragm of mdx mice to levels comparable to those seen in WT mice, an effect which was not present in any other treatment groups. Body weight was unchanged in all groups treated (Figure 4A). The fast and slow twitch skeletal muscles of mdx mice treated with dystrophin
mRNA-loaded exosomes demonstrated a significant reduction in size, suggesting that pseudohypertrophy (an early sign of DMD) was reduced and thus, an improvement in the quality of muscle present when compared to the other treatment groups (Figure 4B-D). Corresponding with an improvement in muscle quality, only the mdx mice treated with dystrophin mRNA-loaded exosomes experienced a significant increase in muscle strength, indicating improved muscle functionality (Figure 5). Lastly serum CK (a hallmark characteristic of the active muscle damage from DMD) was reduced to WT levels only in mdx mice treated with dystrophin mRNA-loaded exosomes, further demonstrating improved muscle health in this group (Figure 6).
[00113] These findings show that the administration of dystrophin mRNA-loaded exosomes was able to largely protect mdx mice from the development of a muscular dystrophy phenotype, a finding not observed with prednisolone therapy. Thus, exosomes loaded with mRNA encoding a functional protein were confirmed herein to be delivered to muscle and subsequently to restore the amount of the dystrophin protein to wildtype levels, indicating the efficacy of the disclosed method for treating genetic myopathies.
Example 3 - Treatment of acid alpha glucosidase deficiency with protein loaded exosomes
[00114] To determine the efficacy of exosomes to efficiently deliver cargo to muscle, exosomes were engineered to incorporate alpha acid glucosidase (OAA) and deliver the protein to the muscle of OAA deficient mice.
Production of Mouse GAA Protein
[00115] Mouse alpha acid glucosidase (OAA) (NCBI Reference Sequence: NM_008064.3) cDNA from skeletal muscle was sub-cloned into a mammalian vector (pOEX GST-fusion vector; OE Healthcare Life Sciences). The vector was maintained using the competent E. coli DHSalpha line (Life Technologies). The pGEX mammalian vector was then transfected into Chinese Hamster Ovary Cells (CHO; ATCC Cat. CCL-661) for mass production of active GAA enzyme. To isolate recombinant GAA in its processed active form, CHO cells transfected with G AA-pOEX vector were lysed and CHO cell lysate was cleared using ultra-performance resins for OST-tagged fusion protein purification (GE Healthcare Life Sciences). Over 80% of the recombinant protein was eluted after 3 washes. Elution #1 and Elution #2 were combined to obtain a high yield of
protein. GST tag was removed from active GAA using PreScission Protease (GE Healthcare Life Sciences).
Introduction of GAA protein into exosomes
[00116] Exosomes were produced as described in Example 1. Exosomes were loaded with GAA protein using cationic lipid-based transfection reagents (Lipofectamine® MessengerMAX™ Transfection Reagent, Life Technologies). After transfection, exosomes were spun for 2 hours at 170,000x g at 4°C followed by re-suspension in 5% (wt/vol) glucose in 0.9% sterile saline solution.
Breeding of GAA mouse and littermate wildtype mice
[00117] Four GAA heterozygous breeding pairs (GAA-/+) were obtained from Jackson Laboratories (Maine, USA) to generate homozygous GAA knock-outs (GAA-/-) and wild-type littermates (GAA+/+). Mice were genotyped at 1 month of age using a standard genotyping kit (REDExtract-N-Amp Tissue PCR Kit; Sigma Aldrich). The birth rate of homozygous mutants was 18%, and significant deficits in front-limb muscle strength were detected as early as 1.5 months of age. During breeding, all animals were housed three to five per cage in a 12-h light/dark cycle and were fed ad libitum (Harlan-Teklad 8640 22/5 rodent diet) after weaning. The study was approved by the McMaster University Animal Research and Ethics Board under the global Animal Utilization Protocol # 12-03-09, and the experimental protocol strictly followed guidelines put forth by Canadian Council of Animal Care.
[00118] Primary mononuclear cells were isolated from skeletal muscle of GAA+/+ (wild- type mice with normal GAA activity) and GAA-/- mice (GAA knock-out mice, a model of Pompe Disease) (n = 3 per group). Cells were pre-plated to obtain a pure population of myoblasts. Cells were differentiated for S days into myotubes, followed by treatment with naked murine GAA recombinant protein (40 mg/kg recombinant GAA in PBS), empty exosomes (10 ug of total exosomal protein in PBS) or GAA protein-loaded exosomes (40 mg/kg of recombinant GAA in 10 ug of total exosomal protein in PBS) for 48 hours in pre-spun growth media devoid of bovine microvesicles and exosomes, Cells were harvested after 48 hours and GAA activity was measured.
GAA enzyme activity
[00119] A standard fluorometric enzyme assay, originally described by Reuser et al. (Am J Hum Genet 30(2), 132-43, 1978), was used to determine GAA (EC 3.2.1.20) activity. In brief, cellular lysates were prepared by homogenizing cells (fibroblasts and myotubes) in 200 μL mannitol buffer (70 mM sucrose, 220 mM mannitol, 10 mM HEPES, 1 mM EGTA, protease inhibitor mixture (Complete Tablets, Roche), pH 7.4). Following BCA assay (Pierce) for colorimetric determination of protein concentration, 10 uL of each sample was loaded in triplicates and mixed with 20 μL. of the artificial substrate (4-methyl-umbelliferyl a-d-gluco-pyranoside in 0.2 M sodium acetate [NaAc] buffer, pH 3.9, heated to 65 °C) in a 96 well black plate. Standards were prepared from a S mM 4-methylumbelHferone/50% ethanol stock by serial dilution in 0.2 M NaAc buffer (pH 3.9), loaded in 10 uL triplicates, and mixed with 20 uL 0.2 M NaAc buffer (pH 3.9). The samples were then incubated in the dark for 1 h at 37.S °C and the reaction was terminated by adding 200 uL of 0.S M sodium carbonate (pH 10.7). The release of the product 4- methylumbelliferone from the artificial substrate 4-methyl-umbelliferyl a-d-gluco-pyranoside is proportionate to acid a-glucosidase activity (nmol/mg protein/hr), and the resulting fluorescence was read at 360 nm excitation/460 nm emission with a monochromator-based microplate detection system (Tecan Safire 2). RESULTS
[00120] Primary myotubes from GAA+/+ (wild-type mice with normal GAA activity) and GAA-/- (GAA knock-out mice, a model of Pompe Disease) were treated with naked murine GAA recombinant protein, empty exosomes (not loaded with GAA recombinant protein) or GAA protein-loaded exosomes, for 48 hours. Primary myotubes show a greater rescue of GAA activity when treated with GAA protein-loaded exosomes in comparison with naked GAA (currently utilized enzyme replacement therapy for Pompe disease) (Figure 7). Data is represented as mean ± SD (experiment independently repeated three times). *P < 0.05. Data were analyzed using an unpaired t-test.
[00121] Thus, exosomes modified to incorporate functional protein were shown to effectively deliver protein to muscle cells.
Example 4 - Biogengineering Tangerine Exosomes Enhances Exosome Delivery to Muscle
[00122] To prepare non-targeting exosomes (not tagged with a membrane fusion product), DC cells were grown to about 80% confluency before exosome collection as described above. To prepare targeting exosomes (tagged with a membrane fusion product), on the third day of growth, DC were transfected with mammalian expression Lamp 1 -skeletal muscle targeting sequence (MTS) fusion plasmid 0.1-1 ug (depending on cell density) using Lipofectamine 2000 reagent (Life Technologies). The Lampl -MTS fusion plasmid was made using Gateway® technology and vectors (Life Technologies) with amplified mouse skeletal muscle cDNA that corresponds to the skeletal muscle targeting sequence (TARGEHKEEELI; SEQ ID NO: 1). The mouse LAMP1 cDNA exosome marker (NM_001317353.1) was amplified from mouse dendritic cell cDNA. The skeletal muscle targeting sequence and the exosome marker were linked via PCR, and then were incorporated into a mammalian expression vector. On the fifth day, the dendritic cells were washed and combined with fresh growth media (GlutaMAX-DMEM, pre-spun at 170,000x g for 2 hours to generate media virtually free of contamination from bovine exosomes or microvesicles).
[00123] Primary mouse muscle (differentiated into myotubes) were isolated from C57B1/6 mice using standard protocols. The cells were differentiated for 2-5 days prior to treatment. To test the efficiency of in vitro delivery of potential therapeutic agents (siRNA, proteins, mRNA, DNA, or small molecules), siRNA targeting a house-keeping gene GAPDH (abundantly expressed in almost all cell types) was used as proof of principle. Primary mouse myotubes were treated with 100 ng of GAPDH siRNA or scRNA (scrambled RNA obtained from Sigma; control for siRNA) as follows: l OOng of naked scRNA or siRNA, scRNA or siRNA transfected with Lipofectamine 2000 (LF2000), scRNA- or siRNA-loaded non-targeting exosomes, and scRNA- or siRNA-loaded skeletal muscle targeting exosomes (100 ng of scRNA or siRNA packaged in 10 ug of total exosomal protein in 0.9% sterile saline). scRNA and GAPDH siRNA were purchased from Sigma.
[00124] GAPDH qPCR was carried out to assess down-regulation of GAPDH mRNA. Treatment of myotubes with GAPDH siRNA-loaded skeletal muscle targeting exosomes exhibited greater down-regulation of GAPDH compared to GAPDH siRNA loaded non-targeting exosomes and conventional GAPDH siRNA transfected with LF2000 (Figure 8).
Example 5 - Muscle targetins exosomes efficiently deliver PGC-1 alpha siRNA to muscle cells
[00125] Skeletal muscle-targeting exosomes prepared as described in Example 4 were transfected with PGC-1 alpha siRNA or scRNA. Primary mouse myotubes, obtained as described in Example 4, were treated with 100 ng of naked PGC-1 alpha siRNA or scRNA, scRNA or PGC- 1 alpha siRNA transfected with LF2000, 100 ng of scRNA- or PGC-1 alpha siRNA-loaded non- targeting exosomes and scRNA- or PGC-1 alpha siRNA-loaded skeletal muscle targeting exosomes (100 ng of scRNA or siRNA packaged in 10 ug of total exosomal protein in 0.9% sterile saline). PGC-1 alpha siRNA as purchased from Sigma.
[00126] PGC-1 alpha siRNA-loaded skeletal muscle targeting exosomes and PGC-1 alpha siRNA loaded non-targeting exosomes were determined to down-regulate PGC-1 alpha expression, which resulted in the subsequent down-regulation of mitochondrial genes that are known to be regulated by PGC-1 alpha including: NRF-1, Tfam, COX-IV, COX-VIIa, and Cycs (Figure 9A). This reduction in PGC-1 alpha mRNA and downstream mitochondrial genes also resulted in a reduction in mitochondrial electron transport chain complex IV (cytochrome c oxidase; COX) activity (Figure 9B). Importantly, the PGC-1 alpha siRNA had no effect on those genes which are not believed to be under the influence of PGC-1 alpha (being PGC-1 beta and PRC), demonstrating both the desired specificity and functionality of the siRNA administered via exosomes. Furthermore, the down-regulation in gene expression and reduction in mitochondrial biofunctional capacity was more effective in cells treated with PGC-1 alpha siRNA-loaded skeletal muscle targeting exosomes in comparison to cells treated with PGC-1 alpha siRNA-loaded non- targeting exosomes or PGC-1 alpha siRNA transfected with LF2000 (Figure 9A-B). Thus, exosomes can be bioengineered to deliver cargo to skeletal muscle for the purpose of modulating cellular activity.
[00127] The foregoing demonstrates for the first time that the present genetically modified exosomes can be used to treat genetic myopathies (such as muscular dystrophy, congenital myopathy, and metabolic myopathies), and that muscle targeting exosomes may also be used to deliver cargo into muscle.
Example 6 - Exosome Isolation from human biological samples
[00128] The following is another method that may be used to isolate exosomes.
[00129] For serum isolation, blood was allowed to clot for 1 hour at room temperature followed by spinning at 2,000x g for 15 min at 4°C. Human immature dendritic cells (IDC) were grown to 65-70% confluency in alpha minimum essential medium supplemented with ribonucleosides, deoxyribonucleosides, 4 mM L-glutamine, 1 mM sodium pyruvate, 5 ng/mL murine OM-CSF, and 20% fetal bovine serum. For conditioned media collection, cells were washed twice with sterile phosphate buffered saline (PBS) (pH 7.4, Life Technologies) and the aforementioned media (with exosome-depleted fetal bovine serum) was added. Conditioned media from human immature dendritic cell culture was collected after 48 hours. From this point onwards, all samples (serum- lmL and IDC media- 10mL) were treated exactly the same. Debris was removed from the biological sample by centrifugation of the supernatant at 2000x g for 24 min at 4°C. The supernatant was then spun at 2000x g for 60 min at 4°C and the subsequent supernatant was spun at 14,000x g for 60 min at 4°C. The resulting supernatant was then filtered through a 0.22 μm syringe filter (twice). This resultant filtrate is ready for purification via immunoaffinity.
[00130] Magnetic beads were prepared by vortexing magnetic bead-protein A solution (30 mg Dynabeads® suspension/mL in PBS, pH 7.4, with 0.01% Tween®-20 and 0.09% sodium azide) (Dynabeads®-Protein A; Cat. no. 10610D, Life Technologies) for 15-30 seconds to resuspend the beads. This sequence was repeated with the magnetic bead-protein O solution (30 mg Dynabeads® suspension/mL in PBS, pH 7.4, with 0.01% Tween®-20 and 0.09% sodium azide) (Dynabeads®-Protein O; Cat. no. 10612D, Life Technologies). 500 each μL of magnetic bead-protein A and magnetic bead-protein G (herein referred to as magnetic bead-protein A/G) were transferred into a microfuge tube. The tube was placed on a magnetic rack for 1 min at room temperature (RT) to separate the magnetic bead-protein A/O from the solution, and the supernatant was carefully removed without disturbing the magnetic beads. The tube was removed from the magnet. A selected antibody was then bound to the magnetic bead-protein A/O complex. This involved the following: 100 ug each of antibodies (ALIX, TSG101 and CD9 (referred to as 3Ab- a method); or CD9, CD81 or CD63 (referred to as 3Ab-b method); and CD9 (ab92726, Abeam), CD63 (abl93349, Abeam), CD81 (sc-9158, SantaCruz), ALIX (abl l7600, Abeam), TSG101
(ab83, Abeam) and flotillin 1 (ab41927, Abeam) for the antibody cocktail (6Ab) method) was diluted in a protease inhibitor solution (1 mL of sterile PBS (pH 7.4) including 0.1% Tween®-20 and 1/10th of a Roche complete mini protease inhibitor cocktail tablet). The antibody solution was added to the magnetic bead-protein A/O. The resultant solution was men incubated at 4°C overnight using an end-over-end mixer. The tube was placed on the magnet for 1 min at RT and then the supernatant was removed carefully without disturbing the magnetic bead-protein A/G- antibody complex. The tube was removed from the magnet and the magnetic bead-protein A/G- antibody complex was resuspended in 0.1 mL of protease inhibitor solution. The magnetic bead- protein A/G-antibody complex was washed for 5 minutes with 1 mL of fresh protease inhibitor solution, using an end-over-end mixer. This was repeated three more times.
[00131] The antibody was then crosslinked to the protein A/O affinity ligand. This involved the following. The magnetic bead-protein A/O-Antibody complex was resuspended in 500 μL of 5 mM Bis(sulfosuccinimidyl)suberate in antibody conjugation buffer (20 mM sodium phosphate, 0.1SM NaCl (pH 7.4,prepared fresh on day of use). The resultant solution was incubated at room temperature for 40 min with gentle mixing using an end-over-end mixer. 25 μL of quenching buffer (1M Tris HC1 (pH 7.4,prepared fresh on day of use) was then added and the solution was incubated at room temperature for 24 min with gentle mixing using an end-over-end mixer. The tube was placed on the magnet for 1 min and the supernatant carefully removed without disturbing the magnetic bead-protein A/G-antibody complex. The crosslinked magnetic bead-protein A/G- antibody complex was washed for 5 minutes with 1 mL of fresh protease inhibitor solution, using an end-over-end mixer. This was repeated three more times.
[00132] The exosomes were then isolated using the following steps. 1 mL of the exosome filtrate was resuspended in 400 uL of magnetic bead-protein A/G-antibody complex and incubated overnight at 4°C with gentle mixing using an end-over-end mixer. The magnetic bead-protein A/G-antibody-exosome complex was then washed for 5 minutes with 1 mL of fresh PBS (pH 7.4) with 0.1% Tween®-20 and protease inhibitor solution, using an end-over-end mixer. This wash was repeated three more times. The exosomes were eluted by resuspending the magnetic bead- protein A/G-antibody-exosome complex in elution buffer (20 mMTris HC1 (pH 8), 137 mM NaCl, 1% Nonidet P-40, 2 mM EDTA).
[00133] A BCA assay (Pierce™) was used to determine the yield of exosomes in each sample. Total protein yield obtained from human serum for the three-antibody cocktail was 5.2 μg/μL for 3Ab-a and 11.9 μg/μL for 3Ab-b, and for the six-antibody cocktail was 17.0 μg/μL for 6Ab. The total protein yield obtained from human IDC cells was 4.0 μg/μL for 3Ab-a and 5.7 μg/μL, for 3Ab-b, and 8.7 μg/μL for 6Ab. Since it is assumed that all exosomes bear certain standard exosomal markers (such as CD9, CD63, ALIX, etc.), it would be expected that immunoprecipitation using any antibody having specificity for these markers in isolation should be equally effective at immunocapturing all exosomes.
[00134] The size distribution and stability of the exosomes was also determined using a Beckman DelsaMax dynamic light scattering analyzer. Exosomes isolated from human serum using the three antibody cocktail (3Ab) and six antibody cocktail (6Ab) were each within the established exosomal size range of 20-100nm, indicating a high degree of purity. Correspondingly, the zeta potential of exosomes isolated from human serum using each antibody cocktail (3Ab and 6Ab) was determined to be between 102 to 164mV, indicating excellent stability.
[00135] Relevant portions of references referred to herein are incorporated by reference.
Claims
CLAIMS 1. Exosomes genetically modified to incorporate a functional muscle protein and/or nucleic acid encoding a functional muscle protein.
2. The exosomes of claim 1 , essentially free from particles having a diameter less than 20 nm or greater than 140 nm.
3. The exosomes of claim 1, which exhibit a zeta potential having a magnitude of at least about 30 mV, and preferably 40 mV or greater.
4. The exosomes of claim 1, wherein the muscle protein is a native muscle protein or a modified muscle protein.
5. The exosomes of claim 1 , which are mammalian exosomes.
6. The exosomes of claim 1, wherein the muscle protein is encoded by a gene selected from the group consisting of Myotilin (MYOT), Lamin A/C (LMNA), Caveolin 3 (CAV3), DnaJ heat shock protein family (Hsp40) member B6 (DNAJB6), Spectrin repeat containing, nuclear envelope 1 (SYNE1), Spectrin repeat containing, nuclear envelope 2 (SYNE2), Desmin (DES), Crystallin alpha B (CRYAB), LIM domain binding 3 (LDB3), Filamin C (FLNC), BCL2 associated athanogene 3 (BAG3), Dystrophia myotonica protein kinase (DMPK), CCHC-type zinc finger, nucleic acid binding protein (CNBP), Poly(A) binding protein, nuclear 1 (PABPN1), Titin (TTN), Double homeobox 4 (DUX4), Structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1), Calpain 3 (CAPN3), Dysferlin (DYSF), Sarcoglycan gamma (SGCO), Sarcoglycan alpha (SGCA), Sarcoglycan beta (SGCB), Sarcoglycan delta (SGCD), Titin-cap (TCAP), Tripartite motif containing 32 (TRIM32), Fukutin related protein (FKRP), TTN, Protein O-mannosyltransferase 1 (POMT1), Anoctamin 5, Fukutin (FKTN), Protein O- mannosyltransferase 2 (POMT2), Protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2) (POMGnTl), Dystroglycan 1 (DAG1), Plectin (PLEC), DES, Trafficking protein particle complex 11 (TRAPPC 11), GDP-mannose pyrophosphorylase B (GMPPB), Tafazzin (TAZ), Dystrophin (DMD), Emerin (EMD), Four and a half LIM domains 1 Ly (FHL1), Lysosome-associated membrane protein 2 (LAMP-2), VMA21 vacuolar H+-ATPase homoiog (S. cerevisiae) (VMA21), Laminin subunit alpha 2 (LAMA2), Integrin subunit alpha 7 (ITGA7),
Selenoprotein N, 1 (SEPN1), Collagen type VI alpha 1 (COL6A1), Collagen type VI alpha 2 (COL6A2), Collagen type VI alpha 3 (COL6A3), Docking protein 7 (DOK7), Protein O- mannosyltransferase 1 (POMT1), Protein O-mannosyltransferase 2 (POMT2), Protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-) (POMGNT1), FKTN, FKRP, Like- glycosyltransferase (LARGE), Isoprenoid synthase domain containing (ISPD), Protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-) (POMGNT2), Transmembrane protein 5 (TMEM5), GDP-mannose pyrophosphorylase B (GMPPB), Choline kinase beta (CHKB), Ryanodine receptor 1 (RYR1), Collagen type VI alpha 1 (COL6A1), Collagen type VI alpha 2 (COL6A2), Collagen type VI alpha 3 (COL6A3), Selenoprotein N, 1 (SEPNl), DES, Myosin, heavy chain 2, skeletal muscle, adult (MYH2), Valosin containing protein (VCP), Heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1), Heterogeneous nuclear ribonucleoprotein Al (HNRNPA1), Glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase (GNE), Glucan (1,4-aIpha-), branching enzyme 1 (GBE1), Amylo-alpha-1, 6-glucosidase, 4-alpha- glucanotransferase (AGL), Enolase 3 (beta, muscle) (EN03), Glycogen synthase 1 (GYS1), Glycogenin 1 (GYG1), Hexokinase 1 (HK1), Lactate dehydrogenase A (LDHA), Phosphofructokinase, muscle (PFKM), Phosphoglucomutase 1 (PGM1), Phosphoglyceratemutase 2 (PGAM2), Phosphorylase, glycogen, muscle (PYGM), LAMP2, Phosphoglycerate kinase 1 (PGK1), Phosphorylase kinase, alpha 2 (liver) (PHKA2), Phosphorylase kinase, alpha 1 (muscle) (PHKA1), Carnitine palmitoyltransferase 1 A (CPT1 A), Carnitine palmitoyltransferase 2 (CPT2), Acyl-CoA dehydrogenase, C-4 to C-12 straight chain (ACADM), Acyl-CoA dehydrogenase, very long chain (ACADVL), Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (Afunctional protein), alpha subunit (HADHA), Hydroxyacyl-CoA dehydrogenase/3- ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit (HADHB), Electron transfer flavoprotein alpha subunit (ETFA), Solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 (SLC25A20), Solute carrier family 22 (organic cation/carnitine transporter), member 5 (SLC22AS) and Glucosidase, alpha; acid (GAA).
7. The exosomes of claim 1 , further modified to incorporate or express a target-specific fusion product comprising a skeletal muscle targeting sequence linked to an exosomal membrane marker.
8. The exosomes of claim 7, wherein the exosomal membrane marker is selected from the group consisting of CD9, CD37, CD53, CD63, CD81, CD82, CD151, an integral, ICAM-1,
CDD31, an annexin, TSG101, ALIX, lysosome-associated membrane protein 1, lysosome- associated membrane protein 2, lysosomal integral membrane protein and a fragment of any exosomal membrane marker that comprises at least one intact transmembrane domain.
9. The exosomes of claim 7, wherein the skeletal muscle targeting sequence is selected from the group consisting of SERCA2, acetylcholine receptor epsilon, SCN4A, muscle specific creatine kinase (CK-MM) and TARGEHKEEELI.
10. The exosomes of claim 1, wherein the muscle protein and nucleic acid encoding the functional muscle protein are exogenous.
11. A composition comprising genetically modified exosomes as defined in claim 1 combined with a pharmaceutically acceptable carrier.
12. The composition of claim 11, comprising exosomal protein in an amount of about 100- 2000
13. A method of treating myopathy in a mammal comprising administering to the mammal exosomes genetically modified to incorporate a gene-editing system, selected from the group consisting of CRISPR, TALEN and zinc finger nuclease systems, that corrects mutation leading to the myopathy.
14. A method of treating myopathy in a mammal comprising administering to the mammal exosomes genetically modified to incorporate gene-silencing systems such as siRNA to reduce the expression of a mutated gene that results in the myopathy followed by administering to the mammal exosomes genetically modified to incorporate a functional protein useful to treat the myopathy and/or nucleic acid encoding the functional protein.
15. A method of increasing the level or amount of a muscle protein in mammalian muscle comprising administering to the mammal exosomes genetically modified to incorporate the functional muscle protein and/or nucleic acid encoding the functional protein.
16. A method of treating myopathy in a mammal comprising administering to the mammal exosomes genetically modified to incorporate a functional muscle protein useful to treat the myopathy and/or nucleic acid encoding the functional protein.
17. The method of claim 16, wherein the genetic myopathy is selected from the group consisting of Muscular dystrophy, limb-girdle, type IA, Muscular dystrophy, limb-girdle, type IB, Muscular dystrophy, limb-girdle, type IC, Muscular dystrophy, limb-girdle, type IE, Emery- Dreifuss muscular dystrophy 4, Emery-Dreifuss muscular dystrophy 5, Myopathy, myofibrillar, 1, Myopathy, myofibrillar, 2, Myopathy, myofibrillar, 4, Myopathy, myofibrillar, S, Myopathy, myofibrillar, 6, Myotonic dystrophy 1, Myotonic dystrophy 2, Oculopharyngeal muscular dystrophy, Tibial muscular dystrophy, tardive, Facioscapulohumeral muscular dystrophy 1, Facioscapulohumeral muscular dystrophy 2, digenic, Muscular dystrophy, limb-girdle, type 2A, Muscular dystrophy, limb-girdle, type 2B, Muscular dystrophy, limb-girdle, type 2C, Muscular dystrophy, limb-girdle, type 2D, Muscular dystrophy, limb-girdle, type 2E, Muscular dystrophy, limb-girdle, type 2F, Muscular dystrophy, limb-girdle, type 2G, Muscular dystrophy, limb-girdle, type 2H, Muscular dystrophy, limb-girdle, type 21 / Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, S, Muscular dystrophy, limb-girdle, type 2J, Muscular dystrophy, limb- girdle, type 2K / Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 1, Muscular dystrophy, limb-girdle, type 2L, Muscular dystrophy, limb-girdle, type 2M / Muscular dystrophy- dystroglycanopathy (limb-girdle), type C, 4, Muscular dystrophy, limb-girdle, type 2N / Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2, Muscular dystrophy, limb-girdle, type 20 / Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3, Muscular dystrophy, limb- girdle, type 2P / Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 9, Muscular dystrophy, limb-girdle, type 2Q, Muscular dystrophy, limb-girdle, type 2R, Muscular dystrophy, limb-girdle, type 2S, Muscular dystrophy, limb-girdle, type 2T / Muscular dystrophy- dystroglycanopathy (limb-girdle), type C, 14, Barth syndrome, Muscular dystrophy, duchenne type, Muscular dystrophy, becker type, Emery-Dreifuss muscular dystrophy 1, X-linked, Emery- Dreifuss muscular dystrophy 6, X-linked, Danon disease, Myopathy, X-linked, with excessive autophagy, Muscular dystrophy, congenital merosin-deficient, 1A, Muscular dystrophy, congenital, due to ITGA7 deficiency, Myopathy, congenital, with fiber-type disproportion, Ullrich congenital muscular dystrophy 1, Ullrich congenital muscular dystrophy 1, Ullrich congenital muscular dystrophy 1, Myasthenic syndrome, congenital, 10, Muscular dystrophy- dystroglycanopathy (congenital with brain and eye anomalies), type A, 1 / Muscular dystrophy- dystroglycanopathy (congenital with mental retardation), type B, 1, Muscular dystrophy- dystroglycanopathy (congenital with brain and eye anomalies), type A, 2 / Muscular dystrophy-
dystroglycanopathy (congenital with mental retardation), type B, 2, Muscular dystrophy- dystroglycanopathy (congenital with brain end eye anomalies), type A, 3 / Muscular dystrophy- dystroglycanopathy (congenital with mental retardation), type B, 3, Muscular dystrophy- dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 / Muscular dystrophy- dystroglycanopathy (congenital without mental retardation), type B, 4, Muscular dystrophy- dystroglycanopathy (congenital with brain and eye anomalies), type A, 5 / Muscular dystrophy- dystroglycanopathy (congenital with or without mental retardation), type B, 5, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 6, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 8, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 10, Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14 / Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 14, Muscular dystrophy, congenital, megaconial type, Central core disease, Bethlem myopathy 1, Bethlem myopathy 1, Bethlem myopathy 1, Muscular dystrophy, rigid spine, 1, Inclusion body myopathy 1 / Myopathy, myofibrillar, 1, Inclusion body myopathy 3 / Proximal myopathy and ophthalmoplegia, Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1, Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2, Inclusion body myopathy with early-onset Paget disease without frontotemporal dementia 3, Inclusion body myopathy 2 / Nonaka myopathy, Glycogen storage disease IV, Glycogen storage disease Ilia / Illb, Glycogen storage disease XIII, Glycogen storage disease 0, muscle, Glycogen storage disease XV, Glycogen storage disease XI, Glycogen storage disease VII, Glycogen storage disease X, Glycogen storage disease V / McArdle disease, Danon disease, Phosphoglycerate kinase 1 deficiency, Glycogen storage disease, type IXal / Glycogen storage disease, type IXa2, Muscle glycogenosis, CPT deficiency, hepatic, type IA, CPT deficiency, hepatic, type II, Acyl-CoA dehydrogenase, medium chain, deficiency of, VLCAD deficiency, Mitochondrial trifunctional protein deficiency, Mitochondrial trifunctional protein deficiency, Multiple acyl-CoA dehydrogenase deficiency (MADD) / Glutaric acidemia IIA, Carnitine-acylcarnitine translocase deficiency, Carnitine deficiency, systemic primary and Glycogen storage disease II.
18. The method of claim 17, wherein the muscle protein is encoded by a gene selected from the group consisting of Myotilin (MYOT), Lamin A/C (LMNA), Caveolin 3 (CAV3), DnaJ heat shock protein family (Hsp40) member B6 (DNAJB6), Spectrin repeat containing, nuclear envelope I (SYNE1), Spectrin repeat containing, nuclear envelope 2 (SYNE2), Desmin (DES), Crystallin alpha B (CRYAB), LIM domain binding 3 (LDB3), Filamin C (FLNC), BCL2 associated athanogene 3 (BAG3), Dystrophia myotonica protein kinase (DMPK), CCHC-type zinc finger, nucleic acid binding protein (CNBP), Poty(A) binding protein, nuclear 1 (PABPN1), Titin (TTN), Double homeobox 4 (DUX4), Structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1), Calpain 3 (CAPN3), Dysferlin (DYSF), Sarcoglycan gamma (SGCO), Sarcoglycan alpha (SGCA), Sarcoglycan beta (SGCB), Sarcoglycan delta (SGCD), Thin-cap (TCAP), Tripartite motif containing 32 (TRIM32), Fukutin related protein (FKRP), TTN, Protein O-mannosyltransferase 1 (POMT1), Anoctamtn 5, Fukutin (FKTN), Protein O-mannosyltransferase 2 (POMT2), Protein O-linked mannose N-acetylglucosaininyltransferase 1 (beta 1,2) (POMGnTl), Dystroglycan 1 (DAG1), Plectin (PLEC), DES, Trafficking protein particle complex 11 (TRAPPC11), GDP-mannose pyrophosphorylase B (GMPPB), Tafazzin (TAZ), Dystrophin (DMD), Emerin (EMD), Four and a half LIM domains 1 Ly (FHL1), Lysosome-associated membrane protein 2 (LAMP-2), VMA21 vacuolar H+-ATPase homolog (S. cerevisiae) (VMA21), Laminin subunit alpha 2 (LAMA2), Integrin subunit alpha 7 (ITGA7), Selenoprotein N, 1 (SEPN1), Collagen type VI alpha 1 (COL6A1), Collagen type VI alpha 2 (COL6A2), Collagen type VI alpha 3 (COL6A3), Docking protein 7 (DOK7), Protein O-mannosyltransferase 1 (POMT1), Protein O-mannosyltransferase 2 (POMT2), Protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-) (POMGNT1), FKTN, FKRP, Like-glycosyltransferase (LARGE), Isoprenoid synthase domain containing (ISPD), Protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-) (POMGNT2), Transmembrane protein 5 (TMEM5), GDP-mannose pyrophosphorylase B (GMPPB), Choline kinase beta (CHKB), Ryanodine receptor 1 (RYRl), Collagen type VI alpha 1 (COL6A1), Collagen type VI alpha 2 (COL6A2), Collagen type VI alpha 3 (COL6A3), Selenoprotein N, 1 (SEPN1), DES, Myosin, heavy chain 2, skeletal muscle, adult (MYH2), Valosin containing protein (VCP), Heterogeneous nuclear ribonucleoprotem A2/B1 (HNRNPA2B1), Heterogeneous nuclear ribonucleoprotem Al (HNRNPAl), Glucosamine (UDP-N- acetyl)-2-epitnerase/N-acetylmannosamine kinase (GNE), Glucan (1,4-alpha-), branching enzyme 1 (GBE1), Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase (AGL), Enolase 3 (beta, muscle) (EN03), Glycogen synthase 1 (GYS1), Glycogenin 1 (GYG1), Hexokinase 1 (HK1), Lactate dehydrogenase A (LDHA), Phosphofhictokinase, muscle (PFKM), Phosphogtucomutase 1 (PGM1), Phosphoglycerate mutase 2 (PGAM2), Phosphorylase, glycogen, muscle (PYGM), LAMP2, Phosphoglycerate kinase 1 (PGK1), Phosphorylase kinase, alpha 2 (liver) (PHKA2), Phosphorylase kinase, alpha 1 (muscle) (PHKA1), Carnitine palmitoyltransferase 1A (CPT1A), Carnitine palmitoyltransferase 2
(CPT2), Acyl-CoA dehydrogenase, C-4 to C-12 straight chain (ACADM), Acyl-CoA dehydrogenase, very long chain (ACADVL), Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit (HADHA), Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit (HADHB), Electron transfer flavoprotein alpha subunit (ETFA), Solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 (SLC25A20), Solute carrier family 22 (organic cation/carnitine transporter), member S (SLC22A5) and Olucosidase, alpha; acid (GAA).
19. The method of claim 17, wherein the genetic myopathy is creatine transporter deficiency 1 and the protein is acid creatine transporter protein.
20. The method of claim 17, wherein the myopathy is Duchenne Muscular Dystrophy and the protein is dystrophin.
21. The method of claim 17, wherein the myopathy is a glycogen storage disease.
22. The method of claim 17, wherein a dosage of exosomes sufficient to deliver about 0.1 mg/kg to about 100 mg/kg of the muscle protein, or an exosome dosage that delivers an amount of nucleic acid to yield about 0.1 mg/kg to about 100 mg/kg of the muscle protein, is
administered to the mammal.
23. A method of increasing the activity of a target muscle protein in a mammal, comprising administering to the mammal exosomes which are genetically modified to incorporate the functional muscle protein and/or nucleic acid encoding the functional protein.
24. The method of claim 23, wherein the exosomes are essentially free from particles having a diameter less than 20 nm or greater than 140 nm.
25. The method of claim 23, wherein the exosomes exhibit a zeta potential having a magnitude of at least about 30 mV, and preferably 40 mV or greater.
26. The method of claim 23, wherein the exosomes are isolated from a biological sample using a method comprising the following steps: i) exposing the biological sample to a first centrifugation to remove cellular debris greater than about 7-10 microns in size from the sample and obtaining
the supernatant following centrifugation; ii) subjecting the supernatant from step i) to centrifugation to remove microvesicles therefrom; iii) microfiltering the supernatant from step ii) and collecting the microfiltered supernatant; iv) subjecting the microfiltered supernatant from step iii) to at least one round of ultracentrifugation to obtain an exosome pellet; and v) re-suspending the exosome pellet from step iv) in a physiological solution and conducting a second ultracentrifugation in a density gradient and removing the exosome pellet fraction therefrom.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562235786P | 2015-10-01 | 2015-10-01 | |
US62/235,786 | 2015-10-01 | ||
US201662303089P | 2016-03-03 | 2016-03-03 | |
US62/303,089 | 2016-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017054086A1 true WO2017054086A1 (en) | 2017-04-06 |
Family
ID=58422477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2016/051141 WO2017054086A1 (en) | 2015-10-01 | 2016-09-30 | Treatment of genetic myopathies using bioengineered exosomes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017054086A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018222926A1 (en) * | 2017-05-31 | 2018-12-06 | Ultragenyx Pharmaceutical Inc. | Therapeutics for glycogen storage disease type iii |
WO2019077534A1 (en) * | 2017-10-18 | 2019-04-25 | Tubitak | An exosomal therapeutic carrier production method and an exosomal therapeutic carrier properly obtained with this method |
US10617768B2 (en) | 2016-07-12 | 2020-04-14 | Santa Clara University | Engineered exosomes for the delivery of bioactive cargo using transmembrane tetraspanins |
CN111194210A (en) * | 2017-08-04 | 2020-05-22 | 俄亥俄州创新基金会 | Method for preparing therapeutic exosomes by utilizing nano electroporation and other non-endocytic cell transfection |
WO2020106099A1 (en) * | 2018-11-22 | 2020-05-28 | (주)프로스테믹스 | Exosome and various uses thereof |
EP3682868A1 (en) * | 2019-01-16 | 2020-07-22 | University Of Seoul Industry Cooperation Foundation | Method of manufacturing vesicles by delivery of rna nanoparticles and vesicles manufactured using the same |
US10758486B2 (en) | 2017-07-12 | 2020-09-01 | Santa Clara University | Engineered exosomes for the delivery of bioactive cargo using transmembrane VSV-G |
KR20210020959A (en) * | 2018-11-22 | 2021-02-24 | (주)프로스테믹스 | Exomsome and various uses thereof |
KR20210020960A (en) * | 2018-11-22 | 2021-02-24 | (주)프로스테믹스 | Exomsome and various uses thereof |
WO2021026353A3 (en) * | 2019-08-06 | 2021-03-11 | Ohio State Innovation Foundation | Therapeutic extracellular vesicles |
CN112843234A (en) * | 2021-01-20 | 2021-05-28 | 四川大学华西第二医院 | Device for regulating and controlling concentration of GDP-mannose in organism |
WO2021110920A1 (en) * | 2019-12-04 | 2021-06-10 | University Of Ulster | A method of isolating exosomes |
CN113272426A (en) * | 2018-11-16 | 2021-08-17 | 医福斯治疗有限公司 | Extracellular vesicles for replacement of urea cycle proteins and nucleic acids |
US11491483B2 (en) | 2018-02-15 | 2022-11-08 | Ohio State Innovation Foundation | Microfluidic devices and methods for high throughput electroporation |
KR102667894B1 (en) * | 2017-08-04 | 2024-05-22 | 오하이오 스테이트 이노베이션 파운데이션 | Methods for generating therapeutic exosomes from nanoelectroporation and other non-endocytic cell transfections |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007126386A1 (en) * | 2006-05-03 | 2007-11-08 | Loetvall Jan Olof | Exosome transfer of nucleic acids to cells |
WO2009105044A1 (en) * | 2008-02-22 | 2009-08-27 | Agency For Science, Technology And Research (A*Star) | Mesenchymal stem cell particles |
WO2013048734A1 (en) * | 2011-09-28 | 2013-04-04 | Tufts Medical Center, Inc. | Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes |
WO2014168548A2 (en) * | 2013-04-12 | 2014-10-16 | El Andaloussi, Samir | Therapeutic delivery vesicles |
-
2016
- 2016-09-30 WO PCT/CA2016/051141 patent/WO2017054086A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007126386A1 (en) * | 2006-05-03 | 2007-11-08 | Loetvall Jan Olof | Exosome transfer of nucleic acids to cells |
WO2009105044A1 (en) * | 2008-02-22 | 2009-08-27 | Agency For Science, Technology And Research (A*Star) | Mesenchymal stem cell particles |
WO2013048734A1 (en) * | 2011-09-28 | 2013-04-04 | Tufts Medical Center, Inc. | Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes |
WO2014168548A2 (en) * | 2013-04-12 | 2014-10-16 | El Andaloussi, Samir | Therapeutic delivery vesicles |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10617768B2 (en) | 2016-07-12 | 2020-04-14 | Santa Clara University | Engineered exosomes for the delivery of bioactive cargo using transmembrane tetraspanins |
JP2020522244A (en) * | 2017-05-31 | 2020-07-30 | ウルトラジェニクス ファーマシューティカル インク.Ultragenyx Pharmaceutical Inc. | Remedy for glycogen storage disease type III |
JP7284101B2 (en) | 2017-05-31 | 2023-05-30 | ウルトラジェニクス ファーマシューティカル インク. | Therapeutic agents for glycogen storage disease type III |
US11377643B2 (en) | 2017-05-31 | 2022-07-05 | Ultragenyx Pharmaceutical Inc. | Therapeutics for glycogen storage disease type III |
WO2018222926A1 (en) * | 2017-05-31 | 2018-12-06 | Ultragenyx Pharmaceutical Inc. | Therapeutics for glycogen storage disease type iii |
US10758486B2 (en) | 2017-07-12 | 2020-09-01 | Santa Clara University | Engineered exosomes for the delivery of bioactive cargo using transmembrane VSV-G |
EP3661485A4 (en) * | 2017-08-04 | 2021-05-12 | Ohio State Innovation Foundation | Method for producing therapeutic exosomes from nanoelectroporation and other non-endocytic cell transfection |
CN111194210A (en) * | 2017-08-04 | 2020-05-22 | 俄亥俄州创新基金会 | Method for preparing therapeutic exosomes by utilizing nano electroporation and other non-endocytic cell transfection |
KR102667894B1 (en) * | 2017-08-04 | 2024-05-22 | 오하이오 스테이트 이노베이션 파운데이션 | Methods for generating therapeutic exosomes from nanoelectroporation and other non-endocytic cell transfections |
CN111194210B (en) * | 2017-08-04 | 2024-02-20 | 俄亥俄州创新基金会 | Method for preparing therapeutic exosomes by using nano electroporation and other non-endocytic cell transfection |
US11674130B2 (en) | 2017-08-04 | 2023-06-13 | Ohio State Innovation Foundation | Method for producing therapeutic exosomes from nanoelectroporation and other non-endocytic cell transfection |
WO2019077534A1 (en) * | 2017-10-18 | 2019-04-25 | Tubitak | An exosomal therapeutic carrier production method and an exosomal therapeutic carrier properly obtained with this method |
US11491483B2 (en) | 2018-02-15 | 2022-11-08 | Ohio State Innovation Foundation | Microfluidic devices and methods for high throughput electroporation |
CN113272426A (en) * | 2018-11-16 | 2021-08-17 | 医福斯治疗有限公司 | Extracellular vesicles for replacement of urea cycle proteins and nucleic acids |
KR102342902B1 (en) | 2018-11-22 | 2021-12-24 | (주)프로스테믹스 | Exomsome and various uses thereof |
KR102342901B1 (en) | 2018-11-22 | 2021-12-24 | (주)프로스테믹스 | Exomsome and various uses thereof |
WO2020106099A1 (en) * | 2018-11-22 | 2020-05-28 | (주)프로스테믹스 | Exosome and various uses thereof |
KR20210020960A (en) * | 2018-11-22 | 2021-02-24 | (주)프로스테믹스 | Exomsome and various uses thereof |
KR20210020959A (en) * | 2018-11-22 | 2021-02-24 | (주)프로스테믹스 | Exomsome and various uses thereof |
JP2020110142A (en) * | 2019-01-16 | 2020-07-27 | ユニバーシティー オブ ソウル インダストリー コーオペレイション ファンデーション | Method for producing endoplasmic reticulum by transfer of rna nanoparticles and endoplasmic reticulum produced therefrom |
EP3682868A1 (en) * | 2019-01-16 | 2020-07-22 | University Of Seoul Industry Cooperation Foundation | Method of manufacturing vesicles by delivery of rna nanoparticles and vesicles manufactured using the same |
WO2021026353A3 (en) * | 2019-08-06 | 2021-03-11 | Ohio State Innovation Foundation | Therapeutic extracellular vesicles |
WO2021110920A1 (en) * | 2019-12-04 | 2021-06-10 | University Of Ulster | A method of isolating exosomes |
CN112843234A (en) * | 2021-01-20 | 2021-05-28 | 四川大学华西第二医院 | Device for regulating and controlling concentration of GDP-mannose in organism |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017054086A1 (en) | Treatment of genetic myopathies using bioengineered exosomes | |
US20230365971A1 (en) | Methods and compositions for macrophage polarization | |
US10723782B2 (en) | Exosomes for immuno-oncology and anti-inflammatory therapy | |
Zhang et al. | Knockdown of NEAT1 induces tolerogenic phenotype in dendritic cells by inhibiting activation of NLRP3 inflammasome | |
WO2016187717A1 (en) | Exosomes useful for genome editing | |
Wildenberg et al. | Autophagy attenuates the adaptive immune response by destabilizing the immunologic synapse | |
US20210290556A1 (en) | Methods of suppressing delivery of exosomes to liver and spleen | |
Demonbreun et al. | Myoferlin regulation by NFAT in muscle injury, regeneration and repair | |
Tourneur et al. | Cyclosporine A impairs nucleotide binding oligomerization domain (Nod1)-mediated innate antibacterial renal defenses in mice and human transplant recipients | |
WO2016033695A1 (en) | Exosome isolation | |
WO2016115632A1 (en) | Method for treating mitochondrial disease | |
Chen et al. | Foxo1 controls gut homeostasis and commensalism by regulating mucus secretion | |
WO2017075708A1 (en) | Exosomes useful to treat cystic fibrosis | |
Karim et al. | Nox2 is a mediator of ischemia reperfusion injury | |
Mohammadi et al. | Isolation and characterization of microvesicles from mesenchymal stem cells | |
WO2017147719A1 (en) | Method for treating neuropathy | |
Wache et al. | Myeloid-related protein 14 promotes inflammation and injury in meningitis | |
Morioka et al. | Chimeric efferocytic receptors improve apoptotic cell clearance and alleviate inflammation | |
Byun et al. | Rebamipide attenuates autoimmune arthritis severity in SKG mice via regulation of B cell and antibody production | |
Gorman et al. | IgGFc-binding protein and MUC2 mucin produced by colonic goblet-like cells spatially interact non-covalently and regulate wound healing | |
Ojogun et al. | Overproduction of acyloxyacyl hydrolase by macrophages and dendritic cells prevents prolonged reactions to bacterial lipopolysaccharide in vivo | |
JP2022526012A (en) | A method of suppressing insulin signal transduction through a catalyst-independent mechanism by PIP4K and enhancing immune function. | |
KR20150016589A (en) | Inflammation-enabling polypeptides and uses thereof | |
Pernaa et al. | Heterozygous premature termination in zinc-finger domain of Krüppel-like factor 2 gene associates with dysregulated immunity | |
KR102530161B1 (en) | Exosomes derived from umbilical cord blood plasma or their mimics and imunosuppression use of thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16849988 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16849988 Country of ref document: EP Kind code of ref document: A1 |